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ABSTRACT
TGF-pl and MIP-la have recently been identified as potent inhibitors of 
haemopoietic stem cell proliferation. From previous studies, these molecules 
appear to have similar functions in the control of stem cell proliferation. This study 
was designed to investigate the relationship, if any, of these two negative 
regulators in an attempt to elucidate possible distinctive roles for each within the 
haemopoietic system. The results presented in this thesis demonstrate that both 
M IP-la and TGF-p are capable of potently inhibiting the same stem cell 
population (colony forming unit [CFU]-A/CFU-S). It is further shown that all 
three mammalian isoforms of TGF-p are capable of potently inhibiting M IP-la 
gene expression in bone marrow-derived macrophages, a likely source of M IP-la 
in the bone marrow. These molecules differ slightly in their potency in this regard, 
and more diverse members of the TGF-p superfamily such as activin and BMP-2 
do not exhibit this effect within the same spectrum of concentrations as TGF-pi,- 
p2 or -p3. This inhibition is not specific to MIP-la in that expression of MIP-lp, 
a related molecule that does not exhibit potent stem cell inhibitory properties, is 
inhibited in a similar manner. However, expression of RANTES, which is a more 
diverse member of the MIP-la superfamily, appears to be unaffected by TGF-p. 
The inhibition of MIP-la gene expression is also seen as a reduction in M IP-la 
protein production by the murine macrophage cell line RAW 264.7. These in vitro 
results suggest that in the presence of active TGF-p in vivo, and in the absence of 
upregulators of MIP-la expression, very little M IP-la wül be produced. To 
address how the target cells of MIP-la, the stem cells, would respond to TGF-p, 
and the consequently low levels of MIP-la produced, the effect of TGF-P on 
M IP-la receptor levels on FDCP-MIX cells, a murine stem cell line was analysed. 
TGF-P (lOOpM) reversibly downregulates MIP-la receptor levels on these cells to 
a maximum of around 50-70% after 24hrs. This level of downregulation does not 
change upon increasing the concentration of TGF-P or the length of time of
exposure of the cells to TGF-p. Scatchard analysis shows that TGF-p 
downregulates MIP-la receptor number numbers with no change in affinity of the 
remaining receptors for ligand. Further, this reduction in M IP-la receptor 
numbers by TGF-p is reflected in reduced ability of FDCP-MIX cells to mobilise 
calcium in response to MIP-la. These results suggest that TGF-p may be capable 
of interfering with the role of MIP-la as a stem cell inhibitor. Indeed, they 
suggest that in the presence of active TGF-p in vivo, and in the absence of 
upregulators of MIP-la expression, MIP-la may only be a weak contributor to the 
overall physiological inhibition of stem cells. To fully understand the interactions 
between these two molecules, and to address the possibility that M IP-la functions 
either wholly or in part through induction of TGF-p, the effect of M IP-la on 
TGF-pl gene expression and protein production was investigated. The results 
demonstrate that MIP-la acts as an inducer of both TGF-p gene expression and 
protein production in bone marrow macrophages. This suggests that M IP-la may 
act through upregulation of TGF-P in these and possibly other secondary cell 
types. However, inactivation of endogenous TGF-p in the in vitro CFU-A assay 
does not reduce the ability of MIP-la to inhibit CFU-A colony formation. This 
suggests that although MIP-la can induce TGF-pi in bone marrow macrophages, 
it does not function as a stem cell inhibitor through this action. Indeed, the results 
presented in this thesis suggest that while MIP-la and TGF-p appear to have 
overlapping roles with respect to inhibition of stem cell proliferation, they both act 
via independent mechanisms. In summary, the results from my PhD suggest that in 
cells expressing both MIP-la and TGF-p, TGF-p wül be dominantly expressed 
and may therefore be the major contributor to physiological inhibition of stem cells.
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CHAPTER 1
INTRODUCTION
THE HAEMOPOIETIC SYSTEM
CHAPTER 1: THE HAEMOPOIETIC SYSTEM
1.1 Structure of the haemopoietic system.
Adult mammalian haemopoiesis occurs primarily in the bone marrow and is 
a highly complex developmental system in which self-renewing pluripotent stem 
cells give rise, through processes of cellular differentiation and proliferation, to 
lineage restricted progenitor cells and then to mature functional end cells. This 
system has classically been viewed as being pyramidal in shape with three 
overlapping compartments comprising around 0.1-0.4% stem cells, approximately 
3% progenitor cells and greater than 90% maturing end cells (Metcalf 1984, Testa 
and Gale 1988). Haemopoiesis gives rise to at least eight functionally distinct 
mature populations (see figure 1.1) which have remarkably diverse functions 
ranging from specific host defence by B and T lymphocytes to oxygen distribution 
by erythrocytes. In a steady state situation, vast numbers of mature cells need to 
be manufactured daily due to their relatively short life span. For example, 
neutrophils expire after around eight hours and erythrocytes after approximately 
120 days (Golde 1991). It has been estimated that humans produce around 
3.7x10^1 haemopoietic cells per day simply to maintain homeostasis, and that this 
number can increase up to tenfold when the body is stressed due to infection or 
disease (Golde, 1991). Cellular disorders in haemopoiesis can lead to a variety of 
diseases such as leukaemias, anemias and immunodeficiencies. However, the rarity 
of these disorders in such a vast pool of proliferating cells demonstrates 
haemopoiesis to be under elaborate and highly efficient mechanisms of control.
1.2 Stem cells
Production of mature blood cells is ultimately controlled at the level of the 
stem cell and these stem cells constitute a minute population in overall 
haemopoiesis. The very small numbers of stem cells implies that they must be 
under tightly regulated control to avoid possible exhaustion. In fact, only about 
10% of CFU-S stem cells (see below) are in cell cycle in a steady state situation.
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Figure 1.1 A schematic representation of the haemopoietic system
the remainder being quiescent or in the Go stage of the cell cycle (Hodgson et al 
1982). When the system is stressed, for example by chemotherapy or irradiation, 
stem cells are triggered into active cell cycle in order to replenish progenitor and 
mature cell compartments. When this has been accomplished, the stem cells re­
enter quiescence. The overall numbers of stem cells do not decrease over the 
lifetime of an individual however (Zipori 1990).
A stem cell can be defined as that cell which has the capacity to self-renew, 
or to differentiate. The stem cell is pluripotent i.e. has the potential to differentiate 
into all haemopoietic cell lineages. Further, stem cells have the property to 
repopulate a tissue after injury (Lajtha 1979), and indeed to repopulate the 
haemopoietic system of an animal after otherwise lethal irradiation (Spangrude et 
al 1988, 1991). Stem cells are very difficult to distinguish morphologically, and 
thus our knowledge of them originates from a series of in vivo and in vitro assays. 
These shall be discussed below. It has become apparent from the results of the 
assays described below that stem cells comprise of a highly heterogeneous 
population, that can be arranged into distinct but overtyping compartments. Cell 
types can be arranged into a hierarchical order defined by their "primitiveness". 
That is, those cell types which possess high self renewal potential and low 
differentiation tendency are more primitive than those which have limited self 
renewal potential and high differentiation tendency.
Some insight into the abilities of stem cells to self renew has been gained 
from repopulation experiments using retrovirally marked stem cells. Capel et al 
(1990) have demonstrated that very few long term repopulating cells (LTRC) are 
required to maintain adult haemopoiesis, and that they are long lived. Further, 
other groups have demonstrated that haemopoiesis is maintained by a number of 
different clones, which can repopulate the system and then return to quiescence 
allowing other clones to proliferate and differentiate thus continuing the mature cell 
repopulation (Snodgrass and Keller 1987, Abkowitz et al 1990, Harrison et al 
1988).
1.2.1 The in vivo CFU-S assay
The existence of multipotent and self renewing haemopoietic cells can be 
demonstrated using the murine colony forming unit-spleen assay (CFU-S) (Till and 
McCulloch 1961). This assay involves lethally irradiating a mouse such that its 
haemopoietic system is severely compromised, and then intravenously injecting 
bone marrow from a syngeneic animal. Injection of donor bone marrow results in 
stem cell mediated rescue of the animal and formation of macroscopic colonies on 
the spleen which are derived from the inoculated haemopoietic stem cells. The 
time at which such colonies appear on the spleen indicates their "primitiveness". 
Put simply, this means that colonies appearing early after transplantation are 
derived from more mature cells while colonies appearing later are derived from 
more primitive cells. For example, colonies appearing at day 7/8 after irradiation 
have been shown to be clonogenic (Williams et al 1984) and contain mature 
haemopoietic lineages. When cells from these colonies are injected into a similarly 
irradiated animal however, little CFU-S colony formation occurs indicating CFU-S 
day 7/8 to be relatively lineage restricted and to have limited self renewal capacity 
(Wolfe and Priestley 1986). Colonies appearing at day 12 however are derived 
from stem cells capable of generating multilineage colonies. Further, serial 
transplantation of cells from day 12 colonies results in further CFU-S colony 
formation indicating both their pluripotency and their extensive self-renewal 
capacity. Thus, day 12 CFU-S are more primitive than day 7/8 CFU-S as assessed 
by both their ability to differentiate into a wider range of mature cell types and self 
renew (Wolfe and Priestley 1986). It was first assumed that day 12 colonies were 
derived from day 7/8 colonies through differentiation and self renewal. Magli et al 
(1982) have shown however that this may not be the case and that around 50% of 
the day 7/8 colonies, which are largely erythroid in nature, subsequently regress 
and are replaced by multilineage day 12 colonies. Two possibilities for the origin 
of the day 12 colonies not directly derived from day 7/8 colonies have been 
proposed. The first is that they arise from stem cells which originally seeded in the 
bone marrow, but were then consequently attracted to the spleen later in the
repopulation process (Van Zant 1984). The second possibility is that they are 
derived from stem cells which have migrated out from the day 7/8 colonies (Lord 
et al 1989). This remains to be confirmed.
Studies using phase specific cytotoxic drugs have further demonstrated that 
day 7/8 CFU-S cells are extremely sensitive to killing by these drugs indicating 
them to be largely in cycle whereas day 12 CFU-S cells are much more refractory 
to their cytotoxic properties indicating them to be largely quiescent (Hodgson et al 
1982). Thus, this assay system demonstrates that the portion of the stem cell 
compartment detectable by its ability to form spleen colonies consists of a 
heterogeneous population of cells with differing abilities to differentiate and self 
renew. It was initially believed that day 12 CFU-S might represent the true 
totipotent haemopoietic stem cell in vivo. However, a number of observations 
suggested that this was not the case. Firstly, CFU-S are incapable of giving rise to 
lymphoid precursors. Secondly, although donor CFU-S are crucial in the rescue of 
an otherwise lethally irradiated mouse in the short term (Jones et al 1990), they are 
incapable of setting up long term haemopoiesis in vivo or in vitro. Thirdly, there is 
little correlation between CFU-S numbers in the donor marrow and its ability to 
initiate long term haemopoiesis in an irradiated animal (Chertkov et al 1985). This 
implies that there is a more primitive stem cell type, pre-CFU-S, which can give 
rise to both lymphoid progenitors and myeloid progenitors such as CFU-S. 
Indeed, such cells have been identified and separated from the CFU-S compartment 
by virtue of the fact that they retain the dye Rhodamine 123 (Ploemacher and 
Brons 1988). These cells have been termed long term repopulating cells (LTRC) 
and, as their name suggests, are capable of maintaining long term haemopoiesis. 
They are not in themselves sufficient however to initiate repopulation in an 
irradiated animal, and require the presence of less primitive CFU-S type cells to 
initially and quickly repopulate the mature haemopoietic compartments (Jones et al 
1990). Thus, CFU-S represent a part of the stem cell compartment more primitive 
than committed progenitors such as GM-CFCs, but less primitive than the long 
term repopulating cell which shall be discussed below.
1.2.2 In vitro stem cell assays
As with the in vivo CFU-S assay, in vitro stem ceil assays also demonstrate 
the heterogeneity which exists within the stem cell compartment. These assays rely 
on the fact that clonogenic bone marrow cells treated with the appropriate growth 
factors give rise to colonies in semi solid culture conditions, and the size and 
cellular composition of these colonies indicate the level of immaturity of the cell 
from which they were derived. Although not an exhaustive list, some of these 
assays are described below.
1.2.3 High proliferative potential colony forming cells (HPP-CFC)
The HPP-CFC assay has been used to identify three distinct populations of 
stem cells. These have been termed HPP-CFC 1, 2 and 3 whereby HPP-CFC 1 
represent the more primitive cells while HPP-CFC 3 are the more mature 
(reviewed in Bertoncello 1992). Cell cycle toxicity studies have shown that HPP- 
CFC 1 are highly refractory to the effects of 5-FU treatment (Bradley and Hodgson 
1979) whereas HPP-CFC 2 and 3 are more sensitive (Bradley et at 1991, McNiece 
et at 1987). Since 5-FU is cytotoxic to cycling cells, this demonstrates that HPP- 
CFC 2 and 3 are cycling more rapidly than HPP-CFC 1, and are thus more mature. 
Further, McNiece et at (1987) have also demonstrated that HPP-CFC 1 can 
generate CFU-S day 12 cells suggesting that HPP-CFC 1 in fact represent a pre- 
CFU-S population, and are probably the most primitive colony forming 
haemopoietic cell type detectable in vitro.
1.2.4 The CPU-A assay
This assay detects a primitive haemopoietic progenitor similar if not 
identical to day 12 CFU-S (Pragnell et at 1988, Lorimore et at 1990). The 
development of this assay has been successfully used to examine a number of 
regulators of stem cell proliferation, and was used as a screening assay during 
purification to homogeneity of the stem cell inhibitor macrophage inflammatory 
protein-la (Graham et al 1990). The assay is set up using two layers of agar
medium, of which the underlayer consists of a 0.6% agar/medium mixture 
containing the growth factors and additives. Conditioned medium from the cell 
line L929 is used primarily as a source of the growth factor M-CSF while 
conditioned medium from the cell line AF-1 is used primarily as a source of GM- 
CSF. These molecules are believed to act in synergy to promote colony formation. 
However, Holyoake et al (1993a) have recently shown that stem cell factor (SCF) 
is also required in the human equivalent of the CFU-A assay. The top layer 
consists of 0.3% agar and normal bone marrow cells. When incubated at 37®C/5% 
O2 for 11 days, these conditions give rise to the formation of macroscopic colonies 
(>2mm) comprised of several haemopoietic lineages including macrophages, 
granulocytes and megakaryocytes.
1.2.5 Long term bone marrow cultures (LTBMC)
Long term bone marrow cultures represent a novel in vitro culture system 
which involves adding fresh normal bone marrow cells into a tissue culture flask. 
This results, under the appropriate conditions, in the formation of an adherent 
stromal layer on the surface of the dish which is capable of maintaining 
haemopoiesis. The resultant cultures displayed haemopoietic characteristics, and 
indeed, the presence of all stages of CFU-S cells persisted at readily detectable 
levels for many weeks, even in the absence of added growth factors (Dexter and 
Spooncer 1987, Schofield and Dexter 1985). Further, Frazer et al (1991) have 
demonstrated that cells with long term repopulating potential in vivo, and with 
both lymphoid and myeloid repopulating ability are also maintained for many 
weeks. Thus, LTBMC appear to successfully recreate the bone marrow 
microenvironment in vitro. This assay system has since proved invaluable for 
assessing the potential in vivo roles of many positive and negative regulators of 
haemopoietic stem cell proliferation and differentiation (Kittler et al 1992, Eaves et 
al 1991). Another feature of LTBMC worth noting is that studies with 
subpopulations of both human and murine bone marrow cells have shown that 
clonogenic committed progenitors rapidly undergo terminal differentiation in these
conditions. Those which were initially present have disappeared after 
approximately four weeks, and the clonogenic progenitors detected after this time 
period are derived from more primitive cell types termed long term culture 
initiating cells (LTC-IC) (Van der Sluijs et al 1990, Winton and Colenda 1987, 
Sutherland et al 1988). LTC-IC can therefore be quantitated by the number of 
clonogenic progenitors present in the cultures after five weeks, and have also been 
more accurately estimated using limiting dilution techniques. Indeed, LTC-IC 
have been shown to be present at 1 in 2x1 O'* nucleated cells in normal bone marrow 
aspirates (Udomsakdi et al 1992), but the proliferative potential of each LTC-IC 
has also been shown to be highly variable suggesting that the LTC-IC population 
detected using these techniques may be, and almost certainly is, heterogeneous. It 
should be noted that LTC-IC and pre-CFU-S are likely to be identical.
1.2.6 Is there a need for long term repopulating cells?
Whilst the in vitro assays described above clearly demonstrate the 
heterogeneity which exists within the stem cell compartment, it is still unclear what 
contribution cells from each sub-population of the overall compartment make to 
steady state haemopoiesis. It is conceivable for example that long term 
repopulating cells are never actually required throughout normal adult life in order 
to maintain a healthy haemopoietic state, and that mature blood cell production is 
predominantly controlled at the level of CFU-S type cells, or even at the level of 
more mature progenitor cells.
1.3 Progenitor cells
Stem cell division can yield, other than identical stem cells, committed 
progenitors of the megakaryocytic, lymphoid, erythrocytic and myeloid lineages. 
These cells differ from stem cells in that they have a much reduced proliferative 
capacity, and can only further differentiate into one or at most two mature cell 
types. As described above, our knowledge of both stem and progenitor cell types 
is derived from a series of in vitro assays. Progenitor cells are recognised by their
8ability to form colonies containing one or more blood cell types in semi-solid tissue 
culture medium containing agar or methylcellulose and an appropriate "cocktail" of 
growth factors. Originally, cells from blood forming tissues were cultured with 
"feeder layers" containing other cell types such as normal embryo fibroblasts 
(Sachs 1992). These were chosen as possible candidates for the cells which can 
produce the regulatory molecules required for blood cell formation. This work led 
to the discovery of clonogenic cells capable of giving rise to colonies containing 
macrophages, granulocytes or both in various stages of differentiation (reviewed in 
Sachs 1992). Colony assays, similar in principle to this, have now been developed 
for many of the other identified haemopoietic lineages (Metcalf 1984). The mature 
cell types present in the colonies formed in each of these assay systems were used 
to name each of the corresponding progenitor cell types from which they were 
derived. For example, cells giving rise to colonies containing granulocytes and 
macrophages are called CFU-GM or colony forming unit granulocyte-macrophage. 
Concomitantly, these assays also led to the discovery and ultimate cloning of 
soluble factors which may be required for the proliferation, differentiation and 
survival of the progenitor cells under in vitro conditions. These shall be discussed 
in more detail in the following sections.
1.4 Mature End Cells
The ultimate progeny of the stem and progenitor cell compartments are the 
mature end cells. These cells exhibit a remarkable range of functions ranging from 
non specific and specific host defence to oxygen distribution throughout the body. 
At least 8 major cell types are currently recognised (See figure 1.1), although 
others such as Langerhans cells in the skin are also known to be of haemopoietic 
origin. The functions of each of these cell types will not be discussed in detail in 
the text unless relevant.
1.5 Haemopoietic growth factors
A vast array of soluble factors capable of affecting haemopoietic cell 
growth and differentiation have been identified in the past few years. For myeloid 
colony formation, four different proteins were identified initially which induced 
colony formation. These were macrophage colony stimulating factor (M-CSF), 
granulocyte CSF (G-CSF), granulocyte-macrophage CSF (GM-CSF) and 
interleukin 3 (IL-3) (reviewed in Sachs 1992). IL-3 can stimulate formation of 
colonies containing granulocytes, macrophages, eosinophils, mast cells, erythroid 
cells or megakaryocytes. Recently, a number of other growth factors have been 
identified which also appear to play a role in haemopoietic development including 
stem cell factor (Williams et al 1990a, Copeland et al 1990), thrombopoietin or 
megakaryocyte colony stimulating factor (Lok et al 1994, De Sauvage et al 1994, 
Wendling et al 1994), erythropoietin (reviewed in Ridley et al 1994), and a host of 
molecules termed interleukins. It has become clear from studies analysing the 
actions of the haemopoietic growth factors that, although some of them e.g. IL-3 
can support limited survival of stem cells (Kittler et al 1992), combinations of 
various factors are required for optimum proliferation and differentiation induction 
(Quesenberry 1992a,b).
It is still unclear what overall role growth factors and cytokines play in 
regulation of haemopoiesis, and a number of hypotheses have been proposed. It is 
possible for example that they may direct primitive cells to differentiate along one 
or another lineage e.g. erythropoietin would stimulate production of erythrocytes 
and G-CSF production of neutrophils. It is also possible however that they may 
just be "happiness" factors required to prevent the cells from apoptotic cell death 
(Koury 1992, Williams et al 1990b), and they are not in fact required to instruct 
stem and progenitor cells to differentiate into multiple lineages. The stem cells may 
simply follow a "preprogrammed" pattern of proliferation and differentiation as 
long as the necessary "happiness" factors are present. In agreement with this 
possibility, Fairbaim et al (1993) transfected murine FDCP-MIX cells, an IL-3 
dependent, multipotent haemopoietic cell line with the human bcl-2 gene. The bel-
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2 protein has been demonstrated to be involved in suppressing apoptosis. Indeed, 
FDCP-MIX cells transfected with this gene become less dependent on IL-3 for 
survival, and further, are capable of multilineage differentiation in the absence of 
added growth factors. This data suggests that stem cell differentiation may be 
intrinsically determined, and that the presence of growth factors is enabling rather 
than inductive. It should be noted however that horse serum used in these 
experiments was capable of affecting the differentiation outcome of the cells 
suggesting that some factors present in the serum are capable of instructive 
interference.
Although this intrinsically determined stem cell differentiation pathway may 
be operating, studies using mice defective for certain growth factors have 
suggested that the presence of these factors may still be required in vivo for certain 
differentiation steps. For example, mice deficient for G-CSF suffered severe 
neutropenia which was fully reversible upon addition of exogenous G-CSF 
(Lieschke et al 1994a). Low levels of mature neutrophils were still present in the 
peripheral blood of these mice however, indicating that other factors are capable of 
compensating for the lack of G-CSF to some extent. Presumably however, 
absence of these other factors also would result in absolute neutrophil deficiency, 
stressing the importance of growth factors in normal haemopoietic development. 
Indeed, mice deficient for both M-CSF and GM-CSF exhibit symptoms common to 
both the M-CSF and the GM-CSF deficient mice (Stanley et al 1994) alone such as 
defects in osteoclast and macrophage formation (op/op M-CSF deficient mice), 
and alveolar-proteinosis-like lung pathology (GM-CSF knockout) (Lieschke et al 
1994b). Further, both Steel (SI) and white spotting (W) anaemic mice, now known 
to be deficient in stem cell factor and c-kit, its receptor, respectively, have some 
similar phenotypic abnormalities including severe anaemia and deficient activity of 
very primitive haemopoietic stem cells (Russell 1979). Gurney et al (1994) have 
generated c-mpl-deficient mice. C-mpl is the receptor for thrombopoietin, and 
these mice suffered from an 85% decrease in platelets and megakaryocytes but had
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normal amounts of other haemopoietic cell types, demonstrating the importance of 
c-mpl, and indeed thrombopoietin in megakaryocytopoiesis.
1.5.1 Functional redundancy between positive growth factors?
As mentioned above, very few growth factors are capable of stimulating 
proliferation of primitive haemopoietic cells on their own. A combination of two 
or more growth factors is required. It has become apparent from the many studies 
analysing growth factor actions on haemopoietic cells that there is considerable 
overlap in their activities. For example, IL-6, leukaemia inhibitory factor (LIF) and 
IL-11 all share pleiotropic actions on haemopoietic stem cells and hepatic cells. 
This is not fully understood but may arise from the fact that the receptors for these 
molecules all share a common (3 chain called gpl30 (Miyajima et al 1993). In fact, 
receptor subunit sharing is a common feature of the haemopoietic growth factor 
receptor family, and may indeed explain the apparent functional redundancy 
between certain members (e.g. GM-CSF, IL-3 and IL-5 (Miyajima et al 1992)). It 
should be noted however that the term redundancy used by many workers may be 
misleading, and that more detailed analysis of the precise signal transduction 
pathway of each of the haemopoietic growth factors may reveal subtle but 
important differences in their functions.
Studies of growth factor receptor expression on primitive haemopoietic 
cells has suggested that there may be some hierarchical response structure to the 
synergistically acting haemopoietic growth factors. That is, cells may 
predominantly respond to one factor initially, and this results in upregulation of 
specific receptors for a different molecule and so on. Bone marrow progenitor 
cells express relatively low levels of growth factor receptors, and thus any change 
in number or affinity of these receptors could be manifest as an altered biological 
response. Jacobsen et al (1992) have shown that the synergistic effect of growth 
factors on colony formation by lin- cells is preceded by an increase in growth factor 
receptor expression. For example, the synergistic stimulatory effect apparent 
between G-CSF and GM-CSF in their system was preceded by an upregulation of
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GM-CSF receptors of 300%. This effect was apparent at the single cell level and 
interestingly, combinations of growth factors which did not synergise failed to 
upregulate receptor expression. They further showed that preincubating lin- cells 
with IL-1, IL-6, and IL-3 was also capable of increasing GM-CSF induced colony 
formation. As will be discussed in the following sections, modulation of growth 
factor receptors has also been proposed as a potential mechanism through which 
negative regulators of stem cell proliferation may act.
When discussing the roles of growth factors in haemopoiesis, one also has 
to consider the origin of such factors, and indeed if they are actually present in sites 
of haemopoiesis.
1.6 The role of stroma in haemopoiesis
Long term bone marrow cultures, mentioned above, clearly indicate the 
importance of other cell types in maintaining haemopoiesis in the absence of added 
growth factors. These cultures suggest that an intimate relationship between 
primitive haemopoietic cells and stromal cells occurs in vivo. This relationship 
does not require direct cell-cell contact however, and Verfaille et al (1992) have 
shown that stromal cells separated from haemopoietic cells by a thin porous mesh 
can still support haemopoiesis in LTBMC. This suggests that the stromal cells are 
producing soluble factors required for maintenance of haemopoiesis. As shall be 
discussed below, detection of these factors in vivo and in LTBMCs has proved, in 
many cases, difficult.
The bone marrow stroma is composed of extracellular matrix and multiple 
cell types including fibroblasts, macrophages, reticular adventitial cells, endothelial 
and epithelial cells (reviewed in Quesenberry & Lowry 1992). Using LTBMC as a 
model, attempts to detect mRNA expression and protein production of various 
candidate growth factors thought to play a role in maintenance of haemopoiesis 
have largely produced negative results. For example, several groups have 
attempted to detect both mRNA and protein of a wide range of growth factors, but 
could only detect constitutive expression of M-CSF and SCF (Piersma et al 1984,
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Fibbe et al 1988, Sieff et al 1988, Schaafsma et al 1989, Kittler et al 1992). 
Expression of other cytokines such as IL-6, IL-7, G-CSF, GM-CSF is detectable, 
but only after stimulation implying that the presence of these molecules in the 
steady state situation will be very low (Gualtiera et al 1984, Quesenberry et al
1990). Interestingly, IL-3 has only been detected in LTBMC using sensitive 
polymerase chain reaction (PCR) techniques (Kittler et al 1992). Addition of 
antibodies directed against IL-3 and GM-CSF to haemopoietic cell depleted 
stromal cells however results in abolition of the ability of these cells to support the 
growth of factor dependent haemopoietic cells (Kittler et al 1992). Thus, it 
appears that although many of the positive growth factors may be undetectable in 
LTBMC and normal bone marrow by conventional techniques, their actual 
presence there cannot be discounted. It has been suggested that in the bone 
marrow microenvironment, the stem cell resides in a niche in close association with 
stromal cells (Schofield 1979). Production of growth factors by these stromal cells 
may be very low overall in the bone marrow (thus avoiding detection), but may be 
relatively high in the close proximity of the stem cells (thus fulfilling their assumed 
role).
Another interesting observation is that many growth factors exist in 
biologically active membrane or ECM bound forms. For example, IL-1, M-CSF 
and SCF exist in both soluble and membrane anchored forms (Kurt-Jones et al 
1985, Stein et al 1990). Some growth factors are also capable of binding to ECM 
components e.g. GM-CSF, IL-3 and LIF where they are then presented to their 
specific cell surface receptors in an active form (Gordon et al 1987, Roberts et al 
1988). These observations again suggest that growth factors are important in 
maintenance of haemopoiesis, and yet remain undetectable at the protein level by 
virtue of the fact that they may be bound rather than exist in soluble forms.
CHAPTER 2
INTRODUCTION
INHIBITION OF HAEMOPOIETIC STEM 
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CHAPTER 2 - INHIBITION OF HAEMOPOIETIC STEM CELL 
PROLIFERATION
2.1 Inhibition of haemopoietic stem cell proliferation
The need for negative regulation of stem cell proliferation has been 
questioned. For example, one can postulate that only either positive or negative 
regulators are required to fully control the proliferation kinetics of a cellular 
population. Simply put, this hypothesis argues that upregulation of positive 
regulators will result in increased proliferation whereas downregulation of positive 
regulators will result in decreased proliferation and vice versa for negative 
regulators. However, this argument does not adequately explain the situation 
which occurs in regenerating bone marrow situations. In regenerating bone 
marrow, even the most primitive stem cells are actively cycling (Harrison & 
Lemer 1991) presumably in the presence of high levels of growth factor required 
to stimulate the stem cell. The fact that these primitive stem cells can rapidly 
return to quiescence suggests the presence of molecules which actively inhibit the 
cell cycle, rather than the gradual reduction in positive regulators which would 
result in a much slower return to quiescence. Further, it has been demonstrated 
that primitive haemopoietic cells undergo apoptosis when deprived of positive 
growth factors again suggesting a role for active inhibitors of proliferation (Bendall 
et al 1994, Cowling and Dexter 1994, Fairbaim et al 1993, Muta and Krantz
1993).
As well as the evidence suggesting that stimulation of stem cell 
proliferation is important in haemopoiesis, a number of molecules have been 
identified recently which are capable of inhibiting proliferation of stem cells. As 
shall be discussed below, these molecules include the tetrapeptide (AcSDKP), the 
haemoregulatory peptide (pEEDCK), transforming growth factor beta (TGF-|3) 
and macrophage inflammatory protein 1 alpha (MIP-la). Like the positive growth 
factors, some of these molecules are capable of affecting proliferation and function
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of cells from the stem, progenitor and mature cell compartments, and indeed 
appear to have considerable overlap in some of their actions.
2.2 Tetrapeptide inhibitor
Frindel and Guigon (1977) first described a low molecular weight activity 
present in foetal calf bone marrow extracts which has the ability to inhibit the entry 
of murine bone marrow CFU-S into DNA synthesis following irradiation. They 
subsequently went on to show that this activity could also increase the long term 
survival of mice which had received lethal doses of cytosine arabinoside (AraC), a 
phase specific cytotoxic drug and that this was due to a specific protective effect 
on bone marrow CFU-S (Guigon et al 1981). The active molecule was later 
purified and identified as a tetrapeptide, with the amino acid sequence acetyl-ser- 
asp-lys-pro (AcSDKP) (Lenfantc^a/ 1989).
Presently, it is unclear as to the origin of this small peptide in vivo but 
current evidence supports proteolytic cleavage of a larger precursor molecule 
which contains the SDKP sequence. Several candidate molecules have been 
identified which contain this sequence including rat phenylalanine hydroxylase, 
human and murine tumour necrosis factor a  (TNF-a), human retinal S antigen, 
human amphiregulin and rat, porcine, human and murine thymosin (34 (T(34). Only 
T(34 however contains the sequence at its N-terminus and not internal to its protein 
chain suggesting T(34 to be a possible candidate for the precursor molecule. Also, 
the SDKP sequence is acetylated in the thymosin (34 chain. Lenfant et al (1991) 
have demonstrated that AcSDKP can be formed in the bone marrow by one-step 
enzymatic processing of T(34, and have further demonstrated that this can be 
achieved using the endopeptidase Asp-N.
Due to the potential role of this peptide as a protector of the stem cell 
compartment during chemotherapy using phase specific drugs, much research has 
concentrated on elucidating its mode of action in inhibiting stem cell proliferation. 
The tetrapeptide appears only to exhibit an inhibitory effect on the CFU-S stage of 
the stem cell compartment (Monpezat and Frindel 1989, Bonnet et al 1993).
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AcSDKP had no effect on the proliferation of isolated adult rat hepatocytes, 3T3, 
FDC-P2 or K562 cells (Lauret et al 1989). Further, no effect of AcSDKP can be 
detected on committed GM-CFC progenitors, with respect to either colony 
formation or the proportion of cells in DNA synthesis. The cell cycle specificity of 
AcSDKP has been investigated, and it has been shown that the peptide is only 
capable of inhibiting CFU-S when they are in the early part of G1 or at the Go-Gl 
boundary, not the Gl-S transition or once the cells have entered S phase. This 
suggests that AcSDKP is only capable of preventing quiescent cells from entering 
the cell cycle and is not able to actively inhibit cycling cells. Indeed, work by 
Robinson et al (1993) demonstrated that AcSDKP had no effect on cycling 
populations of murine HPP-CFC, but could prevent quiescent HPP-CFC entry into 
cell cycle when treated with a stimulator of haemopoietic stem cell proliferation 
(Lord et al 1977). These observations may also explain the inability of the 
tetrapeptide to inhibit proliferation of haemopoietic cell lines and committed 
progenitors which are in active cell cycle.
AcSDKP is detectable in both serum and bone marrow of mice and is also 
produced by bone marrow cells in long-term bone marrow cultures (Wdzieczak- 
Bakala et al 1990). AcSDKP like activity has also been detected in both human 
placenta (Lopez et al 1991) and in human white blood cells (Pradelles et al 1990) 
demonstrating a potential physiological role in man. To further investigate the 
potential physiological role of this peptide, Frindel and Monpezat (1989) injected 
polyclonal antiserum raised against AcSDKP into untreated normal mice to 
neutralise endogenous levels of the inhibitor. They observed a dramatic increase in 
the number of CFU-S cycling in the anti-AcSDKP treated animals suggesting 
AcSDKP to be an important physiological regulator of CFU-S proliferation in the 
bone marrow. Further, it appears that levels of AcSDKP in plasma decrease after 
AraC treatment, and that this precedes CFU-S entry into cell cycle suggesting a 
correlation between endogenous AcSDKP levels and CFU-S kinetics (Frindel et al
1992). Recently, Cashman et al (1994) have shown that AcSDKP reversibly 
inhibits high proliferative potential erythroid and granulocytic progenitors in the
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adherent layer of long term bone marrow cultures (LTBMC) without changing 
their numbers. The inhibitory activity of AcSDKP could be abrogated by addition 
of macrophage inflammatory protein 1(3, an antagonist of the stem cell inhibitor 
MIP-la suggesting an indirect mechanism of inhibition via MIP-la. However, no 
increase in either MIP-la mRNA or protein could be detected after AcSDKP 
treatment of cultures. It is still possible that AcSDKP acts indirectly by 
upregulating agonists of MIP-la, or MIP-la related chemokines, but this awaits 
further study.
It appears that AcSDKP has a role to play in maintaining steady state 
haemopoiesis, but it is unlikely that it acts alone in this regard since many other 
negative regulators of CFU-S proliferation have been described (see below). The 
exact role of each however in the overall control of haemopoiesis remains 
uncertain. Interestingly, AcSDKP was inactive on both cycling activity and 
numbers of neoplastic cells in CML LTBMCs perhaps suggesting that lack of 
responsiveness to AcSDKP could contribute to the CML phenotype (Cashman et 
al 1994).
2.3 Haemoregulatory peptide
In 1984, Laerum and Paukovits described the structure of a pentapeptide 
which reversibly inhibited myelopoiesis in vivo and in vitro. This peptide was 
isolated from human leukocytes and has the amino acid sequence pyro-Glu-Glu- 
Asp-Cys-Lys (pEEDCK). Subsequently, a similar peptide (pGlu-Glu-Asp-Ser-Gly) 
was isolated from mouse epidermis which had the ability to reversibly inhibit 
epidermal cell proliferation in vivo and in vitro (Elgjo and Reichelt 1984).
Characterisation of the haemoregulatory peptide has shown that it can exist 
in two forms, a monomer and a dimer. The dimer arises through oxidation of the 
cysteine thiol groups of pEEDCK leading to formation of a disulphide bridged 
homodimer (pEEDCK)2. It is now apparent that the pEEDCK monomer is active 
as an inhibitor of haemopoietic cells both in vivo and in vitro. Interestingly, the 
dimer is active as a stimulator of these cells suggesting that a balance between
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monomer and dimer is involved in controlling aspects of haemopoiesis. Synthetic 
and stable forms of both the pEEDCK monomer and dimer have been 
manufactured and are functionally identical to their native counterparts.
In vitro, the monomer is active in inhibiting both murine and human CFU- 
GM in a dose dependent manner (Laerum and Paukovits 1984, Kreja et al 1986, 
Laerum et al 1987, Laerum et al 1990), with inhibition being seen at 
concentrations as low as IG'^^M. In vivo, CFU-GM numbers are decreased 
following either injection or continuous administration of the monomer, as are 
CFU-S numbers but to a lesser extent. Prolonged monomer application leads to 
reduced numbers of CFU-S and CFU-GM in the femora of mice which is later 
reflected in the mature compartments of haemopoiesis in the periphery (Laerum 
and Paukovits 1984). Further, Paukovits et al (1990) have shown that pEEDCK 
can inhibit CFU-S recruitment into cell cycle following repeated high doses of the 
phase specific drug AraC. A physiological role for pEEDCK has been suggested 
by Paukovits et al since ablation of endogenous peptide levels by immunisation 
leads to an increase in the numbers of CFU-GM progenitors.
The (pEEDCK)2 dimer stimulates the formation of both murine and human 
CFU-GM colonies in a dose dependent manner in vitro. This effect is dependent 
on the presence of the colony stimulating factor GM-CSF however, since no 
stimulation of colonies occurs with the dimer alone. The dimer has also been 
tested for biological effects on a range of normal and malignant cell types (Frostad 
et al 1993). This study concluded that the dimer is an in vitro stimulator of CFU- 
GM with little or no effect apparent on other cell types. In vivo, the dimer 
stimulates an increase in CFU-GM and CFU-S numbers in the femurs and spleens 
of mice, but has little effect on mature granulocytic numbers in the peripheral blood 
(Laerum and Paukovits 1989). As mentioned above, the marked opposing effects 
of the monomer and dimer of pEEDCK have led workers in this field to suggest 
that a fine balance between these forms is involved in controlling stem and 
progenitor cell proliferation. This implies that the haemoregulatory peptide may be 
a valuable myeloprotective agent for use during cancer chemotherapy whereby the
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inhibitor (monomer) protects the stem and progenitor cell compartments during 
drug administration, and then the stimulator (dimer) can enhance recovery of 
mature cells and reduce neutropenia. Indeed, Paukovits et al (1991) have shown 
that administration of pEEDCK with repeated (twice) clinically relevant doses of 
Ara-C results in a sustained number of CFU-S in the bone marrow of mice. Mice 
which did not receive pEEDCK suffered CFU-S losses of approximately 75%. 
(pEEDCK)2 administration during the second injection of Ara-C delayed the onset 
of neutropenia by 2-3 days and improved recovery after depression. It should be 
mentioned however, that cell cycle specific cytotoxic drugs are not widely used in 
cancer chemotherapy and thus the usefulness of the pentapeptide, and indeed the 
other inhibitors discussed here, in protection of normal cycling cells from 
chemotherapeutic damage may be somewhat limited.
Available data indicate that, unlike the tetrapeptide inhibitor discussed 
above, the pentapeptide is capable of exerting its inhibitory effects on cells 
regardless of their cell cycle stage, including S phase. The mechanism by which the 
pentapeptide exerts these effects is still unclear. Paukovits and Paukovits (1975) 
have shown that cell surface proteins are necessary for its inhibitory action and, by 
using a labelled pentapeptide, it appears that murine bone marrow cells but not 
thymic or spleen cells are capable of taking up the molecule (Eriksen et al 1987). 
pEEDCK has been shown to be a sequence motif present in the effector domain of 
Gi alpha proteins. However, the significance of this observation and indeed the 
origin of the pentapeptide in vivo is unclear.
2.4 Transforming Growth Factor beta (TGF-p)
The TGF-p superfamily encompasses a large and increasing number of 
structurally related cytokines with highly diverse activities (Massague 1990, 
Kingsley 1994). Members of this family are related by sequence homology to the 
prototype TGF-pi, the most conserved feature being the spacing of nine cysteine 
residues within the mature carboxy terminus. The members of the TGF-p 
superfamily have been isolated from several different species ranging from insect to
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man. It is remarkable however that sequence identity between homologues from 
different species is very high (usually greater than 95% from mouse to human) 
suggesting TGF-p to have a fundamental role in the normal physiology of several 
species. It is now apparent that this family of molecules contains several 
subfamilies whose members are more related to each other than to other members 
of the superfamily (Figure 1.2). These shall be outlined below.
2.4.1 Transforming growth factors beta
This subfamily consist of at least five members, termed TGF-pi, -p2, -p3, 
-P4 and ~p5 which have been isolated from several different species. The 
prototype TGF-pl was originally isolated from human platelets (Assoian et al 
1983), and subsequently cloned from a human cDNA library (Derynck et al 1985) 
and analysed (Derynck et al 1986). TGF-P2 and -p3 have also been identified in 
humans and other mammals at both the cDNA and protein level (reviewed in 
Massague 1990). TGF-P4 cDNA has only been detected in chicks (Jakowlew et al 
1988) although recent studies have suggested that it is probably the chick 
homologue of mammalian TGF-pl (Burt and Paton 1992, Burt and Law 1994). 
TGF-P5 was identified as a cDNA ixomXenopus Laevis (Kondaiah et al 1990) and 
as yet, no mammalian homologue has been found. The TGF-ps have highly diverse 
activities involving both positive and negative effects (see below) on various 
developmental and mature cell systems. For example, TGF-p has been found to 
induce angiogenesis (Roberts et al 1986), chondrogenesis (Seyedin et al 1985) and 
osteogenesis (Seyedin et al 1987). It can also regulate cellular differentiation and 
proliferation positively or negatively depending on the cell type and growth 
conditions. TGF-p has been implicated in wound repair and fibrosis, since it 
specifically attracts immune cells into the wound site and acts to upregulate 
extracellular matrix (ECM) components and downregulate degraders of ECM 
(reviewed in Massague 1990). TGF-p also has a role in haemopoiesis (Ruscetti et 
û / 1991) which shall be discussed below.
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Figure 1.2 Structure of the TGF-(5 superfamily and percentage 
identity between members
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2.4.2 Inhibîns and Activîns
This family consists of three genes coding for peptides named inhibin |3A 
subunit, inhibin |3B subunit and inhibin a. The products of these genes can 
dimerise via disulphide bridging and form a number of active polypeptides. 
Inhibins are formed through dimérisation of either the |3A or the (3B subunit with 
the inhibin a  subunit yielding inhibin A and inhibin B respectively. Activins are 
formed through dimérisation of (3A-pA subunits generating activin A, pB-pB 
subunits generating activin B, or pA-pB subunits generating activin AB. Activins 
and inhibins were initially characterised as gonadal proteins having the ability to 
stimulate or inhibit respectively the release of follicular stimulating hormone from 
pituitary cells (Vale et al 1986, Ling et al 1986). Homodimeric activin A was also 
independently isolated as a factor produced by human leukaemia cells with the 
capacity to induce erythroleukaemic cell differentiation (Eto et al 1987). 
Interestingly, this action is also antagonised by inhibins, as are other activin 
functions, suggesting that a fine balance between them controls their effects. It has 
been suggested that this antagonistic activity by inhibin is due to competition for 
the same cell surface binding sites. However, a study by Kondo et al (1989) has 
shown that although inhibin can compete with labelled activin for binding to 
specific sites on the cell surface, the affinity with which it binds does not explain its 
highly potent antagonistic activities. It is possible that activin and inhibin may bind 
to distinct cell surface receptors.
It is now apparent that these molecules have a much wider range of 
biological activities, with their gene expression being detected in various tissues 
(Meunier et al 1988). Activin in particular has been shown to be involved in cell 
differentiation. It is capable of inducing human erythroid differentiation and 
stimulating erythroid colony formation in in vitro assays, and also of stimulating 
multipotential progenitor cells in vitro (Yu et al 1987). Inhibin acts 
antagonistically in this context also. Activin has also been suggested to play a 
major role in embryonic development. It has been shown that activin A can 
promote mesoderm formation in the frog Xenopus Laevis (Rupp and Weintraub
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1991). Further, activin A can induce various blood cell types, muscle and 
notochordal tissue from animal caps of Xenopus Laevis in a dose dependent 
manner (Green and Smith 1990). It is unclear what role activin plays in 
development in higher vertebrates, but Albano et al (1993) have demonstrated 
mRNA expression of all three inhibin subunits in the murine oocyte, and have also 
shown that activin protein, but not inhibin, can be detected after the fertilised egg 
stage. High levels of pA and pB mRNA were detected in embryonal stem (ES) 
cell lines, but these levels diminished upon induction of differentiation which is 
consistent with activins proposed role as a regulator of mesoderm induction and 
early developmental processes. Recently, transgenic mice have been generated 
carrying a disrupted pB subunit gene. The phenotype of these animals is 
remarkably mild considering the proposed role of activin in development, with the 
only noticeable defects being that the animals are infertile and have precocious 
eyelid opening (Vassalli et al 1994). Further, Matzuk et al (1995a) have 
demonstrated mice deficient for the pA subunit develop to term but die within 
24hrs of birth. These mice lack whiskers and lower incisors and have secondary 
palate defects indicating that activin-pA has a role in craniofacial development. 
Mice deficient for both activin pA and activin pB have a phenotype representative 
of both individual knockouts, but with no additional abnormalities. To further 
investigate the potential role of activin in development, Matzuk et al (1995c) 
generated mice deficient for follistatin, an activin binding protein and antagonist. 
Interestingly, these mice developed many more defects than the activin deficient 
mice suggesting that follistatin may modulate the actions of several other members 
of the TGF-p superfamily.
Specific receptors for activin have recently been isolated which belong to a 
novel family of transmembrane receptors which have a highly characteristic 
serine/threonine kinase domain on their cytoplasmic surface (Massague et al 1992, 
Lin and Lodish 1993). These receptors shall be discussed in section 2.4.8.1. 
Matzuk et al (1995b) have generated mice deficient for the type II activin receptor 
(ActRcII) and demonstrated a phenotype quite different from mice deficient in
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activin ligand. These mice suffered reduced follicular stimulating hormone 
production and their reproductive performance was defective suggesting a role for 
ActRcn in activin signalling in pituitary gonadotrophs.
2.4.3 The DVR group
This subgroup derives its name from the fact that its members are related to 
the decapentaplegic (DPP) and Vgl products (hence ÜPP and Xgl related). DPP 
is involved in embryonic and larval pattern formation in drosophila (Spencer et al 
1982, Ferguson et al 1992), and two mammalian homologues of DPP have been 
found; bone morphogenetic protein 2 (BMP-2) and BMP-4. BMPs (BMP-2 
through to BMP-8) have the capacity to induce cartilage and bone formation 
(Wang et al 1990). Interestingly, purified samples of DPP protein are also capable 
of exhibiting this activity (Sampath et al 1990) indicating functional as well as 
structural conservation. The BMPs have also been implicated in tissue modelling 
during development (Hogan et al 1994). Interestingly, BMPs may have potential 
clinical roles, particularly in bone healing and repair. Vgl is involved in embryonic 
development in Xenopus Laevis. Other more distant members of this group, 
including growth differentiation factor 1 (GDF-1), GDF-3, dorsalin and nodal have 
all been shown to be involved in embryonic development but shall not be discussed.
2.4.4 Mullerian Inhibiting Substance (MIS)
MIS is distantly related to other members of the TGF-(3 superfamily. It is 
produced in the testes and was identified and purified based on its ability to induce 
regression of the female mullerian ducts in mammalian male embryos (Munsterburg 
and Lovell-Badge 1991). It may also play in a role in development of female 
reproductive organs in the adult female ovary.
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2.4.5 Structure and Biology of Transforming Growth Factor beta
2.4.5.1 Structure of TGF-p proteins - TGF-p is secreted as a latent complex
Structure of TGF-p related proteins is based on the prototype TGF-pi. 
Mature active TGF-pi is a disulphide linked dimer of two identical chains each 
composed of 112 amino acids (2 x 12.5 kD). However, recombinant TGF-pi is 
expressed in mammalian cells as an inactive 105kD precursor known as the small 
latent complex or pro-TGF-p (Gentry et al 1988, Wakefield et al 1988). The 
precursor consists of an N-terminal signal sequence, a pro-region and the C- 
terminal bioactive domain. The pro-region (residues 30-278) is also known as the 
latency associated peptide (LAP 75-80kD), and this too consists of two identical 
disulphide linked chains. The hydrophobic signal sequence is required for transport 
across the endoplasmic reticulum, but is cleaved prior to secretion. LAP is 
proteolytically cleaved from the complex at a basic site immediately preceding the 
bioactive C-terminal domain in a post-golgi compartment. However, it remains 
associated with the bioactive domain after secretion via non-covalent interactions 
yielding an inactive complex (Gentry et al 1988). The small latent complex of 
TGF-pi has been detected in the conditioned media of a number of cell types 
including bone cultures (Jennings and Mohan 1990, Bonewald et al 1991), a 
human erythroleukaemic cell line (Lioubin et al 1991) and a human glioblastoma 
cell line (Olofsson et al 1992), and it is likely that it is ubiquitously expressed.
Another form of latent TGF-(3 has been detected in human platelets 
(Wakefield et al 1988 and Pircher et al 1986), and certain cell lines. This 
complex consists of the small latent TGF-|3 complex bound via disulphide bonds 
from a LAP monomer to a 125-190 kD glycoprotein called latent TGF-|3 binding 
protein (LTBP). The function of LTBP is not clear at present, however it may be 
involved in assisting the assembly and secretion of the large latent TGF-p complex 
(Miyazono et al 1991), and may also stabilise the latent complex. A role for LTBP 
in assisting TGF-p binding to the cell surface via mannose-6-phosphate residues 
has also been proposed (Taipale et al 1994).
25
2.4.S.2 Activation of Latent TGF-p
As mentioned above, TGF-p is secreted as a latent complex. Studies by 
Lawrence et al (1985) and Pircher et al (1986) have demonstrated that latent TGF- 
P is incapable of binding to cell surface receptors. This suggests that a complex 
control mechanism is involved in activation of TGF-p in vivo in order to avoid 
uncontrolled levels of active TGF-p. The exact mechanism of activation in vivo 
remains largely unknown. In vitro, activation can be achieved by exposure to 
extreme pH (<4 or >9), temperature, by exposure to chaotropic agents such as 
sodium dodecyl sulphate (SDS) or by enzymatic and proteolytic cleavage 
(Lawrence et al 1985, Lyons et al 1988). Although, extreme pH conditions can be 
generated in vivo in some circumstances e.g. bone resorption (Silver et al 1988), it 
appears likely that some form of enzymatic or proteolytic cleavage is involved in in 
vivo activation. A number of enzymes have been shown to activate TGF-p 
including sialidases, endoglycosidase F, neuraminidase and A-glycanase (Brown et 
al 1990, Miyanozo and Heldin 1989). However, the very high concentrations of 
enzyme required for activation make this an unlikely mechanism in vivo.
The best in vitro model for a potentially relevant physiological activation 
mechanism involves proteolysis. Both plasmin and cathepsin D are capable of 
activating TGF-P present in cell conditioned media. The levels of active TGF-p 
generated via plasmin activation are not as high as those which are found after acid 
activation (only around 30%) suggesting differential susceptibilities to proteolysis 
within the latent TGF-p pool. However, as with the other enzymes mentioned 
above, potentially unphysiologically high levels of protease are required for 
activation prompting workers to suggest that some form of biological surface 
mediated activation may occur. It has been shown by various groups that 
plasminogen can be converted to plasmin by plasminogen activator on a number of 
biological surfaces including extracellular matrix (ECM), platelets and endothelial 
cells (reviewed by Harpel et al 1992). Sato et al (1993) have demonstrated that 
TGF-p is activated during co-culture of endothelial cells and smooth muscle cells. 
They further show that plasmin located on the surface of endothelial cells, and the
2 6
targeting of latent TGF-p via the LAP to the surface of the smooth muscle cells are 
required for activation to occur. This represents an attractive model for in vivo 
activation of TGF-p such that its functions will be localised to the site of 
activation, either autocrinely on the activating cells or paracrinely on nearby cells. 
In fact, very little active TGF-p can be detected in plasma, lending further credence 
to this argument. Nearly all active TGF-p which is secreted is quickly bound by 
a2-macroglobulin, an abundant serum glycoprotein (O'Connor-McCourt and 
Wakefield 1987). The function of this interaction is unclear, but may serve as a 
means to remove excess active TGF-p from the periphery. This is important since 
overproduction of active TGF-p has been implicated in a number of disorders 
which shall be discussed below. Grainger et al (1994) have further implicated 
plasmin as a potentially important activator of TGF-p in vivo. They generated 
transgenic mice expressing the human apolipoprotein(a) gene, the product of which 
inhibits the activation of plasminogen to plasmin, and demonstrated that the 
activation of TGF-p was inhibited as a consequence of the inability of these mice to 
generate active plasmin. Schultz-Cherry and Murphy-Ullrich (1993) have 
described a novel mechanism whereby thrombospondin (TSF), an ECM protein, 
activates latent TGF-p secreted by bovine aortic endothelial cells. They have 
further shown that both small and large latent TGF-p molecules form specific 
complexes with TSF. This interaction occurs in the soluble phase, that is, no cell 
surface interactions are necessary, and does not require proteolytic activity. More 
recently, this group have also elucidated which region of TSF is responsible for 
activating latent TGF-p and have shown that the type 1 properdin-like repeats 
localised in the chymotrypsin resistant core of TSF are necessary for this activity 
(Schultz-Cherry et al 1994).
Another interesting observation is that TGF-p itself potentially controls its 
own activation. That is, TGF-p downregulates plasminogen activator expression, 
and strongly upregulates expression of its antagonist plasminogen activator 
inhibitor (Laiho et al 1986). If plasmin is involved in in vivo activation of TGF-p, 
then this suggests that TGF-p downregulates its own activation. Faradoxically,
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TGF-P is a potent upregulator of its own mRNA expression in monocytes 
(McCartney-Francis et al 1990), and this autoinduction is mediated by the AP-1 
complex (Kim et al 1990).
2.4.6 Expression patterns of TGF-p
TGF-P is expressed by an astonishingly wide variety of normal and 
transformed cells in culture (Derynck et al 1985 and reviewed in Spom et al 
1987). Its expression is also found in early mouse embryos suggesting a possible 
role in various aspects of development (reviewed by Mummery and Van Den 
Eijnden-Van Raaij 1993). In the adult mouse, most tissues and organs have been 
shown to express mRNA for TGF-pi, p-2 and/or -p3 (Reviewed by Massague
1990) demonstrating TGF-p to be a highly ubiquitous molecule. In particular, 
mature haemopoietic cells are capable of expressing TGF-p, and it is here that I 
shall concentrate on the role of TGF-P in haemopoiesis.
2.4.7 The Role of TGF-p in Adult Haemopoiesis
A number of mature haemopoietic cells have been shown to synthesise 
TGF-p including activated macrophages (Assoian et al 1987), B lymphocytes 
(Kehrl et al 1986a) and T lymphocytes (Kehrl et al 1986b). Platelets in particular 
are a very rich source of TGF-p (Assoian et al 1983), and indeed TGF-p was 
originally isolated from platelets. The high level of production of TGF-p by 
immune cells suggests that TGF-p may be an important immunological mediator, 
and functional studies have demonstrated that this is almost certainly the case.
2.4.7.1 Immiinological effects of TGF-p
The summation of TGF-ps functions on mature blood cells suggest it to be 
an anti-inflammatory molecule. However in contrast, TGF-p is chemotactic for a 
number of mature cell types, and is in fact the most potent neutrophil 
chemoattractant yet identified (Reibman et al 1991, Gold et al 1990, Parekh et al
1994). TGF-p can also inhibit certain functions of a number of mature
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immunologically active cell types. In vitro, this includes ablation of the ability of 
macrophages to carry out the respiratory burst (via suppression of H2O2 release) 
(Tsunawaki et al 1988), impairment of antibody production by B cells (Kehrl et al
1991) and impairment of cytolytic activity of cytotoxic T cells and NK cells (Inge 
et al 1992, Ranges et al 1987, Rook et al 1986). When administered in vivo, the 
effects apparent are also indicative of TGF-(3s potential function as an endogenous 
immunosuppressant. For example, in rodents, prior injection of TGF-pi protects 
animals from the development of arthritis induced by injection of collagen or 
streptococcal cell wall extracts (Brandes et al 1991 and Kuruvilla et al 1991). 
Also, administration of TGF-p delays rejection of ectopic cardiac transplants 
(Palladino et al 1990). A number of immunosuppressive human diseases have been 
associated with overproduction of TGF-p including glioblastomas, where patients 
often suffer from impaired T cell function. Purification of glioblastoma cell 
conditioned medium led to the isolation of TGF-P2 as the property responsible for 
this impairment (Wrann et al 1987). Overproduction of TGF-p is also apparent in 
individuals with acquired immune deficiency syndrome (AIDS). Peripheral blood 
mononuclear cells isolated from these patients produce excessive levels of TGF-p, 
and these levels correlated with those required to cause T and B cell functional 
impairment (Kekow et al 1990, Kekow et al 1991). Zauü et al (1992) and Lotz et 
al (1994) have further shown that HIV tat protein stimulates production of TGF- 
pi by bone marrow macrophages and human articular chondrocytes.
Perhaps the best and most direct evidence that TGF-p acts as an 
endogenous immunoregulatory molecule comes from the TGF-pl gene disruption 
experiments. Schull et al (1992) and Kulkami et al (1993) disrupted the TGF-pi 
gene by homologous recombination in murine ES cells and generated mice which 
carried the disrupted allele. Surprisingly, these TGF-pl null mice were bom with 
no gross developmental abnormalities perhaps indicating some functional 
redundancy between TGF-pi and its related family members with respect to its 
developmental roles. Alternatively, maternal transfer of TGF-pl across the 
placenta could account for this observation (see below). Approximately three
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weeks after birth, mice homozygous for the disrupted allele experienced severe 
wasting and died. Histological analysis revealed a multifocal, mixed inflammatory 
cell infiltration, often with necrosis. Analysis of cytokine mRNA in liver and lungs 
of both control and TGF-pi deficient mice revealed an upregulation of a number of 
pro-inflammatory cytokines in TGF-pl null mice which could contribute to the 
wasting and inflammatory phenotype observed. These included TNF-a, interferon- 
7 and macrophage inflammatory protein la . It is unclear however whether these 
observations are causative of the phenotype or emerge as a secondary effect of it. 
As mentioned above, TGF-pi has been implicated in controlling T cell function. 
Lack of functional TGF-pi may result in aberrant T cell suppression ultimately 
leading to autoreactivity in the animals. Further, since TGF-pl downregulates 
interferon-7 induced MHC class II expression in both lymphoid and non-lymphoid 
cells, absence of TGF-pi may augment increased MHC class II expression and 
presentation of self antigens to immune competent cells, again leading to 
autoimmunity. Thus, these mice are likely to be invaluable as models of 
autoimmune disease.
Letterio et al (1994) have shown in an elegant series of experiments that 
maternal transfer of TGF-pi does indeed contribute to the apparently normal 
development of the TGF-pi null mice. TGF-pl protein can be detected in TGF-pi 
null pups bom from a heterozygous female, but none can be detected in null pups 
bom from a homozygous TGF-pi negative female. Further, they have shown that 
2^51 labelled TGF-pi crossed the placenta from mother to foetus and that it is taken 
up by cells and bound by extracellular matrices. Null pups bom from a null female 
died perinatally as a result of severe cardiac problems, implicating TGF-pl to be 
important in cardiac development. Indeed, this is in agreement with the 
observations that TGF-p expression is detectable in developing cardiac tissue 
(Massague 1990).
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2.4.7.2 Effects of TGF-p on cell proliferation
Perhaps the most documented property of TGF-p is its ability to affect 
proliferation, either positively or negatively, of a number of cell types. However, 
as well as being a reversible inhibitor of proliferation of some cell types, TGF-p has 
also been implicated in inducing rapid growth arrest followed by apoptosis 
(programmed cell death.). For example, TGF-p induces apoptosis in cultured 
primary hepatocytes (Bursch et al 1993) and in Ml myeloid leukaemia cells 
(Selvakumaran et al 1994a,b). Thus, one has to be cautious when describing TGF- 
P as a reversible inhibitor of cell proliferation because, in many of the published 
cases, this may not necessarily be the case. For the purposes of this work, I shall 
describe below cell types whose proliferation is inhibited by TGF-p.
In vitro, TGF-p can inhibit the growth of epithelial cells (Moses et al 
1985), endothelial cells (Roberts et al 1985), fibroblasts (Sorrentino et al 1989), B 
and T lymphoid cells (Kerhl et al 1986a,b) and haemopoietic progenitor cells (Ohta 
et al 1987, Hampson et al 1989). In vivo, intravenous injection of TGF-pl or 
TGF-pZ had an inhibitory effect on the proliferation of regenerating rat liver 
(Russell et al 1988), and TGF-pi can inhibit growth of epithelial end buds of 
immature mammary glands (Silberstein and Daniel 1987). Further, administration 
of both TGF-pi and TGF-pZ can protect mice from acutely lethal doses of 5-FU 
and doxorubicin (Grzegorzewski et al 1994). TGF-p can also stimulate cell 
growth, and was originally isolated by virtue of the fact that it stimulates 
anchorage-independent growth of certain fibroblasts (Roberts et al 1981). TGF-p 
can also stimulate growth of haemopoietic progenitors as shall be discussed below.
2.4.7.S Effects on the haemopoietic stem and progenitor cell compartments
All three mammalian forms of TGF-p are active in the haemopoietic 
system, with differences being generally quantitative rather than qualitative. In 
general, TGF-p appears to act as a selective inhibitor of primitive multipotent 
progenitors, with little inhibitory effect on more committed haemopoietic cells. 
Indeed, in some cases, TGF-p is in fact stimulatory for more mature cells.
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In 1990, Keller et al demonstrated that TGF-p selectively inhibits colony 
stimulating factor driven haemopoietic progenitor cell growth in mice. Using 
highly enriched populations of progenitor cells, they showed that TGF-p could 
prevent IL-3 induced Thy-1 expression in Thy-l" cells and that this was a direct 
effect. TGF-p is extremely potent in this regard with an ED50 of around 5 to 
lOpM. This data suggests that TGF-p may be active as an inhibitor of 
differentiation as well as proliferation, although in constrast, Krystal et al (1994) 
have recently shown that TGF-pi is active as an inducer of erythroid 
differentiation. Further, Sillaber et al (1992) have demonstrated that TGF-p 
promotes IL-3 dependent differentiation of human basophils, but inhibits IL-3 
driven eosinophil differentiation.
Keller et al (1990) have demonstrated that TGF-p inhibited the 
proliferation of all subpopulations of the primitive HPP-CFC compartment 
suggesting it to play a role in controlling stem cell proliferation throughout the 
stem cell compartment. Hampson et al (1989) have shown that TGF-p suppresses 
the growth of the IL-3 dependent cell line FDCP-MIX. This cell line is non­
transformed, and is capable of generating multilineage colonies in vitro akin to the 
properties ascribed to stem cells. Interestingly, TGF-p had no effect on FDC-Pl or 
FDC-P2 cells which are unable to undergo further differentiation suggesting that 
responsiveness to TGF-p is differentiation linked. Sargiacomo et al (1991) have 
reported a direct inhibitory effect by TGF-p on BFU-E and CFU-GM colony 
formation. Both TGF-pl and TGF-p2 were active, although TGF-pi 
approximately 10 fold more so. Ohta et al (1987) found that TGF-pi was 100 fold 
more potent that TGF-pZ in inhibiting B6SUtA cell multilineage colony formation, 
and that this was probably due to the 20 fold lower affinity of TGF-p2 for binding 
to the specific TGF-p type I receptor.
An obvious problem when interpreting in vitro experiments like these is 
that they are, more often than not, very artificial and may bear little resemblance to 
what actually happens in vivo. For example, the concentrations of exogenous 
TGF-p required to inhibit cells in colony forming assays may be misleading, in that
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it is very difficult to predict in vivo localised concentrations around the actual 
producing and responding cell types. This is especially true with respect to in vitro 
stem cell assays, whereby primitive cells are isolated and then grown in culture 
with a plethora of positive growth factors. It is now widely accepted that a balance 
between positive and negative regulators is involved in controlling haemopoietic 
stem cell proliferation. Indeed, it is apparent that some of the suppressive effects 
of TGF-p on primitive haemopoietic cells can be abrogated by increasing the 
concentrations of certain growth factors. For example, Kishi et al (1989) have 
demonstrated that IL-6 and G-CSF can abrogate TGF-ps inhibitory effects on IL-3 
and Epo dependent murine progenitors from both normal and 5FU treated mice. 
Bradley et al (1991) have also shown that TGF-p inhibits murine HPP-CFC colony 
formation and that this effect is antagonised by increasing concentrations of the 
relevant growth factors.
TGF-p is readily detectable in long term bone marrow cultures (LTBMC). 
Cashman et al (1990) have shown that TGF-p can prevent primitive progenitor cell 
entry into cycle in LTBMCs in response to a variety of growth stimulators. Eaves 
et al (1991) have further shown that adding anti-TGF-p antibodies to LTMC could 
prolong the period of proliferation of previously cycling cells and activate the 
proliferation of quiescent primitive progenitors suggesting TGF-p to have an 
important role in controlling the normal quiescent state of the stem cell 
compartment, both in this assay system and possibly in normal bone marrow.
As well as being a potent inhibitor of primitive haemopoietic cell 
proliferation, TGF-p can also act as a stimulator of more mature lineage restricted 
progenitors (Moses et al 1990). Jacobsen et al (1991a) have shown that TGF-pl 
and -p2 can exert bimodal dose dependent stimulation of GM-CSF and G-CSF 
induced day 7 granulocyte-macrophage colony forming units. This effect was due 
to an increase in granulopoiesis, and was restricted to low doses (0.01 to 1.0 
ng/mL) of TGF-p. Thus, TGF-p, like both the haemoregulatory pentapeptide and 
MIP-la (see below) appears to be capable of both inhibiting and stimulating 
proliferation of haemopoietic stem and lineage restricted progenitor cells
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respectively. Further, Fan et al (1992) have demonstrated that TGF-p can either 
inhibit or stimulate proliferation of peritoneal exudate macrophages depending on 
the type of CSF present. That is, TGF-p enhanced proliferation of these cells when 
they were stimulated with GM-CSF, but inhibited them in the presence of M-CSF.
2.4.8 Mode of action of TGF-p in inhibiting primitive haemopoietic cells
How TGF-p actually achieves inhibition of primitive haemopoietic cells 
remains largely unknown. While actual cellular mechanisms remain elusive, it has 
been postulated that TGF-p may inhibit proliferation by somehow preventing the 
stem cells from responding to positive growth signals. One such mechanism could 
be by downregulating growth factor receptors on the stem cells themselves. 
Indeed, Jacobsen et al (1991b) have shown that TGF-p specifically inhibits the 
expression of GM-CSF, IL-3 and G-CSF receptors on both factor dependent and 
independent murine haemopoietic progenitor cell lines. This was due to a 
reduction in receptor number with no change in affinity of the remaining receptors 
for ligand. Interestingly, this receptor downregulation preceded TGF-ps growth 
inhibitory action, and TGF-ps ED50 for both receptor modulation and inhibition 
were very alike (1 to lOpM). Similarly, Dubois et al (1994) have demonstrated 
that TGF-p downregulates c-kit message stability and cell surface protein 
expression in haemopoietic progenitors, c-kit is the receptor for stem cell factor, a 
molecule important for the maintenance of haemopoiesis, and TGF-p has 
previously been shown to inhibit the action of this molecule on both murine and 
human progenitors (McNiece et al 1992). Taken together, these studies suggest 
that TGF-p is capable of altering, and indeed lessening the response of primitive 
haemopoietic cells to the actions of positive growth factors and this may be a 
contributory mechanism to inhibition of proliferation.
In order to fully understand the inhibitory mechanisms of TGF-p, it is 
necessary to elucidate the molecular events initiated by binding of TGF-p to the 
cell surface, and the resultant changes in gene expression in the nucleus.
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2.4.8.1 Receptors for the TGF-p family
Virtually all cell types examined display cell surface receptors for TGF-p. 
So far, at least nine distinct proteins have been shown to bind TGF-p (reviewed by 
Massague 1992 and Massague et al 1994). Cross linking to radiolabelled TGF-p 
has revealed two most widely expressed proteins of 43 kDa and 70 kDa termed 
TGF-p type I and type II receptors respectively. A third ubiquitous proteoglycan 
molecule, betaglycan (300 kDa), has been named TGF-p receptor type III. An 
insight into how TGF-p exerts its highly pleiotropic actions may now be revealed 
with the recent cloning of these TGF-p receptors.
A number of related type II receptors have been identified including 
Caenorhabditus Elegans daf-4 for bone morphogenetic proteins (Estevez et al
1993), a human TGF-p type II receptor named TpR-II (Lin et al 1992) and two 
mouse activin receptors named ActR-II (Matthews & Vale 1991) and ActR-IIB 
(Attisano et al 1992). These receptors have a small ectodomain rich in cysteine, 
with the cytoplasmic region largely comprising of a serine/threonine kinase domain. 
This kinase domain is z^proximately 40% conserved throughout the type II 
receptors whereas the extracellular domain similarity is only around 10% (reviewed 
by Lin & Lodish 1993). However, TpRII can mimic the action of the activin 
receptor in early Xenopus differentiation in that expression of TpRII in Xenopus 
embryos allows TGF-pl to induce mesoderm formation suggesting similar signal 
transduction pathways are utilised. The kinase domains of the type II receptors are 
highly characteristic in that they phosphorylate serine/threonine residues on their 
substrates differing from the classical tyrosine kinase receptors (Dijke et al 1994).
Expression cloning and characterisation of the TGF-p type III receptor 
(Wang et al 1991, Lopez-Casillas et al 1991, 1994) has revealed it to be an 853 
amino acid protein. This protein has a large N-terminal region with at least one site 
for glycosaminoglycan addition and six glycosylation domains, a hydrophobic 
transmembrane region and a short 49 amino acid cytoplasmic tail. Interestingly, 
this tail appears to have no obvious signalling motif, and functional studies of the 
receptor suggest it is involved in binding of ligand and presentation to the type II
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receptor which is capable of further signal transduction. Indeed, Lopez-Casillas et 
al (1993) have demonstrated that betaglycan presents TGF-p directly to the type II 
receptor forming a ternary complex. Thus, betaglycan may serve as a means to 
capture TGF-p from the periphery and concentrate it on the cell surface for 
presentation to the signalling receptors. This possibility is strengthened by the fact 
that the type II receptors have a very low affinity for TGF-p in cells that do not 
express functional betaglycan (Lopez-Casillas et al 1993).
Several TGF-p type I receptors have recently been cloned and 
characterised (Ebner et al 1993, Franzen et al 1993, Attisano et al 1993). 
Although these receptors are also transmembrane serine/threonine kinases, their 
kinase domains are quite divergent from those of the type II receptors.
2.4.8.2 Signalling through the TGF-p receptors
Much work has concentrated on trying to elucidate the signal transduction 
pathways of TGF-p. This work is still at a very early stage, but studies so far 
indicate that both TGF-p type I and type II receptors are required for TGF-p to 
exert its physiological effects.
Wrana et al (1992) have shown that in MvlLu cells defective for the type I 
receptor, the type II receptor is capable of binding ligand but does not signal TGF- 
P responses. TGF-p responsiveness is restored however when the type I receptor 
is introduced via transfection into these cells (Franzen et al 1993, Attisano et al
1993). Cells expressing defective type II receptors which have no functional 
kinase domain are able to bind TGF-p but unable to signal in response (Wieser et 
al 1993). These experiments demonstrate that both types of receptor are essential 
for the biological actions of TGF-p to be realised. Recent work by Wrana et al 
(1994) has elucidated the initial mechanics involved in this interaction. TGF-p is 
bound by the type II receptor which then forms a complex with the type I receptor. 
Data by Yamashita et al (1994) further suggests that the hetero-oligomeric 
receptor complex formed consists of two molecules each of TpR-I and TpR-II. 
The kinase domain of the type II receptor phosphorylates serine/threonine residues
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on both itself and the cytoplasmic domain of the type I receptor, but has no role in 
phosphorylating downstream substrates. "Activation" of the type I receptor by this 
phosphorylation leads to downstream substrate phosphorylation and subsequent 
changes in gene expression and/or cellular phenotype. Interestingly, inactivation of 
the type II receptor in MvlLu cells reveals two receptor pathways suggesting that 
the antiproliferative actions of TGF-p are mediated through the type II receptor 
possibly in conjunction with the type I receptor, while the type I receptors are 
responsible for TGF-Ps actions on extracellular matrix, such as increased 
fibronectin and plasminogen activator inhibitor expression (Chen et al 1993).
The actual details of the TGF-P signal transduction pathway remains a 
mystery. It has been postulated however that TGF-ps anti-proliferative properties 
are ultimately mediated at the level of tumour suppresser genes and proto­
oncogenes in the nucleus which are involved in cell cycle progression such as the 
product of the retinoblastoma gene and c-myc.
2.4.8.3 TGF-p effects on gene expression and cell cycle progression
It is likely that TGF-p modulates cellular proliferation in such a vast variety 
of cells by affecting common genes involved in cell cycle progression. Due to the 
difficulty of obtaining pure populations of primitive pluripotent stem cells, most of 
the work in this area has focused on other more homogenous cellular types which 
are responsive to inhibition by TGF-p. The general consensus regarding TGF-p 
inhibition is that it prevents cell entry into DNA synthesis at a stage late in G1 or at 
the Gl/S phase boundary.
In both rapidly growing murine kératinocytes and EGF stimulated quiescent 
kératinocytes, TGF-p inhibits c-myc and KC gene expression, both of which are 
implicated in growth stimulation (Coffey et al 1988). Inhibition of c-myc is post- 
transcriptional and requires protein synthesis. In agreement with these findings, 
Pietenpol et al (1990a,b, 1991) have also demonstrated TGF-p mediated inhibition 
of c-myc in kératinocytes. They further show that treatment of murine BALB/MK 
kératinocytes with c-myc antisense oligonucleotides inhibits proliferation of these
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cells in a manner analogous to TGF-p. They demonstrated that this inhibition 
occurred at the level of transcriptional initiation implying that TGF-p inhibits 
proliferation in these cells indirectly by inducing synthesis or modification of a 
protein which can then specifically interact with the c-myc promoter.
A controversial candidate for one possible intermediary protein is the 
product of the retinoblastoma gene (pRB) (Laiho et al 1990). This gene encodes a 
protein with presumptive growth suppresser activity (reviewed in Zacksenhaus et 
al 1993). Indeed, loss or inactivation of the RB gene has been found in a variety of 
malignant cell types including retinoblastomas, osteosarcomas, small cell lung 
carcinoma, breast carcinoma and bladder carcinoma (reviewed in Pietenpol et al 
1990). Mice deficient for Rb die before birth with defects in neurogenesis and 
haemopoiesis (Lee et al 1992). In normal cells, pRB is expressed throughout the 
cell cycle in various states of phosphorylation. Significantly, pRB acts as a growth 
suppresser when in it is underphosphorylated and this form is in abundance in G1 
and in growth arrested cells (De Caprio et al 1989, Buchkovich et al 1989, Chen et 
al 1989). This growth suppressive form of pRB is also selectively bound by the 
transforming gene products of several DNA tumour viruses including SV40 large 
T antigen, adenovirus type 5 El A and human papilloma virus type 16 E7 (Whyte et 
al 1988, DeCaprio et al 1989, Dyson et al 1989) implying that inactivation of the 
growth suppressive pRB is essential for cellular transformation in these contexts. 
Indeed, transient expression of these proteins in human foreskin kératinocytes 
blocks TGF-(3s inhibitory action, and its inhibitory effect on c-myc, implicating 
pRB to be crucial to TGF-|3s function (Pietenpol et al 1990b). Interestingly 
however, a report by Ong et al (1991) demonstrates that inactivation of the 
retinoblastoma gene does not lead to loss of TGF-|3 receptors or response to TGF- 
(3 in breast cancer cell lines. Chen et al (1993) have recently shown that TGF-(3 
selectively inhibits FDC-Pl cells, a factor dependent murine myeloid progenitor 
cell line, possibly through inhibition of M-CSF induced c-myc expression.
Recently, it has become clear that progression through the cell cycle is 
regulated by a number of cyclin dependent protein kinases (CDKs). TGF-|3 has
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been shown to inhibit Cdk4 synthesis, and that this is related to growth arrest 
(Ewen et al 1993). MvlLu cells growth inhibited by TGF-|3 failed to stably 
assemble cyclin E-Cdk2 complexes or accumulate cyclin E-associated kinase 
activity (Koff et al 1993). Also, G1 phase extracts from TGF-|3 treated cells did 
not support activation of endogenous cyclin-dependent protein kinases by 
exogenous cyclins. Interestingly, these effects were concomitant with inhibition of 
phosphorylation of the RB gene product suggesting that TGF-(3 acts to keep RB in 
its underphosphorylated and growth suppressive form by inactivating the kinases 
responsible for this phosphorylation. This led to the identification of kip 1, a 27 
KDa protein present in extracts from cells made quiescent by TGF-(3. This protein 
binds to cyclin E-Cdk2 and cyclin D-Cdk4 complexes and inhibits their activity in 
vitro in a stoichiometric manner (Polyak et al 1994, Toyoshima and Hunter 1994). 
Another study by Longstreet et al (1992) has demonstrated that TGF-(3 can 
prevent activation of p34“*®2 kinase. This kinase has been associated with 
phosphorylation of RB, and TGF-(3s inhibitory effects on this kinase may be 
responsible for keeping RB in its unphosphorylated form.
2.4.9 Summary
As has been described above, TGF-|3 is produced by a bewildering array of 
cells, and is capable of acting on an equally broad spectrum of cellular types. The 
high degree of conservation of TGF-(3s between species suggests that they are 
likely to be fundamentally important in normal physiology. With respect to 
haemopoiesis, TGF-|3 acts as both an inhibitor of primitive pluripotent cell types, 
but as a stimulator of less primitive progenitors. This action is also apparent with 
the haemoregulatory pentapeptide, and also with macrophage inflammatory protein 
l a  as shall be described below. Further, TGF-(3 is active in inhibiting epidermal 
kératinocytes in a manner analogous to that of both the epidermal version of the 
pentapeptide and of MIP-la. This suggests that some functional redundancy may 
occur between the inhibitors of stem cell proliferation in both haemopoiesis and 
keratopoiesis and possibly in other cellular systems.
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2.5 Macrophage Inflammatory Protein 1 alpha (MIP-la)
In 1990, Graham et al reported the identification and characterisation of an 
inhibitor of haemopoietic stem cell (CFU-S/CFU-A) proliferation. Using the in 
vitro CFU-A assay, they purified to homogeneity an activity from the murine 
J774.2 macrophage cell line which was capable of reversibly inhibiting CFU-A and 
CFU-S stem cell proliferation. They named this activity stem cell inhibitor, and 
sequence analysis revealed that this molecule was identical to a previously 
described protein, macrophage inflammatory protein-la (MIP-la). During 
purification of MIP-la, they also isolated a related molecule which was identical to 
the previously described MIP-1(3. However, this molecule did not have potent 
stem cell inhibitory properties. The biological functions of these chemokines are 
quite diverse ranging from inhibition of proliferation to potentiating inflammatory 
responses and will be discussed below.
2.5.1 Structure of the MIP-la superfamily
MIP-la belongs to a relatively new family of cytokines, related by limited 
sequence homology, termed the chemokine family (Schall 1991). Members of this 
family are also related by the characteristic spacing of four cysteine residues, and it 
is on the basis of this conserved motif that the family can be further subdivided into 
two classes. Molecules in which the first two conserved cysteine residues are 
adjacent have been designated the "C-C" or (3 branch of the superfamily, whilst 
molecules whose first two cysteines are separated by an intervening amino acid 
belong to the "C-X-C" or a  branch. All members of this superfamily are small 8- 
18 kDa heparin binding proteins. The members of each of these subfamilies will be 
described in the following sections.
2.5.1.1 C-X-C chemokines
This subfamily consists of the prototype platelet factor 4 (PF-4), (3 
thromboglobulin, 7IP-IO, gro/MGSA, NAP-l/IL-8, migc and ENA-78. These 
names refer to the human homologues, except migc which is murine and has no
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known human counterpart. A number of them do however have murine 
homologues, but for the purposes of this brief overview and to avoid 
complications, only the human homologues will be referred to in the text. The 
genes for all of these molecules are located on chromosome 11 in the mouse and 4 
in humans.
2.5.1.2 Platelet Factor 4 (PF-4)
PF-4 is stored in the alpha granules of platelets, and was first discovered in 
1961 by Deutsch et al by virtue of its ability to bind to heparin and thus inhibit 
heparins anticoagulating properties. Subsequent work has revealed that PF-4 is a 
potent chemoattractant for neutrophils, monocytes and fibroblasts suggesting it to 
be involved in inflammation and wound repair (Deuel et al 1981). Further, Malone 
et al (1990) have also demonstrated that PF-4 is active as an inhibitor of 
angiogenesis in the chicken chorioallantoic membrane and a specific inhibitor of 
growth factor stimulated endothelial cell proliferation in vitro. Further, Gupta and 
Singh (1994) have demonstrated that PF-4 inhibits endothelial cells by blocking 
entry of cells into S-phase. PF-4 is also active as an inhibitor of human 
erythroleukaemia cells (Han et al 1992).
2.5.1.3 (3 thromboglobulin
(3 thromboglobulin is also stored in the a  granules of platelets, and it too is 
a potent fibroblast chemoattractant (Senior et al 1983). Proteolysis of (3 
thromboglobulin leads to formation of NAP-2, which is a potent chemoattractant 
and activating factor for neutrophils (Walz et al 1989).
2.5.1.4 The gro proteins
Three distinct human gro genes have been identified, namely gro a , gro |3 
and gro 7 (Tekamp-Olsen et al 1990, lida and Grotendorst 1990, Haskill et al 
1990). The nucleotide sequences of gro (3 and gro 7 are 90% and 86% identical to 
that of gro a  respectively. It has been reported by several groups that gro a  has
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neutrophil chemotactic and activating properties (reviewed in Miller et al 1992), 
and gro a  also stimulates autocrine growth of a human melanoma cell Une and as 
such is also known as melanoma growth stimulating activity (MGSA) (Richmond 
e r a /1988).
2.5.1.5 Interleukin 8 (IL-8)
Interleukin 8 (IL-8), also known as neutrophil activating protein 1 (NAP- 
1), is by far the most extensively studied member of the C-X-C branch of the 
chemokine family. Human IL-8 (there is no known murine homologue) is 
produced by a wide variety of haemopoietic ceU types including monocytes, 
macrophages, T cells and neutrophils, as well as non-haemopoietic cell types 
including, amongst others, fibroblasts, kératinocytes and hepatocytes. In general, 
IL-8 appears to play a role in potentiating inflammatory responses. Indeed, its 
expression, as is the expression of other members of the superfamily, is regulated 
by a number of proinflammatory cytokines such as IL-la, IL-ip and TNF as weU 
as bacterial endotoxin indicating IL-8 to be involved in potentiating inflammatory 
cytokine cascades. IL-8 seems to act predominantly on neutrophils, both in that it 
is a potent chemoattractant for these cells (Yoshimura et al 1987) and it induces 
degranulation and the neutrophil respiratory burst (Walz et al 1987). Webb et al
(1993) have further demonstrated that co-treatment of neutrophils with IL-8 plus 
heparan sulphate enhances the ability of IL-8 to increase cytosolic free calcium 
levels and neutrophil chemotaxis up to 4-fold. A putative receptor for the as yet 
unidentified murine homologue of IL-8 has been "knocked out" in mice generating 
animals which suffered from an increase in B cells and neutrophils (Cacalano et al
1994). Further, this receptor was a major mediator of neutrophil migration to sites 
of inflammation.
2.5.1.6 Other C-X-C chemokines
Monokine induced by IFN-y {migc), has only been identified in mice 
(Farber 1990) and although sequence analysis places it within the C-X-C
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chemokine family, nothing is known to date regarding its possible functions. Also, 
little is known about ENA-78 other than it too is chemotactic and activatory for 
neutrophils (Walz et al 1991). 7 IP-10 was identified by Luster et al (1985), and 
has been suggested to play a role in delayed type hypersensitivity inflammatory 
situations (Kaplan et al 1987).
In summary, members of the C-X-C branch of the chemokine superfamily 
appear to be proinflammatory molecules which act predominantly, though not 
entirely, through neutrophils.
2.5.2 C-C chemokines
This subfamily consists of murine MIP-la (human homologue 
LD78/GOS19-1), murine MIP-ip (human homologue ACT-2), TCA-3 (human 
homologue 1-309), JE (human homologue MCP-1), RANTES, human HC14 and 
murine CIO. In addition to these, an alternatively spliced form of TCA-3, 
designated p500 has been cloned (Brown et al 1989). Recently, the product of a 
novel growth factor-activated gene, /zc, has also been identified and characterised 
as a C-C chemokine (Heinrich et al 1993). The genes for these molecules are 
located on chromosome 11 in the mouse and chromosome 17 in humans.
2.5.2.1 MIP-la and MIP-ip
M IP-la and MIP-ip exert a wide range of biological activities including 
chemotaxis for monocytes and T cell subsets. MIP-la has also been shown to be a 
potent inhibitor of both primitive haemopoietic progenitor cell proliferation in vivo 
and in vitro, and of clonogenic epidermal cell proliferation. The biology of these 
molecules shall be discussed in detail in the following sections.
2.5.2.2 JE and MCP-1
JE was first characterised by Rollins et al in 1988 as a gene massively 
inducible in murine fibroblasts by platelet derived growth factor. This "immediate 
early gene" property is also shared by other members of the chemokine
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superfamily. Subsequently, a human homologue was identified and named 
monocyte chemoattractant protein-1 (MCP-1) by virtue of its potent monocyte 
chemoattractant properties (Yoshimura et al 1989, Ernst et al 1994).
2.5.2.3 RANTES
RANTES (regulated on activation normal T-cell expressed, and secreted) 
was originally identified and characterised by Schall et al in 1988 as a T cell 
expressed gene. This gene directs synthesis of an 8kD protein, and is expressed by 
T cells, peripheral blood mononuclear cells and human rheumatoid synovial 
fibroblasts (Miller et al 1989, Rathanawami et al 1993). Recently, it has become 
apparent that a number of other cell types express RANTES in response to TNF-a 
stimulation including fibroblasts, renal epithelial and mesangial cells (Nelson et al 
1993). RANTES functions as a potent chemoattractant for monocytes, eosinophils 
(Kameyoshi et al 1992, Ebisawa et al 1994) and specific T cell subsets in vitro 
(Schall er al 1990).
2.5.2.4 Other C-C chemokines
T cell activation gene-3 (TCA-3) was first cloned in 1987 by Burd et al, 
and has been shown to be expressed by antigen activated T cells and murine mast 
cells. TCA-3 is unique among the chemokine family in that it contains an extra pair 
of cysteine residues. Interestingly, it is active on both neutrophils and monocytes. 
The functions of the product of this gene and its human homologue 1-309 remain 
largely unknown. A role for TCA-3 in inflammation, and in particular neutrophil 
chemotaxis, has been proposed since injection of partially purified recombinant 
TCA-3 into the footpads of mice elicited an inflammatory response involving 
neutrophils (Wilson cf al 1988).
HC14 is a relatively new member of the C-C family expressed in human 
macrophages following IFN-y stimulation (Chang et al 1989), and to date nothing 
is known regarding its function. Murine CIO was identified by virtue of its ability 
to be induced in GM-CSF stimulated bone marrow cells i.e. myeloid cells (Orlofsky
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et al 1991). In addition to those chemokines mentioned above, Kelner et al (1994) 
discovered a novel molecule, related to both C-X-C and C-C chemokines which 
they have named lymphotactin by virtue of its chemotactic activity for 
lymphocytes. Interestingly, this molecule lacks two of the four cysteine residues 
that are characteristic of the other chemokines. It is expressed in activated CD8+ 
T cells and in CD4-/CD8- ap  T cell receptors thymocytes.
Thus, both the C-X-C and the C-C subfamilies of the chemokine 
superfamily appear to have potentially important roles to play in immune regulation 
and inflammation, with such effects by the C-X-C members being generally 
apparent on neutrophils while C-C members generally act on monocytes. 
However, as mentioned above, M IP-la also acts as a potent inhibitor of both 
haemopoietic stem cells and of epidermal kératinocytes demonstrating this 
molecule to possess both similar and unique properties to its related family 
members. Below, I shall discuss these diverse properties of MIP-la in detail.
2.5.3 Structure of the MIP-1 proteins
MIP-la and MIP-ip were originally co-isolated by Wolpe et al in 1988 
and named MIP-1. MIP-1 resolves as a doublet on denaturing SDS-PAGE gels, 
and is composed of two distinct 8kD peptides designated MIP-la and MIP-1|3. 
Although MIP-ip contains a potential N-terminal glycosylation domain, both of 
these proteins appear to be non-glycosylated. MIP-la and MIP-1 p are coded for 
by distinct genes, present on mouse chromosome 11 and share 60% amino acid 
identity across their entire lengths and 69% identity in the mature peptide 
sequences. One feature of the both the murine and human MIP proteins which has 
hampered the progress of investigators searching for specific cell surface receptors 
is the propensity of them to form high molecular weight self aggregates in 
physiological buffers in vitro. These aggregates are noncovalent and electrostatic 
in nature and can be disrupted to varying degrees by high ionic strength solutions 
(Graham et al 1992). These aggregates tend to be approximately lOOkDa at a 
concentration of 0.1 mg/ml (Graham et al 1992), and controversy has reigned over
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whether the aggregated form is biologically active, or if disruption of the aggregate 
to produce monomeric MIP-la is required. The functional significance of the self 
aggregation of this molecule is unclear, but may be to stabilise the protein or 
protect it from proteolysis. Recently, Mantel et al (1993) have demonstrated that 
the aggregated form is biologically inactive with respect to the myelosuppressive 
effects of MIP-la, and that the active form is in fact the 8kD monomer. Further, a 
recent study by Graham et al (1994) has shown, by systematically neutralising 
carboxyl-terminal acidic residues, that these mutants of MIP-la display native 
molecular weights representative of tetramers, dimers and monomers of MIP-la. 
However, and in contrast to the results of Mantel et al (1993), these mutants of 
MIP-la appear to be biologically equipotent to each other and to wild type MIP- 
l a  in both stem cell inhibition assays and monocyte shape change assays, 
suggesting that the wild type multi-aggregate, tetramers and dimers spontaneously 
dissaggregate and function as monomers in these assay conditions. Thus, the 
aggregation of MIP-la appears to have little effect on biological activity in vitro. 
As shall be discussed below, MIP-la is currently being assessed as a potential 
myeloprotective drug for use during cancer chemotherapy, and initial results from 
our laboratory are very encouraging (Dunlop et al 1992). Injection of a large 
molecular weight molecule such as aggregated MIP-la is unappealing since 
quantitation of the exact levels of active molecule circulating in the bloodstream 
are difficult to assess. Thus, these mutants are likely to be prove invaluable when 
using MIP-la in such a clinical context.
2.5.4 Expression Patterns of MIP-la and MIP-1(3
2.5.4.1 Expression in normal conditions
MIP-la and MIP-1(3 are predominantly expressed by cells of haemopoietic 
origin. Further, since it appears that the expression of both of these genes is co­
regulated, I will only refer to M IP-la below. Macrophages (Davatelis et al 1988, 
Wolpe et al 1988), activated T cells (Yamamura et al 1989), stimulated B cells
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(Lipes et al 1988), mast cells (Burd et al 1989), eosinophils (Costa et al 1993), 
neutrophils (Kasamac/ al 1993, 1994) and epidermal Langerhans cells (Heufler et 
al 1992) express MIP-la mRNA. Thus, it is likely that all haemopoietic cell types 
are capable of expressing MIP-la mRNA. However, and like other haemopoietic 
growth factors, although MIP-la mRNA expression is detectable in normal bone 
marrow using sensitive PGR based techniques (Cluitmans et al 1995), quantitation 
and indeed detection of protein remains difficult. It is possible that although MIP- 
l a  is produced in very low and therefore undetectable levels overall in the bone 
marrow, local concentrations around the target stem cells, perhaps aided by the 
proteoglycan binding abilities of MIP, may well be high enough to exert 
physiological effects. In addition to expression of MIP-la by haemopoietic cells, a 
report by Nakao et al (1990) demonstrates detection of MIP-la gene transcripts in 
phorbol ester treated fibroblasts and U105MG cells, a human glioma cell line. 
Interestingly, both astrocytes and spermatogonia have also been shown to express 
MIP-la transcripts (Kim et al 1995, Hakovirta et al 1994).
An interesting feature of MIP-la is that its expression can be rapidly super­
induced in macrophages by treatment with LPS (Davatelis et al 1988), and in T 
cells by phorbol esters (PMA) and or PHA and cyclohexamide (Obaru et al 1986, 
Yamamura et al 1989, Blum et al 1990). These inducibility features of MIP-la 
suggest that it falls within the class of the rapid-response or immediate early genes. 
Analysis of the MIP-la gene reveals five major nuclear protein binding sites in the 
proximal promoter which bind C/EBP, NF-xB and or c/Ets family members. 
Changes in promoter binding by members of the C/EBP and NF-xB families 
correlates with the transcriptional up-regulation seen in serum or endotoxin- 
stimulated macrophages (Grove and Plumb 1993).
2.5.5 Expression in disease
Aberrant expression of M IP-la has also been observed in a number of 
haematological and inflammatory disorders. For example, Maciejewski et al 
(1992) have shown that human M IP-la mRNA levels are significantly increased in
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normal human bone marrow nucleated cells from patients with aplastic anaemia 
and myelodysplastic syndrome when compared to normal bone marrow. It is 
unclear however whether or not this upregulation is a secondary effect of 
dysregulated cytokine production in such patients or if it is in fact partly causative 
of the diseased state. Similarly, and as mentioned in the previous section 
describing TGF-(3, MIP-la expression is also upregulated in inflammatory lesions 
present in TGF-(31 null mice although again, it is unclear if this is primary or 
secondary to the diseased phenotype of the mice. M IP-la is also over expressed 
in alveolar macrophages of patients with interstitial lung disease, again possibly 
contributing to the inflammatory phenotype observed (Standiford et al 1993). 
Further, Smith et al (1994) have demonstrated that passive immunisation of 
bleomycin-challenged mice with anti-MIP-la antibodies significantly reduced 
pulmonary mononuclear phagocyte accumulation and reduced fibrosis.
2.5.6 The role of MIP-la in adult haemopoiesis
2.5.6.I Inflammatory functions of MIP-la and MIP-1|3
As mentioned above, both of these proteins were originally co-isolated 
from the conditioned medium of the murine macrophage cell line RAW 264.7 by 
Wolpe et al in 1988 and were known collectively at that time as MIP-1. They 
found that injection of MIP-1 subcutaneously into the footpads of mice elicited an 
inflammatory response consisting largely of a neutrophil infiltrate. Further, MIP-1 
was a mild chemoattractant for neutrophils in vitro and could potentiate the 
neutrophil respiratory burst. However, the concentration of MIP-1 protein 
required to induce these effects was relatively high (>lpg/ml), perhaps indicating 
that this was not the primary physiological role of MIP-1 in vivo.
Recently, it has become clear that MIP-la and MIP-1|3 are involved in 
potentiating the immune response through effects on a wider variety of cell types 
than was first thought. For example, Fahey et al (1992) have shown that MIP-1 
protein can enhance the ability of macrophages to kill tumour target cells. Also,
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MIP-1 stimulated the proliferation of mature tissue macrophages and this effect 
was increased in the presence of M-CSF or GM-CSF. They also demonstrated 
that MIP-la, but not MIP-ip could increase macrophage secretion of the pro- 
inflammatory cytokines TNF, IL-6 and IL-1. In fact, an eightfold excess of MIP- 
ip  could abrogate the ability of MIP-la to exert some of these effects (i.e. 
increased TNF expression) suggesting that M IP-la and MIP-ip are in fact 
antagonistic. However, and unlike TGF-p described in the previous section, MIP- 
1 could not induce the macrophage respiratory burst or increase MHC expression. 
A recent study by Taub et al (1993) has shown that MIP-la and MIP-ip can 
actually exhibit independent functions. They showed that MIP-la and MIP-Ip 
were potent chemoattractants for CD3 stimulated CD8"*' and CD4‘^  T cells 
respectively, and that they enhanced the ability of T cells to bind to an endothelial 
monolayer implicating these cytokines in the initiation of specific immune 
responses. In support of this, Tanaka et al (1993) have demonstrated that 
proteoglycan immobilised MIP-ip can enhance CD8+ T cell adhesion to the 
vascular cell adhesion molecule VCAM-1. These experiments suggest that the 
proteoglycan binding abilities of the chemokines may be important to some of their 
inflammatory functions such that immune cells can be firstly recruited from the 
periphery, and then attracted to sites of inflammation or infection.
In addition to having effects on neutrophils and lymphocytic cells, MIP-la 
has also been found to activate basophils and mast cells (Aam et al 1992). 
Further, Aam et al (1994) injected recombinant M IP-la into the footpads of mice 
and observed a significant swelling which was due to a severe inflammatory 
reaction consisting of neutrophils, monocytes and degranulated mast cells. MIP- 
la , but not MIP-ip, can induce the migration and activation of normal human 
eosinophils (Rot et al 1992). Davatelis et al (1989) have reported that MIP-1 acts 
as an endogenous pyrogen i.e. is capable of rapidly inducing fever. This function is 
analogous to that of other inflammatory cytokines such as tumour necrosis factor 
(TNF) and interferon 7 (IFN-7). However, and unlike these other pyrogens, the 
fever induced by MIP-1 could not be abrogated by administration of the
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cyclooxygenase inhibitor ibuprofen indicating that MIP-1 induces the febrile 
response via a prostaglandin independent pathway. This role of MIP-1 in fever 
induction must therefore be considered when administering antipyretics in fever 
treatment. Further to this work, Minnano et al (1990) have shown that MIP-1 
exerts these effects by acting directly on the hypothalamus and at very low 
concentrations (10"^  ^M). Saukkonen et al (1990) have demonstrated that M IP-la 
is also capable of inducing inflammatory responses in the central nervous system, in 
that it induces inflammatory cell infiltration into the subarachnoid space located 
behind the blood-brain barrier.
In summary, these data indicate that MIP-la and MIP-1(3 have important 
roles to play in inflammation. These cytokines act to recruit specific and non­
specific immune cells from the circulation and then attract them to the site of 
inflammation. Upon arrival, the MIP proteins then contribute to activation of these 
cells and potentiate many of their cytotoxic functions. MIP-la,(3 may also 
contribute to the cytokine cascade by inducing production of other inflammatory 
cytokines in fibroblasts and macrophages such as IL-1, IL-6 and TNF (Fahey et al
1992).
2.5.7 Effects of MIP-la on cellular proliferation
Like TGF-(3, as well as being an inflammatory mediator, M IP-la is also 
capable of controlling cellular proliferation, both positively and negatively in a 
number of different cell types. The most documented abilities of M IP-la with 
respect to proliferative control has come from studies examining its effects on the 
haemopoietic stem and progenitor cell compartments and these shall be discussed 
below.
It was not realised until 1990, when Graham et al isolated a potent inhibitor 
of stem cell proliferation identical to MIP-la, that M IP-la and its related family 
members may be involved in control of cellular proliferation and/or differentiation. 
Subsequent work has revealed that this is indeed the case although conflicting
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reports have emerged regarding exactly what members of this family are capable of 
exhibiting these properties.
MIP-la is capable of potently (pM concentrations) inhibiting both colony 
formation by CFU-A type stem cells and the proportion of these same cells in DNA 
synthesis. It also inhibits their in vivo correlate day 12 CFU-S, but is unable to 
inhibit the proliferation of more committed GM-CFC progenitors (Graham et at 
1990). This appeared to be a specific effect by M IP-la since administration of 
polyclonal antiserum directed against MIP-1 abrogated its inhibitory effects. 
Further, similar concentrations of MIP-1 (3 were unable to inhibit these same 
cellular populations. These results indicate that MIP-la, but not MIP-1 (3, is a 
potent inhibitor of primitive stem cell proliferation, and the concentrations at which 
it is active strongly suggest that this may be an important physiological property of 
this molecule.
Subsequently, a number of other groups have also reported on the 
inhibitory properties of MIP-la. Broxmeyer et al demonstrated in 1990 that 
recombinant murine M IP-la was active in inhibiting in vitro colony formation by a 
number of primitive haemopoietic progenitor cells. These included suppression of 
murine CFU-GM stimulated with pokeweed mitogen spleen-conditioned medium 
(PWMSCM), hu CFU-GM stimulated with optimal recombinant human GM-CSF 
(rhGM-CSF) + recombinant human IL-3 (rhIL-3), and both murine and human 
BFU-E and CFU-GEMM stimulated with PWMSCM + erythropoietin or 
erythropoietin + rhIL-3 or rhGM-CSF respectively. In agreement with the findings 
of Graham et at (1990), MIP-113 was inc^able of these effects, and a more recent 
report by Broxmeyer et al (1991) has shown that a 4:1 molar ratio of MIP-1 (3 to 
MIP-la can block these inhibitory actions of MIP-la. Interestingly, they also 
reported that both recombinant MIP-la and -1(3 were capable of enhancing murine 
CFU-GM colony formation when stimulated by sub-optimal doses of rhM-CSF and 
rhGM-CSF indicating that, like TGF-|3, MIP-la is active as an inhibitor of 
primitive haemopoietic stem cells but as a stimulator of more mature lineage 
restricted progenitors. The apparent contradiction that MIP-la can both stimulate
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CFU-GMs and yet also inhibit them could be representative of differing stages of 
"maturity" within this progenitor cell compartment. That is, MIP-la is active as an 
inhibitor when CFU-GM are more immature and open to stimulation by a plethora 
of early acting growth factors, and as a stimulator when the presumably more 
mature CFU-GM are stimulated by a single CSF, as is the case for TGF-(3. 
Broxmeyer et al also demonstrated that MIP-la inhibited highly enriched human 
progenitor cell populations suggesting that this was a direct effect. However, there 
remains the possibility that MIP-la may inhibit stem cell proliferation indirectly. 
This could be achieved by inducing other inhibitors from secondary contaminating 
cells or perhaps even autocrinely from the target stem cells. Recently, Cooper et al
(1994) have performed in vivo experiments using monomeric rmMIP-la rather 
than the previously used aggregated form (see earlier discussion) and demonstrated 
that the monomer was around 1000 fold more active than previously described. 
However, in light of the recent data reported by Graham et al (1994), this issue 
remains unresolved.
Like the other stem cell inhibitors mentioned previously, M IP-la is 
currently being evaluated as a possible myeloprotective agent for use during 
chemotherapeutic regimes (Graham and Pragnell 1991). Dunlop et al (1992) have 
demonstrated protection by MIP-la of the CFU-S/CFU-A compartment from 
double injections of cytosine arabinoside (ara-C). Clements et al (1992) have also 
demonstrated that in vivo injection of MIP-la into mice can protect CFU-S from 
subsequent in vitro killing by tritiated thymidine. Similarly, Lord et al (1992) have 
demonstrated that MIP-la can protect the CFU-S population in mice from the 
cytotoxic effects of the cell cycle specific drug hydroxyurea (HU). In a dose 
dependent manner, MIP-la either reduced HU mediated kill of CFU-S cells and 
accelerated recovery or completely protected the CFU-S compartment. Maze et al 
(1992) have also shown that MIP-la (2-10 pg/mouse i.v.) but not MIP-lp rapidly 
decreased cycling rates and absolute numbers of myeloid progenitor cells in the 
bone marrow and spleen. These studies indicate that MIP-la may well be useful in 
protecting stem cells from cycle specific cytotoxic drugs, but it should be stressed
52
that these drugs are rarely used alone in cancer chemotherapy in favour of 
combination regimes using other drugs which do not distinguish between cells 
according to their cell cycle status. Thus, the actual potential usefulness of MIP- 
l a  in this context is debatable.
In addition to the inhibitory effects of MIP-la on normal stem and 
progenitor cells, it has been shown by Ferrajoli et al (1994) that it can also inhibit 
proliferation of progenitors from subsets of acute myelogenous leukaemia in a dose 
dependent manner. Further, MIP-la gene expression is detectable in peripheral 
blood cells from both AML and acute lymphocytic leukaemia patients, and yet 
appears to have little or no function in endogenous inhibition of these neoplastic 
cells. This perhaps suggests that although MIP-la mRNA is expressed, this is not 
translated into protein in these cells. However, this possibility awaits further study. 
It has been shown by various groups that MIP-la is, unlike TGF-p, inactive in 
inhibiting chronic myeloid leukaemia cell proliferation (Holyoake et al 1993b, 
Eaves et al 1993, Chasty et al 1993). This suggests that M IP-la may have clinical 
potential as a protective agent during chemotherapy or for chemotherapeutic 
purging of CML bone marrow grafts in vitro such that MIP-la will inhibit and 
protect the normal stem cell population, whereas the malignant cells will be more 
susceptible to drug toxicity.
The role of MIP-la in long term bone marrow cultures (LTBMC) has also 
been investigated. Eaves et al (1993) have demonstrated that exogenous addition 
of MIP-la to LTBMCs reversibly and specifically blocks the entry into cycle of 
primitive high proliferative potential progenitors present in the adherent layer, but 
has no effect on more mature progenitors. Further, MIP-la had no such effect 
when the LTBMCs were supporting growth of CML cells. An interesting report 
by Verfaille et al (1993) also investigated the role of MIP-la in LTBMCs, and in 
particular its effect on the recovery of LTBMC-initiating cells (LTBMC-IC). 
These cells are capable of setting up secondary LTBMC. This group had 
previously described a novel stroma-noncontact culture in which haemopoietic 
progenitors are grown at a distance from the stromal layer via separation by a
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0.4mm filter membrane. This membrane is however permeable to soluble factors, 
and these factors alone are capable of maintaining progenitor viability, and indeed 
production of committed progenitors. However, in both the traditional LTBMC 
and the noncontact version, it was apparent that after approximately five weeks, up 
to 50% of the initial LTBMC-IC inoculated into the cultures were lost. As 
mentioned above, a number of growth factors are capable of increasing total cell 
expansion and committed progenitor cell numbers, but none are capable of 
increasing recovery of LTBMC-ICs. The prolonged addition of IL-3 alone to 
these cultures results in eventual depletion of primitive LTBMC-ICs, likely to be as 
a result of their terminal differentiation. Co-addition of MIP-la and IL-3 however 
results in greatly increased maintenance of LTBMC-IC for up to eight weeks. 
Verfaille et al suggest that this observation may not be due to growth inhibition by 
MIP-la but rather as a result of this cytokine blocking terminal differentiation 
since administration of the known anti-proliferative cytokine TGF-|3 with IL-3 
results in a decreased recovery of LTBMC-IC. In a more recent publication, 
Verfaille and Miller (1994) show that up to 30% of CD34+/CD33- cells present in 
MIP-la + IL-3 supplemented cultures are capable of initiating and sustaining long 
term in vitro haemopoiesis compared with only around 6% in cultures not 
receiving the MIP-la supplement. Thus, treatment of such cultures with both 
MIP-la and IL-3 may prove an excellent method of obtaining large numbers of 
very primitive stem cells for both phenotypic analysis, and for clinical stem cell 
expansion.
Although MIP-la inhibits subpopulations of progenitors that are activated 
in myelodepressed animals, a study by Quesniaux et al (1993) has shown that MIP- 
l a  has no inhibitory effect on the induction of long term repopulating cells (LTRC) 
into the cell cycle by treatment with two doses of 5-FU in vivo. However, the 
concentrations of MIP-la used in this experiment were significantly lower than 
those required to inhibit CFU-S/CFU-A type progenitor cells. Further, a recent 
report by Keller et al (1994) also demonstrated that MIP-la was inc^able of 
inhibiting LTRC at concentrations analogous to those required to inhibit CFU-
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S/CFU-A. Thus, it appears that the inhibitory properties of M IP-la are apparent 
on a very small window of the stem cell compartment, namely CFU-S/CFU-A. 
LTRC represent the most primitive stem cells detectable, and are capable of 
sustaining long-term haemopoiesis in vivo. Thus, the definition of M IP-la as a 
stem cell inhibitor may not be generally accurate since the most primitive stem cells 
appear to be refractory to its inhibitory properties.
As well as being able to inhibit and enhance sub-populations of 
haemopoiesis, MIP-la, like TGF-(3, is also active as an inhibitor of both murine 
and human clonogenic epidermal keratinocyte proliferation (Parkinson et al 1993). 
Further, MIP-la mRNA is detectable in epidermal Langherans cells, but not in 
kératinocytes or other epidermal cellular populations (Heufler et al 1992, 
Parkinson et al 1993). These cells have been shown to be intimately associated 
with the epidermal keratinocyte (Potten and Allen 1976), suggesting local 
production of MIP-la to play an important role in the regulation of this constantly 
regenerating tissue. A recent paper by Hakovirta et al (1994) also suggests that 
MIP-la may function as a regulator of germ cell development, by both increasing 
DNA synthesis in primitive spermatogonia and inhibiting DNA synthesis of more 
mature & differentiated spermatogonia. They also demonstrated using 
immunohistochemical analysis that MIP-la protein was localised in these cell types 
and in areas where cells were undergoing DNA synthesis.
As mentioned above, controversy exists over exactly which members of the 
chemokine superfamily are capable of stem cell inhibitory effects. Work from our 
laboratory by Graham et al (1993) has shown that MIP-la, its human homologue 
LD78 and ACT-2 (human MIP-lj3) are active in this context, while JE, TCA-3, 
MCAF (human JE) and all of the C-X-C family members are inactive. In contrast 
to these findings, Broxmeyer et al (1993) has demonstrated dose dependent 
inhibition of progenitors by a different but wider range of chemokines. The 
differences are difficult to explain, but may result from differing growth factor 
combinations present in the different types of assay system utilised by each group.
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2.5.8 The mode of action of MIP-la in inhibiting stem cell proliferation
To date, very little is known regarding the mechanisms by which MIP-la 
inhibits these cell types. Studies on the actual kinetics of inhibition by MIP-la 
have been hampered by lack of a suitable homogeneous cell system which is 
responsive to these inhibitory effects. Aronica et al (1994) have recently described 
a human cell line M07e, whose proliferative status could be downregulated by a 
number of chemokines, so it may > now be possible to investigate the 
antiproliferative signal transduction pathway utilised by MIP-la. It is tempting to 
speculate that due to the many similarities between MIP-la and TGF-(3 in this 
regard, MIP-la too may ultimately mediate its effects via genes and proteins 
implicated in cell cycle control which are affected by TGF-|3. This possibility 
however awaits further study.
With the recent cloning and characterisation of a receptor for the C-C 
chemokine family (Neote et al 1993), some of the initial mechanisms of the mode 
of action of MIP-la may now be studied.
2.5.9 Receptors for MIP-la and the chemokine family
Two receptors for human IL-8 (designated A and B) were the first 
receptors to be cloned for the chemokine family (Holmes et al 1991, Murphy and 
Tiffany 1991). Recently, Neote et al (1993) isolated a cDNA fi-om phorbol 
myristate acetate treated HL60 cells encoding a protein acting as a receptor for C- 
C chemokine family members. This receptor has been named C-C CKRl and has a 
predicted molecular mass of around 41 kD. Functional expression of this receptor 
in human embryonic kidney cells confers both binding ability for MIP-la and a 
consequent mobilisation of calcium. Subsequently, another chemokine binding 
receptor has been identified on red blood cells and shown to be identical to the 
cloned Duffy antigen, which also acts as a receptor for the malarial parasite 
Plasmodium vivax (Neote et al 1994). Interestingly, this receptor is capable of 
binding all members of the C-C and C-X-C branches of the superfamily with the 
notable exception of MIP-la. The significance of this, and indeed the role of the
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Duffy antigen is unclear, but as this receptor is present on cell types incapable of 
further signal transduction such as erythrocytes, it may act as a "sink" for excess 
chemokine levels present in the periphery. Charo et al (1994) have recently cloned 
two MCP-1 receptors, and functional expression of these receptors in Xenopus 
oocytes reveals them to be alternatively spliced at the carboxy tail. Four potential 
viral counterparts of the chemokine receptors have also been identified (reviewed 
in Horuk 1994). Interestingly, CC-CKRI shows approximately 33% homology to 
the US28 open reading frame encoded by human cytomegalovirus (Neote et al
1993). US28 can act as a functional receptor when transfected into 293 cells, and 
elicit calcium fluxes in response to MIP-la, MIP-1 (3, RANTES and MCP-1, but 
not C-X-C chemokines (Neote et al 1993, Gao and Murphy, 1994). The biological 
significance of this observation is unclear.
Functional and structural analysis of these receptors has revealed them to 
belong to the seven-membrane spanning G-protein linked receptor superfamily. 
This family also includes receptors for the chemoattractant molecules f-Met-Leu- 
Phe and complement molecule C5a. Classically, signalling through such G-protein 
linked receptors results in a dissociation of the heteromeric G proteins into Ga and 
(3y subunits. The a  subunits then activate phospholipase C, an enzyme which then 
generates diacylglycerol (DAG) and inositol triphosphate (IP3). DAG then 
activates protein kinase C, while IP3 diffuses into the cytosol and releases the 
secondary messenger calcium from intracellular stores. Both IL-8 RA and IL-8 
RB have been shown to elicit these effects in response to IL-8 and MGSA, 
although two different pertussis toxin sensitive and insensitive pathways appear to 
be involved in activation of phospholipase C (Wu et al 1993). It has been 
demonstrated by Sozzani et al (1993) that MIP-la, MCP-1 and RANTES 
stimulate calcium influx in human monocytes, and by Rot et al (1992) that M IP-la 
and RANTES induce calcium influx in normal human eosinophils suggesting that 
many of these chemokines may utilise similar initial signal transduction pathways.
Receptors for MIP-la and related C-C chemokines have been found on a 
variety of haemopoietic cell types including monocytes (Napolitano et al 1990),
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murine T cells and macrophages (Oh et al 1991) and primitive haemopoietic cell 
lines. Graham et al (1993) have demonstrated that the primitive human 
myeloerythroleukaemic cell line K562 expresses around 15,000 receptors of a 
single class (Kd of 600pM) which can recognise both M IP-la and the rest of the 
C-C chemokines (with the exception of TCA-3) perhaps indicating that this is a 
general receptor for this branch of the superfamily. Further, the murine stem cell 
like line FDCP-MIX displays around 18,000 receptors of a single class (Kd of 
330pM), but M IP-la binding to this receptor is less prone to competition by more 
diverse MIP family peptides. It should be noted at this point that the receptors 
present on FDCP-MIX cells are most likely distinct from the cloned C-C CKRI 
receptor based on both the apparent "affinity for ligand" differences between them, 
and on their different binding and competition patterns using other chemokines. 
That is, the FDCP-MIX receptor recognises only MIP-la, MIP-1|3 and their 
human homologues LD78 and ACT-2, while C-C CKRI binds MIP-la, MIP-1(3 
and RANTES and MCP-1. Thus, it is possible that MIP-la exerts its many 
diverse effects on different cell types by signalling through a number of different 
receptor types. Further, it has been suggested by Graham et al (1993) that the high 
affinity receptor present on FDCP-MIX cells may be responsible for mediating the 
inhibitory function of MIP-la since it can only bind members of the chemokine 
family with inhibitory properties. However, confirmation of this awaits cloning and 
functional characterisation of this receptor type.
A recent report by Avalos et al (1994) has demonstrated the presence of 
both high and low affinity receptors for monomeric MIP-la on human leukaemic 
CD34"  ^ blast cells, promyelocytic cells, monocytes, peripheral blood neutrophils 
and T cells. They show that THP-1 monocytes express a single class of high 
affinity receptor for MIP-la, that also binds MIP-1(3, LD78 and ACT-2, with no 
detectable competition for binding by RANTES. Further, they detected both this 
receptor, and a low affinity receptor present on neutrophils which binds MIP-la, 
MIP-1(3, LD78, RANTES but not ACT-2. Compilation of the data discussed 
above suggests that the high affinity receptor detected on a number of cell types by
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Avalos et al may be identical to that observed on FDCP-MIX cells by Graham et 
aly and the low affinity receptor may be identical to the low affinity C-C CKRI 
cloned by Neote et al (1993) and Gao et al (1993).
Understanding of the diverse functions of MIP-la are now only beginning 
to surface. Cloning of receptors for this molecule will provide a valuable tool for 
elucidating many of these mechanisms, perhaps by artificial expression in cell types 
which are not normally responsive to either the inflammatory effects or inhibitory 
effects of MIP-la, or by disruption of the receptor gene in cells which are 
responsive (e.g. IL-8 receptor knockouts). Such experiments should allow us to 
distinguish between the different receptor types with respect to their functional 
roles. However, as yet, little is understood regarding the inhibitory activities of 
MIP-la. Like TGF-|3, MIP-la may ultimately regulate cellular proliferation at the 
level of nuclear proto-oncogenes, tumour suppressor genes and molecules involved 
in cell cycle progression such as the cyclins and cyclin inhibitors. This represents 
an exciting area for future study.
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Aims of Thesis
In order to fully understand the complex process of haemopoiesis, it is 
necessary to understand how the proliferation, differentiation and self renewal of 
the stem cell is controlled. It has become apparent in the last few years that the 
proliferation of the haemopoietic stem cell compartment is open to control by a 
number of both positive and negative regulators. Many of these factors appear to 
be capable of exerting similar if not identical effects on the same stem cell type 
suggesting that there is "functional redundancy" between them. Our group has 
recently identified and characterised a potent inhibitor of haemopoietic stem cell 
proliferation, namely macrophage inflammatory protein 1 alpha (MIP-la). It has 
struck us throughout our studies on this molecule that it bears a number of 
functional similarities to other inhibitors of stem cell proliferation, namely the 
tetrapeptide, the haemoregulatory peptide and in particular, transforming growth 
factor beta (TGF-|3). The aim of this project therefore, was to investigate the 
extent and possible mechanisms of functional similarity between these molecules. 
It is possible for example that one, or all, may act through induction of another in 
secondary cell types present within the bone marrow microenvironment such that a 
heirarchy between the inhibitors may exist. Also, it is possible that one may prime 
the target stem cells to respond to another by upregulating specific receptors for 
that molecule. Investigation of these possibilities could potentially explain the 
functional similarities between them, and also elucidate possible distinctive roles 
for each in the overall control of haemopoietic stem cell proliferation.
CHAPTER 3
MATERIALS
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CHAPTER 3 - Materials
3.1 Tissue Culture Supplies
Beatson Institute Central Services
Amicon (USA)
Gibco Life Technologies (Paisley, UK)
A/S Nunc (Roskilde, Denmark)
Beta Labs (UK)
Biological Industries (Israel)
Costar (USA)
DIFCO Laboratories (Michigan, USA)
Sterile PBS
Sterile glassware and pipettes
Centriprep 10 spin columns
Special Liquid Medium 
Foetal calf serum 
MEM alpha stock 
200mM glutamine 
DH5a competent cells
Tissue culture flasks 
Nunc cryotubes
Yeast extract
RPMI1640 media
96 well cell culture plates 
Cell scrapers
Lipopolysaccharide W
Bactoagar
Bactotryptone
Gelman Sciences (UK)
Becton Dickinson, U.K. Ltd. 
(Plymouth, UK)
SIGMA Chemical Co. (Poole, UK)
3.2 Cytokines and Antibodies
R&D Systems Europe (Abingdon, UK)
Sterile acrodiscs syringe filters 
(0.2pm and 0.45pm)
Tissue culture plates 
(35mm, 60mm)
Falcon tubes (15ml and 50ml)
Ampidllin
Horse serum (donor herd)
Recombinant human TGF-(31 
Natural porcine TGF-(32 
Recombinant human TGF-(33 
Recombinant human LAP (TGF-
pi)
Recombinant anti-murine MIP- 
l a  antibody
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Genetics Institute (Boston, USA)
Sigma Immunochemicals (UK)
3.3 Kits
Amersham International (Amersham UK)
Boehringer-Mannheim UK (Lewes, UK) 
Qiagen Inc. (Chatsworth, CA, U.S.A) 
R&D Systems (Abingdon, UK)
Pharmacia Biotech (St Albans, UK)
3.4 Membranes, paper and X-ray film
Amersham International 
(Amersham, UK)
Dow Chemical Company (UK)
Dupont NEN (UK)
Schleicher & Schuell 
(Dassel, Germany)
Vemon-Carus, Ltd. (Preston, UK)
Whatmann International Ltd.
(Maidstone, UK)
Eastman Kodak Co. (Rochester, USA)
Technical Photo Systems 
(Cumbernauld, UK)
Recombinant murine MIP-la
Recombinant murine activin 
Recombinant murine BMP-2
Anti-goat IgG (peroxidase conjugate)
ECL Western blotting detection 
reagents
SP6/T7 transcription kit
Qiagen plasmid preparation kits
Quantikine transforming growth 
factor-|31 immunoassay
Ready-To-Go DNA labelling kit
Hybond N nylon membranes 
Hybond C nitrocellulose 
membranes
Saranwrap
Genescreen membrane
Nitrocellulose membranes 
Gauze swabs
3MM filter paper
X-OMAT AR X-ray film 
DUP-1 duplicating film 
X-ray cassettes
Fuji Medical RX X-ray film
3.5 Nucleotides, polynucleotides, DNA and restrietion enzymes
Amersham International, pic. 
(Amersham, UK) [a-^P]-dCTP: 3000 Ci/mmol 
[a-^P]-UTP: 800 Ci/mmol
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Boehringer-Mannheim (Lewes, UK)
Dupont NEN (UK)
SIGMA Chemical Co. (Poole, UK)
Gibco Brl
3.6 Gels and columns
GIBCO, Ltd (Paisley, UK)
Severn Biotech Ltd. (Kidderminster, UK)
BDH Chemicals Ltd. (Poole, UK)
Schleicher and Schuell 
(Dassel, Germany)
Pierce & Warriner (UK)
Pharmacia Biotech (St Albans, UK)
[y-^Pl-ATP: 5000 Ci/mmol
GTP, ATP, CTP (lOOmM 
lithium salts)
^25lodine
Salmon sperm DNA 
Polyadenylic acid (5')
Restriction enzymes
Agarose and Low Melting Point 
Agarose
Design-a-Gel 40% (w/v) 
aoylamide, 2% (w/v) bis- 
acrylamide solution
Acrylamide
bis-acrylamide
Elutip-D-columns 
GF5 excellulose column 
NICK columns
3.7 Chemicals
BDH Chemicals (Poole, UK)
Amersham International, pic. 
(Amersham, UK)
SIGMA chemical Co. (Poole, UK)
James Burroughs Ltd. (Witham, UK)
Cinna/ Biotecx Laboratories Inc. 
(Houston, USA)
All chemicals other than those 
listed below
Rainbow molecular weight markers
Bromophenol blue 
Dithiothreitol (DTT)
MOPS 
TEMED 
Triton-X 100 
FURA-2AM
Ethanol
RNazol B reagent
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GIBCO BRL (Paisley, UK)
Northumbria Biologicals Ltd. 
(Cramlington, UK)
TRIzol reagent
Bovine serum albumin (20% 
w/v)
Fisons Scientific Equipment 
(Loughborough, UK) Formaldehyde (38% w/v)
Propan-2-ol
Glycerol
Fluka Chemika-Biochemica AG 
(Switzerland)
Pierce & Warriner (UK)
Formamide 
lodogen reagent
3.8 Solutions
3.8.1 Tissue Culture
MEM Alpha Stock (Gibco)
MEM Alpha x 2 (for 100ml)
RPMI 1640
INT Stain
Dissolve 5 litre pack in water, add 
50ml MEMxlOO vitamins (Gibco) 
and lOOmg gentamycin sulphate.
Make up to 1500ml with water 
and filter sterilise.
MEM alpha stock 21ml
L-Glutamine (200mM) 1ml
Sodium Bicarbonate (7.5%) 3ml 
Donor Horse Serum 25ml
(For MEM Alpha x 1, add equal volume 
of distilled water or agar)
RPMI lOx stock 100ml
Distilled water 860ml
L-Glutamine (200mM) 10ml
Sodium Bicarbonate (7.5%) 1.5ml
50mg of 2-(-4-Iodophenyl) -3-(4- 
nitrophenyl) -5 -pheny Itetr azolium chloride 
(INT) (BDH, UK) was added to 50ml of 
PBS, and the mixture heated to dissolve 
the solid. This solution was allowed to 
cool, and was filter sterilised through a 
0.22pm filter.
L-(3roth (L-Amp broth) Yeast extract 5g
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Bactotryptone
NaCl
Ampicillin (50pg/ml)
lOg
lOg
3.8.2 Agarose Gel Electrophoresis, Northern Blotting and Hybridisation
MOPS Buffer lOx pH 7.0 (for 11)
RNA Sample Loading Buffer
10 X TE (for 1 litre)
20 X SSC pH 7.0 (for 1 litre)
20 X SSPE pH 7.4 (for 1 litre)
50 X Denhardts Solution
(Pre-) Hybridisation Buffer 
(50mls)
(Pre-) Hybridisation Buffer pH 7
MOPS (Sigma) 41.80g
Sodium Acetate 6.80g
EDTA 3.72g
Formamide 55%
lOxMOPS 11%
Formaldehyde 17.9%
Water 7.5%
Glycerol 7.5%
Bromophenol blue to colour
Tris/HCl pH8 12.1g
EDTA 3.7g
Water to 1 litre
Sodium Chloride 175.3g
Sodium Citrate 88.4g
Sodium Chloride 175.3g
Sodium Citrate 88.2g
EDTA 7.4g
Ficoll-400 1% (w/v)
Polyvinylpyrrolidine 1% (w/v)
Bovine Serum Albumin 1% (w/v)
(Pentax Fraction V)
Formamide 25ml
50x Denhardts 2.5ml
20 X SSPE 12.5ml
Poly C (Img/ml) 100ml
Salmon Sperm DNA 
(lOmg/ml) 0.5ml
10% SDS 0.5ml
Complete to 50mls with water
NagHPO^
SDS
0.25M
7%
3.8.3 SDS-PAGE Polyacrylamide Gel Electrophoresis
15% Polyacrylamide gel Water 7.5ml
Acrylamide mix (30%) 12.5ml
1.5M Tris (pH 8.8) 6.3ml
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5% Stacking gel
10% SDS 0.25ml
10% ammonium persulphate 0.25ml 
TEMED 0.01ml
Water 6.8ml
Acrylamide mix (30%) 1.7ml
l.OM Tris (pH 6.8) 1.25ml
10% SDS 0.1ml
10% ammonium persulphate 0.1ml 
TEMED 0.01ml
SDS/DTT
Protein Sample Buffer
SDS/PAGE buffer
Western blot solution 1
Western blot solution 2
Cathode solution
20% SDS 0.1ml
IM DTT 0.1ml
IM Tris (pH 6.8) 30pl
Complete to 1ml with water
SDS/DTT 5pl
Bromophenol Blue (0.2%) 5pl 
Glycerol 5 pi
Glycine 28.8g
Tris.HCl 6.05g
SDS 2.0g
up to 21 with dHgO
0.3M Tris/20% methanol pH 10.4
25mM Tris/20% methanol pH 10.4
40mM 6-amino-n-hexanoic acid 
20% methanol 
pH 7.2
3.8.4 Calcium flux studies
HACM buffer NaCl
KCl
BSA
CaClg (optional)
MgClz
HEPES
Water to appropriate volume
125mM
5mM
0.025%
(w/v)
ImM
ImM
20mM
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CHAPTER 4 - Methods.
4.1 Mice
All mice were housed within the animal facility of the Beatson Institute. Female 
mice, aged between 8-12 weeks were used throughout all experimental procedures. 
For the in vitro CFU-A assay, femora bone marrow from strain B6D2F1 mice was 
used, whereas for the derivation of bone marrow macrophages, femur marrow 
from strain CDl mice was used.
4.2 Cell Lines
All cell lines used in this study were obtained from the frozen stocks of the Beatson 
Institute. All cell lines were maintained at 37°C in a dry atmosphere of 5% COg in 
air.
4.2.1 RAW 264.7
The murine monocyte-macrophage cell line RAW 264.7 (Ralph and Nakoinz 
1977), derived from an Abelson murine leukaemia virus induced tumour was 
maintained in Special Liquid Medium (SLM) (Gibco-BRL, UK) containing 4mM 
glutamine and 10% foetal calf serum (FCS) in NUNC 75cm^ tissue culture flasks. 
RAW cells are an adherent macrophage cell line. Upon reaching near confluence, 
the growth medium was removed using a pipette and the cells were rinsed in warm 
PBS. Approximately 90% of the PBS was discarded and the adherent cells were 
removed by gently scraping using a disposable sterile cell scraper (Costar). The 
cells were then thoroughly resuspended using an automatic pipette aid, and 
suspended in fresh medium at a concentration of 2xlOVml.
4.2.2 WEHI-3B
WEHI-3B cells, a partially adherent cell Line derived from a monocytic leukaemia 
in a BALB/c mouse (Ralph and Nakoinz 1977), was maintained in SLM / 10% 
FCS / 4mM L-glutamine in NUNC 75cm^ tissue culture flasks. Cells were sub­
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cultured every 3 days, and suspended in fresh medium at a concentration of 
2xl0^/ml. These cells were used to generate WEHI conditioned medium for use 
during culture of FDCP-MIX cells (see section 4.2.3).
4.2.3 FDCP-MIX cells
The factor dependent murine stem cell line FDCP-MIX, derived from src-infected 
long term bone marrow cultures (Dexter et al 1977) was maintained in SLM + 
4mM glutamine / 10%DHS / 10%WEHI conditioned medium as a source of 
interleukin 3 in NUNC 75cm^ tissue culture flasks. Such a source of IL-3 is 
essential to maintain these cells in a healthy undifferentiated state. FDCP-MIX 
cells grow in suspension and were subcultured every 2-3 days and resuspended in 
fresh medium at a concentration of 5xlO^/ml.
4.2.4 U937 cells
The human monocytic cell line U937, derived from a histiocytic lymphoma, was 
maintained in RPMI 1640 4- 4mM glutamine / 10%FCS in NUNC 75cm^ tissue 
culture flasks. U937 cells grow in suspension and were subcultured every 2-3 days 
and resuspended in fresh medium at a concentration of 2x l0^/ml.
4.2.5 L929 cells
The murine fibroblast cell line L929 was maintained in SLM/10% FCS in NUNC 
IScvcfi tissue culture flasks. L929 cells are an adherent cell line, and were 
subcultured every 7 days. Firstly, growth medium was discarded, and cells washed 
in lOmls of PBS. Cells were then detached from tissue culture flask by incubating 
in 10 mis of 0.25% trypsin in PBS for 2-3 minutes at room temperature. Cells 
were then resuspended m fresh medium containing serum and quantitated using a 
Coulter counter, after which they were spun down at 1000 rpm for 10 minutes and 
resuspended in fresh medium at a concentration of 3x10^ cells/ml.
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4.2.6 AF1-19T cells
Murine AF-1 cells were maintained in SLM/10% FCS in NUNC 75cm^ tissue 
culture flasks. AF-1 cells are an adherent cell line, and were subcultured every 7 
days. Firstly, growth medium was discarded, and cells washed in lOmls of PBS. 
Cells were then detached from tissue culture flask by incubating in 10 mis of 0.25% 
trypsin in PBS for 2-3 minutes at room temperature. Cells were then resuspended 
in PBS and quantitated using a Coulter counter, after which they were spun down 
at 1000 rpm for 10 minutes and resuspended in fresh medium at a concentration of 
3x10^ cells/ml.
4.2.7 HT-2 cells
The murine helper T cell line was maintained in RPMI 1640 4- 2mM glutamine / 
10% FCS / 0.05mM mercaptoethanol / 200 U/ml IL-2 in NUNC 75cm^ tissue 
culture flasks. These cells were subcultured every 2-3 days and resuspended in 
fresh medium at a concentration of 2x l0^/ml.
4.3 Production of conditioned media
As a source of M-CSF for use in the CFU-A assay and for derivation of bone 
marrow macrophages, conditioned medium (CM) from the murine L929 cell line 
was prepared. As a source of GM-CSF for use in the CFU-A assay, CM from 
AF1-19T cells was prepared. As a source of Interleukin 3 for maintenance of 
FDCP-MIX cells, CM from WEHI-3B cells was prepared. All CM samples were 
prepared by growing each cell line in roller bottles in SLM/10%FCS to around 
50% confluence and then removing spent medium. The medium was renewed and 
the cells grown for a further 3 days to generate conditioned medium. This medium 
was then removed, filter sterilised through a 0.42pm filter and then through a 
0.2pm filter, aliquoted and stored at -20°C.
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4,4 Harvesting of bone marrow
Bone marrow was obtained from femora of mice. Mice were killed either by CO2 
asphyxiation or cervical dislocation. The femurs were then carefully removed 
using surgical scissors, and stripped of excess muscle using a tissue soaked in 
ethanol. Both ends of the femur were removed with scissors and the bone marrow 
plug expelled by flushing with 2mls of SLM through a 21 gauge needle. The cells 
were re-suspended thoroughly by vigorous pipetting using an automatic pipette 
aid. The cells were then washed in PBS and nucleated cells quantitated using a 
haemocytometer. Approximately 1.5x10^ cells were routinely obtained from each 
femur. Cells were then resuspended at the appropriate concentration and in the 
appropriate medium for their application (see below).
4.4.1 Derivation of bone marrow derived macrophages
Total bone marrow cells obtained as above were suspended at SxlOVml in a- 
modified MEM supplemented with 25% DHS and 20% L929 CM as a source of 
M-CSF. 15ml aliquots of this suspension were incubated in Nunc T75 flasks for 7 
days in a dry atmosphere of 5% COg in air. These gave rise to highly 
homogeneous (>95%) populations of macrophages as verified by staining for the 
macrophage specific enzyme alpha-napthyl acetate esterase (see table 4.4.1). Cells 
were used at 7 days, after which they quickly lose their adherence and die, as 
assessed by visual inspection.
4.4.2 Growth factor starvation of bone marrow derived macrophages
Quiescent bone marrow derived macrophages express M IP-la at very low levels. 
In order to obtain a readily detectable level of MIP-la expression, bone marrow 
macrophages were starved of L929 CM and thus M-CSF by removing medium 
from cells after 7 days and adding fresh a-modified MEM supplemented with 25% 
DHS. Cells were maintained for 16 hrs as such and then re-fed with fresh a- 
modified MEM supplemented with 25% DHS and 20% L929. This has previously 
been shown to rapidly induce MIP-la mRNA expression to a peak at around 4 hrs
Time (days) % positive for non specific (alpha
napthyl acetate) esterase
82
96
98.5
99
100
Table 4.4.1 Staining of bone marrow derived macrophages with the macrophage 
specific stain non specific esterase (NSE). This service was carried out by the 
Haematology Laboratory at the Dept, of Veterinary Pathology, University of 
Glasgow. Results are shown as the percentage of cells positively stained with 
NSE, at days 4 to 8 after initiation of cultures.
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post re-feeding (A. Reid. PhD thesis 1993). Expression remains at an elevated 
level for around 24 hours after which it returns to normal levels.
4.5 The In vitro CFU-A Assay
Bone marrow cells were obtained as described above. For the detection of 
primitive progenitor cells, CFU-A assays were carried out. 2x10"* total bone 
marrow cells in 4mls of supplemented a-modified MEM containing 25% DHS and
0.3% Bacto agar (Difco, USA) were seeded on top of an underlayer of the same 
medium containing 0.6% Bacto agar / 10% L929 CM / 10% AF1-19T CM in 
45mm Petri dishes (Sterilin). Cultures were incubated at 37°C in a fully humidified 
atmosphere of 10% COg, 5% Og and 85% Ng for 11 days. This semi solid agar 
culture gave rise to the formation of macroscopic colonies (>2mm in size), which 
histological analysis has previously revealed to consist of mature haemopoietic 
lineages (Pragnell et al 1988, Lorimore et al 1990). Although colonies smaller 
than 2mm in size do appear in the CFU-A assay, only colonies greater than 2mm 
were scored since it has been previously demonstrated that these larger colonies 
are derived from primitive haemopoietic cells. For all experimental procedures 
involving this assay, a "direct addition" protocol was adopted whereby putative 
inhibitory cytokines are assessed for their potential effects on CFU-A colony 
formation by directly adding various concentrations to the bottom layer of agar.
4.6 RNA and DNA Methodology
4.6.1 DNA cloning
The murine MIP-la and MIP-1(3 cDNAs were amplified using EcoRI and Xhol 
tailed primers in a PCR reaction. The PCR products were then ligated into the 
pBluescript II" plasmid (pSK"). Both plasmids were constructed in the Beatson 
Institute.
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The pcDNA-3 murine RANTES construct and the pcDNA-3 human C-C CKRI 
receptor construct were both kind gifts from Dr. Thomas Schall, DNAX Research 
Institute, USA.
The murine pSP65 TGF-[31 construct was a kind gift from Dr. R. Derynck, USA. 
The murine pCRII glyceraidehyde phosphate dehydrogenase (GAPDH) construct 
was obtained from Max Walker at the Beatson Institute.
The 7S RNA specific probe is a 0.4kb Hinf I fragment of the plasmid pATI 53 
containing the 7S cDNA, and was obtained from Frances Fee at the Beatson 
Institute.
4.6.2 Propagation of plasmid DNA in bacterial host cells
Commercially available competent cells, DH5a, were transformed with the 
appropriate plasmid construct as follows. DH5a cells were removed from the - 
70°C freezer and thawed on ice. 20pl aliquots were dispensed into pre-chilled 
sterile 1.5ml Eppendorf tubes, then Ipl of plasmid construct (lOng/pl) was added 
and incubated on ice for 30 minutes. Cells were then heat shocked at 42° C for 40 
seconds, returned to ice for approximately 2 minutes, and 80pl of S.O.C. medium 
(2% w/v bactotryptone, 0.5% w/v yeast extract, lOmM NaCl, 2.5mM KCl, lOmM 
MgClg, lOmM MgSO^, 20mM glucose) was added. Mixture was shaken at 225 
rpm for 1 hour at 37°C to allow expression of the ançicillin resistance gene. The 
transformed cell mixture was spread evenly using a glass spreader sterilised by 
alcohol flaming onto L-amp plates (5mls of 1% w/v bactotryptone, 0.5% w/v yeast 
extract, 1% NaCl, 1.5% bactoagar) supplemented with 60pg/ml ampicillin. Plates 
were then inverted and incubated at 37°C overnight.
4.6.3 Growth of plasmids
5ml of L-|3roth containing ampicillin (50pg/ml) was inoculated with cells from a 
single colony (from plates prepared in section 4.6.2) using a sterile loop. This was 
incubated at 37°C with shaking at 225 rpm overnight in a 20ml Universal 
container. 1ml of this was then added to lOOmls of L-amp broth and incubated
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under the above conditions overnight in a 1 litre conical flask. Suspensions were 
then transferred to 500ml centrifuge bottles (Sorvall instruments) and spun at 
SOOOrpm for 30 minutes in a Beckmann J-6B centrifuge containing a GS-3 rotor. 
Plasmid preparation was begun immediately or pellets were frozen at -20°C until 
use.
4.6.4 Plasmid preparation
Plasmids were prepared using the commercially available QIAGEN plasmid kit 
(Qiagen Inc, USA) as follows. Bacterial pellets were resuspended in 4ml of 
resuspension buffer (lOOmg/ml RNase A, 50 mM Tris/HCl, lOmM EDTA, pH 
8.0). The suspension was transferred to 50ml centrifuge tubes (Sorvall 
Instruments) and 4ml of lysis buffer (200mM NaOH, 1% SDS) was added, the 
solutions mixed by gentle inversion and incubated at room temperature for 5 
minutes. 4ml of chilled neutralisation buffer (3M KAc, pH 5.5) was added, mixed 
and incubated on ice for 15 minutes. Tubes were then spun at 4°C for 30 minutes 
at 10000 rpm in a Sorvall RC-5B superspeed centrifuge containing SS-34 rotors. 
The supernatant was then poured through a double layered gauze swab to remove 
particulate material. To purify the DNA, a QUIAGEN-tip 100 column was 
equilibrated with 4ml of equilibration buffer (750mM NaCl, 50mM MOPS, 15% 
ethanol, 0.15% Triton X-100, pH 7). The filtered supernatant was then applied to 
the column, and the column washed with 2 x 10ml of wash buffer (IM NaCl, 
50mM MOPS, 15% ethanol, pH 7). DNA was then eluted using 5ml of elution 
buffer (1.25M NaCl, 50mM Tris/HCl, 15% ethanol, pH 8.5). DNA was 
precipitated with 0.7 volumes of isopropanol and centrifuged at 10000 rpm at APC 
for 30 minutes as described above. The DNA pellet was washed with 5ml of cold 
70% ethanol, air dried for 5 minutes, and redissolved in a suitable volume of sterile 
distilled water. The DNA concentration was then quantitated using 
spectrophotometry as follows. 5pi of DNA solution was added to 495pl of water 
and the optical density determined at wavelengths of 260nm and 280nm. An 
OD26O of 1 is equal to 50pg of plasmid or genomic DNA, thus allowing sample
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concentrations to be estimated absolutely. Samples were stored in water at -20°C 
until use.
4.6.5 Restriction digests of plasmid DNA
For large scale digests, plasmid DNA was digested in a solution containing 50pg of 
DNA, 50pl of appropriate lOx React™ buffer, lOpl of appropriate enzyme and 
made up to 500pl using distilled water. Choice of React™ buffer was dependent 
on optimum efficiency conditions of each enzyme. Where two different enzymes 
were used, a compromise was reached where both enzymes would work in the 
same buffer at their highest possible efficiency. Digestion was then carried out for 
2 hours at 37°C in 1.5ml Eppendorf tubes, after which DNA was precipitated by 
adding 0.1 volumes of 3M sodium acetate and 2.5 volumes of absolute ethanol. 
Tubes were left on dry ice for 10 minutes at then spun at 13000rpm for 10 minutes 
in a benchtop micro centaur centrifuge (MSE). Supernatant was carefully removed 
using a 1ml Gilson pipetman, the tube respun and residual supernatant removed 
leaving the DNA pellet intact. The pellet was washed x 2 in 70% ethanol and 
resuspended in lOOpl of distilled water. The optical density of the DNA was 
measured using a spectrophotometer as described in the previous section. The 
DNA was then reprecipitated as described above and the DNA pellet dissolved in a 
volume of distilled water to give a stock solution of Ipg/pl.
4.6.6 Isolation of Total RNA
Total RNA was isolated using a commercially available phenol based extraction 
solution, RNAzol™. For RNA isolation from adherent cells, growth medium was 
removed and cells washed twice in PBS. For 75cm^ flasks, lOmls of RNAzol was 
added and left for 5 minutes at room temperature. The flasks were then shaken 
and the solution pipetted several times to ensure complete lysis of cells. The 
solution was transferred to a 15ml polypropylene tube (Falcon 2059) and 1ml of 
chloroform added. Tubes were shaken vigorously for 15 seconds, placed on ice 
for 15 minutes to allow separation of aqueous and non-aqueous phases and spun at
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10000 rpm for 15 minutes in a Sorvall centrifuge using HB4 or HB6 swing-out 
rotors. The top aqueous layer was removed to a fresh tube and an equal volume of 
isopropanol added. Tubes were then incubated at -20°C for 30 minutes to 
facilitate precipitation of RNA, after which they were spun at 10000 rpm for 15 
minutes. Isopropanol was discarded and the RNA pellet was resuspended in 2mls 
of 75% ethanol and agitated to wash the RNA. Tubes were spun at 10000 rpm for 
15 minutes and ethanol was removed. RNA pellets were then air dried to ensure 
complete absence of ethanol and RNA was resuspended in 105pl of sterile distilled 
H2O. RNA was quantitated by adding 5pi to 495pl of distilled H2O and optical 
density assessed using a Beckman spectrophotometer. Readings were taken at 
wavelengths of 260nm and 280nm. The ratio between readings at 260nm and 
280nm gives an indication of the purity of the RNA obtained with a ratio value of 
1.8-2.0 being best. With the knowledge that an OD260 of 1 corresponds to 
approximately 40pg/ml in the case of RNA, then concentrations can be calculated 
for each sample. Samples were then stored, dissolved in water, at -20°C until use. 
The similar TRIzol RNA extraction reagent was sometimes used in place of 
RNazol. The methodology for extraction of RNA with TRIzol is very similar to 
that described above with the only difference being that none of the stages have to 
be incubated on ice or at -20° C. They were left at room temperature.
4.6.7 Agarose gel electrophoresis and Northern Blotting
For further analysis of RNA species, total RNA was visualised and separated in an 
agarose gel as follows. Approximately 20pg of total RNA was freeze-dried in a 
speedivac, and resuspended in 16pl of RNA sample loading buffer (see section 
3.8.2) containing Ipl of ethidium bromide(lOpg/ml stock). Samples were heated 
at 65°C for 5 minutes and placed immediately on ice to prevent renaturation of 
RNA strands. Samples were then resolved on a denaturing gel (1.4% (w/v) 
agarose, 1 x MOPS buffer, 2.2M formaldehyde and made up to a final volume of 
200mls with distilled H2O). Gels were run at a constant 80 volts for approximately 
2-3 hours, after which RNA integrity was checked by visualisation of ethidium
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bromide stained RNA bands on a UV transilluminator (312nm). The gel was then 
photographed using Polaroid Type 57 high speed film alongside a fiuorescent ruler 
to enable subsequent sizing of RNA species. Excess agarose was trimmed from 
the gel, and the RNA transferred to Genescreen or Hybond-N+ membrane 
overnight by capillary transfer in lOx SSC. Briefly, a rectangular piece of 
Whatman 3MM blotting paper was cut and placed on a raised platform in a glass 
tank. lOxSSC was then poured over the paper to partially fill the tank such that 
either end of the paper dipped into the SSC thus forming a paper wick. The 
agarose gel was then placed on top of the wet paper and layered with a prewetted 
Hybond-N+ membrane cut to the size of the gel and then 6 pieces of pre-cut 
Whatmann 3MM paper. The surrounding area of the paper wick was then covered 
using plastic sheets and 3 layers of paper towelling (Scott), each 6 paper towels 
thick, layered over the gel. RNA was fixed onto the membrane following transfer 
either by baking at 80°C for 2 hours or by UV linking on a UV Stratalinker 1800 
(Stratagene). Efficient transfer was confirmed by viewing the agarose gel under 
UV light to ensure no RNA was visibly left on the gel. Membranes were wrapped 
in Saranwrap and stored at room temperature until use.
4.7 Preparation of radiolabelled probes
4.7.1 Uniform labelling of anti-sense RNA riboprobes
The plasmid, either pBluescript II SK (pSK~ or pSK+), containing the gene of 
interest was linearised using the appropriate restriction enzyme as described above. 
This was to prevent vector sequences being used as template by the enzyme (either 
T3 or SP6 polymerase) and thus increase the efficiency and specificity of the 
reaction. Probes were then generated as in vitro transcription products of the 
relevant gene coding sequence. Labelling was carried out using a commercially 
available SP6/T7 transcription kit (Boehringer Mannheim) according to 
manufacturers instructions yielding an [a-^^P]-UTP labelled antisense RNA 
transcript with a specific activity of approximately 10® cpm/pig.
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4.7.2 Olîgolabelling of DNA fragments
Denatured DNA restriction fragments (25-50ng/ml) were labelled for 15 minutes at 
37°C with [a-®2p]-dCTP (3000 Ci/mmol) using a commercially available random 
priming kit, Ready-to-Go (Pharmacia) according to manufacturers instructions. 
This method involves mixing random oligodeoxyribonucleotides with the DNA to 
be labelled which anneal to random sites on the DNA. These then serve as primers 
for DNA synthesis by a DNA polymerase resulting in a labelled DNA fragment of 
high specific activity.
4.7.3 Purification of radiolabelled RNA and DNA probes
All radiolabelled probes were subsequently separated from unincorporated ®^ P- 
labelled nucleotides by passing through a NICK column (Pharmacia), pre­
equilibrated with 1 X TE, according to manufacturers instructions. DNA probes 
were denatured by boiling for 2-3 minutes, and placing on ice prior to use.
4.7.4 Hybridisation conditions for northern blots
Two methods of prehybridisation and hybridisation were utilised in this study.
1. RNA Riboprobe hybridisation: Membranes were incubated in approximately 
lOmls of 50% formamide prehybridisation solution (50% formamide, 5 x SSPE, 5 
X Denhardts, 0.1% SDS, 0.2% Poly (A), 12.8% distilled H2O, and 0.1% salmon 
sperm DNA of a lOmg/ml stock solution) for 3 hours at 42°C or 65°C in a Hybaid 
Mini 10 hybridisation oven. After this time, prehybridisation buffer was removed 
and replaced with lOmls of fresh buffer containing the appropriate radiolabelled 
probe (see below). Membranes were then hybridised at 42°C or 65°C overnight 
after which the radioactive buffer was discarded and the membrane washed as 
follows. The membrane was washed initially in 2 x SSPE/0.1% SDS for 30 
minutes at room temperature, after which the radioactivity still bound to the 
membrane was assessed using a series 900 radiation mini-monitor (Mini- 
Instruments Ltd., UK). If the background radiation was still high, then membrane
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was washed for a further 30 minutes using 2 x SSPE/0.1% SDS at 65°C. If high 
background radiation was still detectable then membrane was washed more 
stringently in 0.2 x SSPE/0.1% SDS for 30 minutes at 65°C, or until background 
radiation was negligible. After washing, the membranes were wrapped in 
Saranwrap and transferred to an exposure cassette containing an intensifying 
screen. Membranes were exposed to Kodak X-Ray film (X OMAT-AR) at -70°C 
for approximately 4 hours in the first instance and then overnight if appropriate.
2. Pharmacia Ready to Go labelling kit hybridisation Prehybridisation and 
hybridisation was carried out essentially as above except pre and hybridisation fluid 
was 0.25M Na2HP0  ^/ 7% SDS, pH7 and pre and hybridisation was carried out at 
65°C. Membranes were then washed x 2 in 20mM Na2HP0  ^ / 5% SDS, pH 7.2 
for 30 minutes at room temperature and/or 65°C, and then x 2 in 20mM Na2HPO^ 
/ 1% SDS, pH 7.2 for 30 minutes at 65°C.
4.7.5 Stripping of Northern blots
Blots were stripped of bound radiolabelled probe by boiling for 10 minutes in 
several hundred millilitres of 0.1% SDS. The efficiency of stripping was verified 
by exposing the membrane to X-ray film for 18hrs. Membranes were then used for 
further hybridisation protocols as described above.
4.7.6 Image analysis of Northern blots
Northern blots were scanned using a Molecular Dynamics laser densitometer, and 
data analysed on a Sun Workstation using Protein Databases Inc. Quantity One 
software. The assistance of Lynn McGarry is gratefully acknowledged.
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4.8 Protein Detection
4.8.1 Preparation of RAW cell conditioned medium
RAW cells were grown in 15mls of SLM/10% FCS as described in section 2.1, and 
then several flasks treated with TGF-(3 at a concentration of 250pM. Medium was 
collected from flasks after 24, 48, 72 and 96hrs, and partially concentrated using a 
Centriprep 10 protein purification column by spinning lOmls of each sample at 
lOOOOrpm for 30 minutes in a benchtop centrifuge.
4.8.2 SDS Polyacrylamide Gel Electrophoresis
15% polyacrylamide gels were prepared using a commercially available acrylamide 
/ bisacrylamide stock solution (30% w/v acrylamide / 0.8% w/v bisacrylamide) 
(Severn Biotech Ltd.) as follows:
Water 7.5ml
Acrylamide mix 12.5ml
1.5M Tris (pH 8.8) 6.3ml
10% SDS 0.25ml
10% ammonium persulphate 0.25ml 
TEMED 0.01ml
This solution was mixed and poured between two minigel glass plates. 
Approximately 500pl of water saturated iso-butanol was layered on top of the 
solution to enable a smooth interface between stacking and resolving gels to be 
formed, and the gel left to set at room temperature. A 5% stacking gel was 
prepared essentially as above but with differing amounts of additives (6.8ml water, 
1.7ml acrylamide mix, 1.25ml IM Tris (pH 6.8), 0.1ml SDS (10% stock), 0.1ml 
ammonium persulphate (10% stock), 0.01ml TEMED). The water saturated 
butanol was poured off, and the top of the gel thoroughly washed using distilled 
water. Approximately 3-4mls of stacking gel solution was then poured between
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the glass plates overlaying the solid gel and an appropriate comb was inserted to 
construct wells. This was then left at room temperature to set and the comb 
carefully removed. Samples were prepared for electrophoresis by adding 20pl of 
each sample to 15pl of gel loading buffer in 1.5ml Eppendorf tubes (5pl SDS/DTT 
(see section 3.8.3), 5pl bromophenol blue solution/ 5pl glycerol) and heated at 
100°C for 5 minutes to denature and reduce the proteins. Samples were loaded 
onto the gel along with low molecular weight rainbow markers (Amersham) to 
enable sizing of discrete bands and to check transfer had occurred during Western 
blotting. Electrophoresis was carried out at room temperature in SDS-PAGE 
electrophoresis buffer (28.8g glycine, 6.05g tris.HCl, 2g of SDS and made up to 2 
litres with dH20) at 150V until the blue dye front almost reached the bottom of 
the gel.
4.8.3 Western blotting
MIP-la content of cell conditioned media was then analysed by Western blotting. 
The contents of the gel were transferred to nitrocellulose membranes (Schleicher & 
Schuell) by semi-dry blotting using minigel electroblotting equipment (Biotech 
Instruments Ltd.) at a constant current of 8mA/cm^ gel area for 30 minutes as 
follows. Briefly, many pieces of Whatman 3MM blotting paper were cut to match 
the dimensions of the polyacrylamide gel (usually 6cm x 9cm), as was a piece of 
nitrocellulose. Six pieces of blotting paper were soaked in western blot solution 1 
(see section 3.8.3) and placed onto the electroblotter, followed by 3 pieces soaked 
in western blot solution 2 (see section 3.8.3). Any air bubbles were removed using 
a plastic pipette. The piece of nitrocellulose was soaked in western blot solution 2, 
and layered on top of the blotting papers, followed by the polyacrylamide gel, 
again removing away any air bubbles. Six pieces of blotting paper soaked in 
cathode solution (see section 3.8.3) were placed on top of the gel and the 
apparatus assembled. The electroblotter was then turned on and run at the above 
mentioned conditions. After blotting, the membrane was incubated in BLOTTO 
solution (5% Marvel dried milk in PBS, 0.1% NP40) overnight to block non­
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specific binding sites, after which washing was continued for 30 minutes in several 
changes of BLOTTO. The membrane was then exposed to the primary polyclonal 
goat anti-MIP-la antibody at the appropriate dilution (usually 1:1000) in lOmls of 
BLOTTO for 1 hour. This was discarded and the membrane washed in several 
changes of BLOTTO for 45 minutes. The membrane was then incubated with the 
secondary anti-goat IgG antibody conjugated to horse radish peroxidase in lOmls 
of BLOTTO for 1 hour after which this was discarded and the membrane washed 
in several changes of BLOTTO for 30 minutes and then in several changes of 
PBS/0.1% tween for 30 minutes. Antibody binding was then visualised using an 
enhanced chemiluminescence (ECL) kit (Amersham), which involved agitating the 
membrane in ECL solutions for 60 seconds. The membrane was then wrapped in 
Saranwrap clingfilm and exposed to X-OMAT AR X-ray film for the appropriate 
time to enable visualisation of protein bands.
4.8.4 TGF-(31 protein quantitation using ELISA
TGF-|31 protein content of bone marrow derived macrophage conditioned media 
was determined using a commercially available "sandwich technique" ELISA kit 
(R&D systems, UK) which detects both murine and human TGF-(31. This kit 
adopts an alternative protocol to traditional ELISA based methodology in that 
initial TGF-(3 binding to the plate is accomplished via TGF-(3 type II receptor 
adherent to the well (rather than an antibody) which recognises all TGF-(3 
isoforms. The kit then specifically detects TGF-(31 via a polyclonal secondary 
antibody conjugated to horse radish peroxidase. As only active TGF-|3 is capable 
of binding to the type II receptor, this method necessitates acid activation of TGF- 
(3 present in conditioned media samples. 1ml of each BMDM conditioned media 
sample, previously concentrated using Centriprep 10 spin columns according to 
manufacturers instructions, was acid treated by adding 200pl of IN HCl for 10 
minutes and then neutralised by adding 200pl of 1.2N NaOH / 0.5M HEPES. As a 
control, a standard curve of pure TGF-(31 was prepared by diluting 500pl of a 
2000pg/ml stock into 500pl of RD5I diluent (see manufacturers instructions).
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Serial dilutions from lOOOpg/ml to 31.25pg/ml were then carried out. Although 
human TGF-(31 was used as a control, the assay kit detects murine TGF-|31 with 
equivalent accuracy. 200pl of standards and samples were then loaded in duplicate 
into a 96 well plate, covered with a plastic film and incubated at room temperature 
for 3 hours. Plate contents were discarded and each well washed x 3 with 400pl of 
wash buffer. 200pl of anti-TGF|31 conjugate was then added to each well and 
incubated at room temperature for a further 90 minutes. Each well was then 
washed x 3 with 400pl of wash buffer after which 200pl of substrate solution was 
added to each well. The plate was incubated at room temperature for 20 minutes 
to allow colour development and 50pl of stop solution was then added to each 
well. The optical density of each well was then determined using a Beckman DU 
650 spectrophotometer set to 450nm. Readings at 570nm were also taken and 
subtracted from the 450nm readings to correct for optical imperfections in the 
polystyrene microtiter plate.
4.9 Receptor Binding Methodology
4.9.1 125% labelling of M IP-Ia protein
MIP-la protein was labelled using lodo-gen (Pierce, U.S.A.), a commercially 
available iodination reagent which resembles a four-fold chloramine T molecule. 
lOpg of MIP-la in PBS was incubated with lOpg of immobilised iodogen and 
ImCi Nai25i (New England Nuclear) in Eppendorf tubes for 15 minutes on ice. All 
work involving was carried out behind a protective lead impregnated screen. 
Unincorporated iodine was then separated from labelled protein by applying the 
reaction mixture to a disposable desalt column (GF5 excellulose columns; Pierce) 
and eluting with PBS. 500pl fractions were collected and counts per minute 
assessed in a gamma counter to detect the peak of protein associated radioactivity. 
The three most active fractions were then pooled yielding a solution of M IP-la 
protein labelled to high specific activity (2.5x10^ cpm/mg). The integrity of the 
labelled protein was then checked by SDS-PAGE, and the proteins biological
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activity checked in the previously described CFU-A assay. Iodination did not 
affect the biological potency of the protein in the CFU-A assay (Graham et al 
1993). Labelled MIP-la was then stored in polypropylene tubes at 4°C and used 
within 1 month.
4.9.2 MIP-la receptor binding studies on FDCP-MIX cells
FDCP-MIX cells were counted in a haemocytometer as previously described, spun 
down at lOOOrpm and washed twice in PBS. Cells were then resuspended at 
IxlO^/ml and 5x10^ cells per point were aliquoted into individual Eppendorf tubes. 
These were spun in a microcentrifuge at 13000rpm for 1 minute and PBS was 
carefully removed using a pipette. To each aliquot, varying concentrations of iz I^ 
labelled MIP-a were added in binding buffer (SLM / 10% DHS / 0.2% azide) and 
either PBS or 100-fold excess unlabelled MIP-la competitor up to a final volume 
of 250pl. Cells were then incubated in the above conditions at 37°C for 90 
minutes after which they were washed x 3 in PBS, and the incorporated radiation 
in the cell pellets assessed in a gamma counter (Beckman Gamma 5500B). To 
detect possible TGF-(3 effects on MIP-la receptor levels on FDCP-MIX cells, 
cells were incubated at a concentration of 1x10* cells/ml for 16 hours in the 
presence of varying concentrations of TGF-|3 (for details see figure legends) prior 
to receptor binding assay. Analysis of binding isotherms was then performed using 
the LIGAND computer program (Munson and Robard 1980).
4.9.3 Calcium flux studies in FDCP-MIX cells
FDCP-MIX cells were counted in a haemocytometer, spun down at lOOOrpm and 
washed twice in PBS. Cells were then resuspended in calcium free HACM buffer 
(see materials) at a concentration of lxlO*/ml. The fluorescent dye FURA-2 AM 
was added to the cell suspension at a concentration of 0.5pM, and the cells 
incubated at 37°C for 45 minutes to allow the FURA-2 to permeate the cells. This 
phase was carried out in the dark since FURA-2 is light sensitive. The cells were 
then spun, washed twice in warm PBS and resuspended at a concentration of
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lxlO*/ml in HACM buffer containing calcium. Cells were then incubated in the 
dark at 37°C for a further 30 minutes prior to use. 2mls of each cell suspension 
was aliquoted directly into a spectrophotometer cuvette, and the appropriate 
stimulants added directly to the cell suspension. Overall changes in the intensity of 
the FURA-2 were assessed using a Perkin Elmer spectrophotometer.
CHAPTER 5
RESULTS
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CHAPTER 5 - Results
5.1 Overview
In order to investigate any potential interactions between the negative 
regulators of stem cell proliferation, it was necessary to firstly find a suitable in 
vitro assay system which was responsive to each individual molecule. Using such a 
system, any potential additive, synergistic or antagonistic effects between them 
should be easily determined. The in vitro CFU-A assay, which as described in 
section 1.2.4 detects a primitive multipotent haemopoietic cell, is in routine use in 
our laboratory and thus represented an attractive possibility.
5.1.1 Effect of MIP-la on CFU-A colony formation
The inhibitory effects of MIP-la on CFU-A colony formation have been 
previously reported (Graham et al 1990). However, in order to standardise the 
methodology for analysis of the other potential inhibitors, the effect and potency of 
MIP-la in this assay was investigated. This assay was performed using a titration 
of MIP-la concentrations up to 500pM. The results, representative of 3 separate 
experiments are shown in figure 5.1. Control plates contained an average of 24 
colonies in this assay. These results show that M IP-la is a potent inhibitor of 
CFU-A colony formation, with an ED50 of approximately lOOpM. This is in 
agreement with the previous findings of Graham et al (1990).
5.1.2 Effect of TGF-(31 on CFU-A colony formation
The inhibitory effects of TGF-pl on haemopoietic cells have been 
previously reported (see introduction). As TGF-pi has been shown to inhibit 
CFU-S type stem cells, it was expected to exhibit an effect in the CFU-A assay, an 
in vitro correlate of the CFU-S assay. Control plates contained an average of 21 
colonies in this assay. Figure 5.1.2 shows that direct addition of a titration of 
TGF-pi concentrations (up to 500pM) resulted in dose dependent inhibition of 
CFU-A colony formation analogous to that shown by MIP-la. Both of these
Figure 5.1.1 Effect of Macrophage Inflammatory Protein 1 alpha (MIP-la) 
on CFU-A colony formation.
MIP-la was tested for inhibitory activity in the direct addition CFU-A assay as 
described in section 4.5. MIP-la was added directly to the feeder layers (0.6% 
agar in a-MEM with sources of M-CSF and GM-CSF) of the CFU-A assays, and 
the target cells were normal bone marrow cells plated at 5xlO^/ml in the upper 
layer (0.3% agar in a-MEM). These assays were carried out in 45mm diameter 
Petri dishes. The assay plates were incubated at 37°C in a fully humidified 
atmosphere of 10% CO2, 5% O2, and 85% N2 for 11 days. Colonies >2mm were 
scored as being CFU-A type. The results represent the effect of increasing 
cytokine concentrations on CFU-A colony formation and are depicted as mean 
values +/- standard deviation. The results depicted are representative of at least 3 
separate experiments.
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Figure 5.1.2 Effect of Transforming Growth Factor beta (TGF-(3) on 
CFU-A colony formation
CFU-A assays were performed as described in section 4.5. The results 
represent the effect of increasing cytokine concentrations on CFU-A 
colony formation and are shown as mean values +/- standard deviation. 
The results depicted are representative of at least 3 separate experiments.
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molecules are active in the picomolar range, again emphasising their apparent 
functional similarities on haemopoietic stem cells.
5.1.3 Effect of tetrapeptide on CFU-A colony formation
As is described in the introduction, the inhibitory effects of the tetrapeptide 
on haemopoietic stem cells appear to be limited to cells falling within the CFU-S 
region of the stem cell compartment. Furthermore, the tetrapeptide appears to be 
unable to actively render cycling cells quiescent, and appears to act by holding 
already quiescent cells in that state. It was anticipated however that the 
tetrapeptide may still exhibit an effect in the CFU-A assay since the cells detected 
by this in vitro assay are very similar phenotypically to CFU-S cells, and also, a 
high proportion (approximately 90%) are quiescent at the onset of the assay. 
However, no inhibitory effect could be routinely obtained using the tetrapeptide in 
a direct addition CFU-A assay. Control plates contained an average of 18 colonies 
in this assay. Figure 5.1.3 represents the mean of three separate assays, and shows 
that no inhibition could be obtained.
5.1.4 Effect of haemoregulatory pentapeptide (pEEDCK) on CFU-A colony 
formation
Like the other inhibitors mentioned above, pEEDCK has previously been 
shown to exert an inhibitory effect of primitive haemopoietic cells including CFU-S 
(Paukovits et al 1990). However, as figure 5.1.4 shows, no inhibition of CFU-A 
colony formation was observed using pEEDCK over a wide range of 
concentrations. Control plates contained an average of 14 colonies in this assay
5.1.5 Summary
These results demonstrate that of the four inhibitors of haemopoietic stem 
cell proliferation analysed in this study, only M IP-la and TGF-pl appear to be 
potently active in inhibiting CFU-A colony formation. Indeed, the similar results 
using these two molecules in this regard confirms the apparent overlz^ in actions of
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Figure 5.1.3 Effect of the Tetrapeptide (AcSDKP) on CFU-A colony 
formation
The tetrapeptide (AcSDKP) was tested for inhibitory activity in the direct 
addition CFTJ-A assay as described in section 4.5. The results represent the 
effect of increasing tetrapeptide concentrations on CFU-A colony formation 
and are shown as mean values +/- standard deviation The results depicted are 
representative of at least 3 separate experiments.
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Figure 5.1.4 Effect of the pentapeptide (pEEDCK) on CFU-A colony 
formation
The pentapeptide (pEEDCK) was tested for inhibitory activity in the 
direct addition CFU-A assay as described in section 4.5. The results 
represent the effect of increasing pentapeptide concentrations on CFU-A 
colony formation and are shown as mean values +/- standard deviation. 
The results depicted are representative of at least 3 separate 
experiments.
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these cytokines on this cellular population. One complicating feature of these 
studies is that the in vitro CFU-A assay, like normal bone marrow, consists of a 
multicellular environment, and it is possible that one or other of these two 
molecules may be acting indirectly by inducing expression of the other in non­
target cells such as macrophages which are known to produce both cytokines. To 
investigate this possibility in more detail, it was decided to firstly address the 
possibility that TGF-|31 may act through possible inductive effects on MIP-la 
expression in normal bone marrow derived macrophages, a potential source of 
MIP-la in the bone marrow.
5.2 Effect of TGF-pi on MIP-la expression in murine bone marrow derived 
macrophages
5.2.1 Inhibition of MIP-la gene expression induction by TGF-pi in murine 
bone marrow derived macrophages
It has been shown previously that murine bone marrow derived 
macrophages starved of the growth factor M-CSF for 16hrs enter growth arrest 
(Tushinski and Stanley 1985). Upon refeeding with M-CSF, MIP-la mRNA 
expression, as detected by Northern blot analysis, is rapidly induced to an optimum 
at around 4 hrs. Given the very low level of M IP-la mRNA expression observed 
in cultured macrophages, it was decided to use this technique of M IP-la mRNA 
expression induction to obtain a readily detectable level of expression. Any 
possible effect, either inhibitory or stimulatory, of TGF-pl on MIP-la mRNA 
expression could then be more easily detennined.
The effect of TGF-pl on the induction of M IP-la mRNA expression was 
investigated. Figure 5.2.1 shows a time course of MIP-la mRNA expression in 
cells after refeeding with M-CSF, with or without TGF-pi (250pM) as measured 
by Northern blot analysis. As previously demonstrated, in the absence of TGF-pi, 
MIP-la expression peaks approximately 4 hrs after feeding, and remains elevated. 
In the presence of TGF-pi however, the induction of MIP-la expression is
Figure 5.2.1 Northern blot analysis of the effect of TGF-pl on MIP-la
expression in bone marrow derived macrophages induced by M-CSF.
Bone marrow derived macrophages were starved for 16hrs of the growth factor 
M-CSF, and refed with fresh medium containing M-CSF at time 0 plus or minus 
TGF-pl at a concentration of 250pM. Total RNA was prepared 0, 1,2, 4, 6 and 
24hrs following addition of M-CSF plus or minus TGF-pi, and 20pg of total RNA 
was run on a 1.4% (wt/vol) agarose gel. The RNA was transferred by Northern 
blotting, and the membrane probed using a radiolabelled M IP-la specific 
riboprobe. The autoradiograph was exposed for 18hrs. Details of each individual 
lane are shown in the figure. This blot is representative of at least three separate 
experiments. Equal loading of total RNA was confirmed by ethidium bromide 
staining and reprobing for GAPDH.
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markedly inhibited throughout all the time-points investigated. Even after 24 hrs, 
densitometric analysis shows that expression of M IP-la mRNA in TGF-pi treated 
cells remains inhibited by approximately 90% compared with the control cells. 
Ethidium bromide staining and reprobing of these blots for the house-keeping gene 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) revealed similar loading of 
RNA in all tracks (data not shown). This demonstrates that the TGF-pi mediated 
inhibition of MIP-la mRNA expression is not sinply due to TGF-pl induced cell 
death since expression of house-keeping genes is unaffected. Further, since 
ethidium bromide staining and GAPDH probing revealed similar loading of RNA, 
ethidium bromide staining was routinely used to standardise RNA loading in 
subsequent experiments.
5.2.2 Titration of the inhibitoiy effect of TGF-pl on M IP-la  mRNA 
expression
To assess the potency of the inhibitory effect of TGF-pi on M IP-la 
mRNA expression in bone marrow macrophages, a titration of TGF-pi (IpM to 
300pM) was used in the same experimental protocol. Cells were studied at 4 hrs 
after feeding as this leads to the optimum induction of M IP-la expression, 
therefore allowing the extent of inhibition by TGF-pl to be easily measured. 
Figure 5.2.2 shows MIP-la mRNA expression to be inhibited in a dose dependent 
manner, and even using concentrations of TGF-pi as low as IpM, densitometric 
analysis shows that MIP-la mRNA expression is reduced by approximately 70% 
compared with control values. This data indicates TGF-pl to be remarkably 
potent with respect to inhibition of M IP-la mRNA expression in macrophages, 
and indeed suggests that TGF-pi is capable of exerting this effect at femtomolar 
concentrations.
5.2.3 Inhibition of M IP -la  gene expression by TGF-pl in RAW 264.7 cells
Although it has been demonstrated that TGF-pi is a potent inhibitor of 
MIP-la expression in bone marrow derived macrophages, it is of more relevance
Figure 5.2.2 Northern blot analysis of the effect of a titration of TGF-pi on
M IP-la expression in BMDM induced by M-CSF.
BMDM were starved overnight of the growth factor M-CSF, and refed with fresh 
medium containing M-CSF at time 0 plus or minus TGF-pl at the concentrations 
shown. Total RNA was prepared 0 and 4hrs after cytokine addition, and 20\ig of 
total RNA was run on a 1.4% (wt/vol) agarose gel. The RNA was transferred by 
Northern blotting, and the membrane probed using a radiolabelled MIP-la specific 
riboprobe. The autoradiograph was exposed for 18 hrs. The blot is representative 
of at least three separate experiments. Equal loading of total RNA was confirmed 
by ethidium bromide staining.
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when considering potential functional consequences to ascertain if this inhibition is 
reflected at the protein level also. It was discovered throughout the course of this 
work that bone marrow derived macrophages express very low and often 
undetectable levels of MIP-la protein as assessed by Western blot analysis. It 
would therefore be very difficult to investigate if TGF-pl inhibited MIP-la protein 
production in these cells. Thus, it was decided to look for similar inhibitory effects 
of TGF-(31 on MIP-la in a murine macrophage cell line which is capable of 
producing readily detectable levels of MIP-la protein. RAW 264.7 cells are such 
a cell line and as with the BMDM, it was desirable to obtain an increased and easily 
detectable level of MIP-la expression in these cells also. Since they are a 
transformed cell line however, they are growth factor independent, and it was 
decided to induce MIP-la expression by starving the cells of FCS for 16 hrs and 
then refeeding with fresh FCS. As shown in figure 5.2.3, TGF-(31 is also active as 
an inhibitor of MIP-la mRNA expression in these cells. This Northern blot also 
demonstrates that the TGF-pl diluent (HCl/BSA) does not potently inhibit MIP- 
l a  mRNA expression in these cells. Although it appears that MIP-la expression 
is slightly inhibited by HCl-BSA in this experiment, this was not the case routinely 
and represents an aberrant point. Addition of equal volumes (equivalent to the 
highest volume of TGF-(3 used) of HCl/BSA was routinely added to all control 
cells.
5.2.4 Inhibitory effect of TGF-pl on MIP-la protein production by RAW 
264.7 cells
Figure 5.2.4 shows an analysis of conditioned medium from control and 
TGF-pi treated RAW cells for presence of MIP-la protein using Western 
blotting. Conditioned medium samples were collected later than total RNA due to 
the potentially longer time required for changes in mRNA to be reflected at the 
protein level. It was anticipated that any inhibitory effect of TGF-pl on MIP-la 
protein synthesis would be apparent around 24hrs after treatment with TGF-pi. 
The results indicate that in the presence of TGF-pi, MIP-la protein levels are
Figure 5.2.3 Northern blot analysis of the effect of TGF-pl on M IP-la
expression in RAW 264.7 cells
RAW 264.7 cells were starved of foetal calf serum (FCS) overnight, and refed with 
fresh medium containing FCS at time 0 plus or minus TGF-p at a concentration of 
250pM. HCl/BSA, the diluent for TGF-p was included as a control. Total RNA 
was prepared 0 and 4hrs after cytokine addition, and 20pg of total RNA was run 
on a 1.4% (wt/vol) agarose gel. The RNA was transferred by Northern blotting, 
and the membrane probed using a radiolabelled MIP-la specific riboprobe. The 
autoradiograph was exposed for 18 hrs. The blot is representative of at least three 
separate experiments. Equal loading of total RNA was confirmed by ethidium 
bromide staining.
o
IT
Oo
3
Oo
3
4^
3 " 3
4-
%
O
C
00
( / )>
H"
H
O
T1
-CD
Figure 5.2.4 Western blot analysis of the effect of TGF-pl on M IP-la  
protein production by RAW264.7 cells
RAW 264.7 cells were starved overnight of foetal calf serum (FCS), and refed with 
fresh medium containing FCS at time 0 plus or minus TGF-pl at a concentration of 
250pM. Medium was harvested after 24, 48, 72 and 96hrs. M IP-la protein 
presence in this harvested medium was determined by Western blotting using a 
commercially available polyclonal antibody to MIP-la (R&D Systems) at a 
concentration of 1:1000. Lane details are shown opposite.
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substantially reduced, and that this effect is evident after 24 hrs. Further, this 
inhibition was maintained over the 96 hr time course of this experiment. These 
results suggest that the inhibition of MIP-la mRNA expression by TGF-pi is also 
observed as an inhibition of protein synthesis and that the potent blocking of MIP- 
l a  production by TGF-pl may have important physiological and functional 
implications.
5.3 Effect of TGF-p 1 on mRNA expression of MIP-la family members
5.3.1 Inhibitory effeet of TGF-pl on MIP-lp mRNA expression in bone 
marrow derived macrophages
As was mentioned in the introduction, M IP-la belongs to a large family of 
related molecules, some of which are capable of exerting stem cell inhibitory 
properties, and some which are not. To determine whether the TGF-pl inhibition 
of M IP-la expression was a specific phenomenon, the effect of TGF-pi on MIP- 
lp  mRNA expression in bone marrow derived macrophages was investigated. 
MIP-ip is a related molecule to MIP-la which exhibits weak stem cell inhibitory 
properties. The blot shown in figure 5.2.1 was stripped of M IP-la specific probe 
as described in section 4.7.5. The results (figure 5.3.1) show firstly that MIP-ip 
mRNA expression miirors MIP-la expression upon refeeding of the cells with M- 
CSF. Further, TGF-pi can also inhibit MIP-ip mRNA expression, and therefore it 
appears that TGF-pl is not specific in inhibiting M IP-la gene expression in bone 
marrow derived macrophages.
5.3.2 TGF-pi inhibits LPS stimulated MIP-la expression induction but does 
not affect LPS stimulated RANTES mRNA expression
To further investigate the specificity of TGF-pi in inhibiting MIP-la and 
MIP-lp mRNA expression, the effect of TGF-pl on more diverse members of the 
chemokine family which display no stem cell inhibitory activity was investigated. 
RANTES, like MIP-la and MIP-lp, is a member of the C-C branch of the
Figure 5.3.1 Northern blot analysis of the effect of TGF-pl on MIP-ip
expression in BMDM induced by M-CSF
The membrane shown in figure 5.2.1 was stripped of MIP-la specific riboprobe by 
boiling for 10 minutes in several hundred millilitres of 0.1% SDS, and the 
membrane probed using a radiolabelled MIP-lp specific riboprobe. The 
autoradiograph was exposed for 18hrs. Details of each individual lane are shown 
in the figure. This blot is representative of at least three separate experiments. 
Equal loading of total RNA was confirmed by ethidium bromide staining.
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chemokine family whereas DL-8 is a member of the C-X-C branch. Both of these 
molecules appear to have important roles in the immune system, and inflammation 
in particular, with no detectable stem cell inhibitory properties in the CFU-A assay. 
It is possible, and indeed likely, that the downregulation of MIP-la and MIP-lp ty 
TGF-pi is a result of the ability of TGF-pi to act as a general anti-inflammatory 
molecule. Indeed, TGF-pi is a potent de-activator of macrophages, and it is 
possible that the observed downregulation falls into this category of cellular 
control. It is interesting to note in this context that TGF-pi is also active in 
inhibiting induction of MIP-la mRNA after treatment of bone marrow derived 
macrophages with LPS, a bacterial mitogen. Figure 5.3.2 shows that MIP-la 
induction by LPS in these cells is inhibited by TGF-pl in a dose dependent manner. 
This lends further credence to the argument that the TGF-pi mediated inhibition of 
MIP-la expression is part of the inflammatory cytokine network (see discussion). 
Such a conclusion would predict that other pro-inflammatory molecules belonging 
to the chemokine family might also be downregulated by TGF-pi. To this end, the 
effect of TGF-pi on RANTES expression in the murine T cell line HT-2 was 
investigated. Figure 5.3.3 shows however, that TGF-pi does not affect, either 
positively or negatively, the expression of RANTES in these cells. Interestingly, 
expression of RANTES does not appear to be induced by LPS in these cells, and 
this is in agreement with results of Xing et al (1994) who demonstrate that 
RANTES is not induced by endotoxin in neutrophils and macrophages in vivo. 
HT-2 cells have previously been shown to be able to respond to TGF-p and thus 
they possess functional TGF-p receptors (Taipale et at 1994, Chao et al 1992). 
Therefore, the fact that TGF-pi does not affect expression of RANTES is not 
simply due to the cells being unable to respond to TGF-pi. Interestingly, Mauviel 
et al (1993) have also demonstrated that TGF-pi and TGF-p2 do not alter 
cytokine induced IL-8 expression in human adult skin fibroblasts. IL-8 is another 
member of the pro-inflammatory chemokine superfamily, and it thus appears that 
TGF-pl appears to specifically inhibit expression of the stem cell inhibitory 
molecules M IP-la and MIP-ip, but not other more diverse members of the
Figure 5.3.2 Northern blot analysis of the effect of TGF-pi on M IP-la
expression in BMDM induced by LPS
BMDM were treated with LPS (20ng/ml) plus or minus TGF-p at the 
concentrations shown opposite. Total RNA was prepared 0 and 4 hrs after 
additions, and 20mg of RNA was run on a 1.4% (wt/vol) agarose gel. The RNA 
was transferred by Northern blotting, and the membrane probed using a 
radiolabelled M IP-la specific riboprobe. The autoradiograph was exposed for 
18hrs. The blot is representative of three separate experiments. Equal loading of 
RNA was confirmed by ethidium bromide staining.
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Figure 5.3.3 Northern blot analysis of the effect of TGF-pl on RANTES
expression in HT-2 cells
HT-2 cells were sub-cultured and then grown for 2 days, after which TGF-pl was 
added at a concentration of 250pM. Total RNA was prepared 0 and 4hrs after 
cytokine addition and, 20pg of total RNA was run on a 1.4% (wt/vol) agarose gel. 
The RNA was transferred by Northern blotting, and the membrane probed using a 
radiolabelled RANTES specific DNA probe. The autoradiograph was exposed for 
24hrs. Details of each individual lane are shown in the figure. This blot is 
representative of at least three separate experiments. Equal loading of total RNA 
was confirmed by ethidium bromide staining.
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chemokine family. It should be noted here that since TGF-pl is also capable of 
potently inhibiting MIP-la expression induced by LPS, this method of MIP-la 
induction was used henceforth rather than starving the cells of M-CSF for 16 hrs. 
This method represented an easier and less time consuming alternative.
5.4 Effect of TGF-p family members on MIP-la expression in BMDM: 
TGF-P2 and TGF-pS inhibit MIP-la mRNA expression in bone marrow 
derived macrophages, but activin and BMP-2 do not
As was discussed in the introduction, TGF-pl belongs to a large family of 
related molecules, some of which, its isoforms in particular, are capable of exerting 
similar if not identical effects to the prototype TGF-pi, where the differences may 
be quantitative rather than qualitative. To more fully understand the interactions 
between MIP-la and TGF-p, it was therefore important to investigate whether or 
not other TGF-p isoforms could also inhibit M IP-la mRNA expression in bone 
marrow derived macrophages. Figures 5.4.1 and 5.4.2 show total RNA made from 
control BMDM and BMDM treated with LPS (20ng/ml) with or without a titration 
of TGF-P2 and TGF-pS respectively. The results demonstrate that both TGF-P2 
and TGF-pS are also capable of inhibiting M IP-la mRNA expression induction in 
a manner analogous to that of TGF-pl. It appears from the data however, that 
TGF-P2 is slightly weaker in this regard than either TGF-pi or TGF-p3. Although 
the Northern shown indicates that TGF-P3 appears more potent than TGF-pl, 
other similar experiments have suggested that TGF-pi and TGF-P3 appear 
equipotent. This observation of differing potencies is of interest, and may be due 
to the differing affinities with which each of these isoforms binds the TGF-p 
receptors (see discussion).
As with MIP-la, the TGF-p family contains many other members which 
have no reported role in inhibition of haemopoietic stem cells such as activin and 
bone morphogenetic protein 2 (BMP-2). To investigate the specificity of TGF-pi, 
-P2 and -p3 isoforms in inhibition of M IP-la mRNA expression, similar 
experiments to those described above were performed using activin and BMP-2.
Figure 5.4.1 Northern blot analysis of the effect of TGF-p2 on MIP-la
expression in BMDM induced by LPS
Bone marrow derived macrophages were treated with LPS at a concentration of 
20pg/ml plus or minus TGF-P2 at the concentrations shown in each lane. Total 
RNA was prepared 0 and 4hrs after cytokine addition, and 20pg of total RNA was 
run on a 1.4% (wt/vol) agarose gel. The RNA was transferred via Northern 
blotting, and the membrane probed using a radiolabelled MIP-la specific 
riboprobe. The autoradiograph was exposed for 18hrs. Details of each individual 
lane are shown in the figure. This blot is representative of at least three separate 
experiments. Equal loading of total RNA was confirmed by ethidium bromide 
staining.
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Figure 5.4.2 Northern blot analysis of the effect of TGF-pS on MIP-la
expression in BMDM induced by LPS
Bone marrow derived macrophages were treated with LPS at a concentration of 
20pg/ml plus or minus TGF-pS at the concentrations shown in each lane. Total 
RNA was prepared 4hrs after cytokine addition, and 20pg of total RNA was run 
on a 1.4% (wt/vol) agarose gel. The RNA was transferred by Northern blotting, 
and the membrane probed using a radiolabelled MIP-la specific riboprobe. The 
autoradiograph was exposed for 18hrs. Details of each individual lane are shown 
in the figure. This blot is representative of at least three separate experiments. 
Equal loading of total RNA was confirmed by ethidium bromide staining.
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Figure 5.4.3 shows M lP-la expression in total RNA made from BMDM 
stimulated with LPS plus or minus a titration of activin ranging from lOpM to 
3nM. The last track shows the inhibitory effect of TGF-P3 on M IP-la mRNA 
expression, and was included as a positive control. This result demonstrates that, 
at low concentrations where the other TGF-p isoforms have been shown to be 
active, activin appears to have little if any inhibitory effect on M IP-la mRNA 
expression in BMDM. It does appear however, that at a concentration of 3nM, 
activin is capable of inhibiting MIP-la expression. Ethidium bromide staining of 
RNA indicated equal loading in each track.
Figure 5.4.4 shows total MIP-la expression in total RNA made from 
BMDM stimulated with LPS plus or minus a titration of BMP-2 ranging from 3pM 
to InM. The last track shows the inhibitory effect of TGF-p3 on MIP-la mRNA 
expression, and was included as a positive control. This figure shows that BMP-2 
appears to have no effect on the induction of expression of MIP-la mRNA by LPS 
using concentrations up to InM.
In summary, it appears that only the TGF-(3 isoforms are capable of 
potently inhibiting the expression of MIP-la mRNA in BMDM, with more diverse 
members of the TGF-(3 superfamily, i.e. activin and BMP-2, being incapable of 
potently inhibiting its expression at equivalent concentrations.
5.5 Effect of TGF-pl on MIP-la receptor levels on FDCP-MIX cells
5.5.1 TGF-p 1 downregulates MIP-la specific receptors on FDCP-MIX cells
Given the observed response of macrophages (a likely in vivo source of 
MIP-la), it was also investigated what, if any, response is observed in the M IP-la 
target cells i.e. stem cells. It is possible for example that, in vivo, in the presence 
of active TGF-pi and therefore the presumed downregulation of MIP-la, the stem 
cells may compensate for this downregulation of MIP-la by upregulating specific 
receptors for that molecule. To address this question, any possible effects of TGF- 
pi on the levels of receptor for MIP-la on a haemopoietic stem cell like line were
Figure 5.4.3 Northern blot analysis of the effect of activin on MIP-la
expression in BMDM induced by LPS
Bone marrow derived macrophages were treated with LPS at a concentration of 
20pg/ml plus or minus activin at the concentrations shown in each lane. Total 
RNA was prepared 0 and 4hrs following cytokine treatment, and 20pg of total 
RNA was run on a 1.4% (wt/vol) agarose gel. The RNA was transferred 
Northern blotting, and the membrane probed using a radiolabelled MIP-la specific 
riboprobe. The autoradiograph was exposed for 18hrs. Details of each individual 
lane are shown in the figure. This blot is representative of at least three separate 
experiments. Equal loading of total RNA was confirmed by ethidium bromide 
staining.
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Figure 5.4.4 Northern blot analysis of the effect of BMP-2 on MIP-la 
expression in BMDM induced by LPS
Bone marrow derived macrophages were treated with LPS at a concentration of 
20pig/ml plus or minus BMP-2 at the concentrations shown in each lane. Total 
RNA was prepared 0 and 4hrs after cytokine addition, and 20pg of total RNA was 
run on a 1.4% (wt/vol) agarose gel. The RNA was transferred by Northern 
blotting, and the membrane probed using a radiolabelled M IP-la specific 
riboprobe. The autoradiograph was exposed for 18hrs. Details of each individual 
lane are shown in the figure. This blot is representative of at least three separate 
experiments. Equal loading of total RNA was confirmed by ethidium bromide 
staining.
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investigated. FDCP-MIX cells, as initially isolated, display considerable similarity 
to the CFU-S stem cell (Spooncer et al 1984). It has been previously 
demonstrated by Graham et al (1993) that these cells have numerous cell surface 
receptors for MIP-la, and further, that these receptors are specific in recognising 
only those members of the MIP-la peptide family that are capable of stem cell 
inhibition. It is therefore a good candidate for a M IP-la responsive cell line. To 
investigate the effect of TGF-pi on MIP-la receptor levels on these cells, cells 
were incubated with TGF-pi for 16hrs and MIP-la receptor binding assays were 
performed as described in materials and methods section 4.9.
Initially, binding was performed using a titration of radiolabelled M IP-la to 
investigate the effects of TGF-pi on MIP-la receptor levels. MIP-la receptor 
levels are typically saturated at around InM. Figure 5.5.1 shows however, that in 
the presence of TGF-pi, specific MIP-la binding to the cell surface appears to be 
inhibited by around 50% at each of the three radiolabelled MIP-la concentrations. 
Binding of radiolabelled MIP-la to the cell surface is substantially competable 
using a 100 fold excess of unlabelled MIP-la, and importantly, is not competable 
by high concentrations of unlabelled TGF-pl (data not shown). This demonstrates 
that the reduced binding of radiolabelled MIP-la to these cells is not simply due to 
TGF-pi directly blocking binding of MIP-la to its receptor.
5.5.2 TGF-pl downregulates MIP-la receptor numbers with no change in 
afTinity of the remaining receptors for ligand
A reduction in binding of a ligand to the cell surface can be the result of 
either a reduction in overall receptor numbers for that molecule on the cell surface, 
or of a reduction in affinity of those receptors for ligand. More comprehensive 
binding curves were carried out (see figure 5.5.2), and Scatchard analysis of the 
data performed to investigate whether the observed downregulation results from 
reduction in receptor numbers or receptor affinity. The results indicate that 
whereas the control cells expressed ^proximately 11,000 receptors per cell, the 
TGF-p-treated cells expressed only around 3,400 receptors per cell, indicating a
Figure 5.5.1 Effect of TGF-|31 on M IP-la  receptor levels on FDCP-MIX cells
FDCP-MIX cells were incubated for 16hrs at a concentration of 10^ cells/ml plus 
or minus TGF-pl at a concentration of lOOpM. This concentration was chosen 
because it results in almost complete inhibition of MIP-la rtiRNA expression in 
macrophages. Cells were then washed twice in PBS and 5x10^ cells per point 
aliquoted into eppendorf test tubes and pelleted. To each aliquot, various 
concentrations of labelled MIP-la were added in binding buffer (Special 
Liquid Medium / 10% DHS / 0.2% azide), and either PBS or 100-fold excess 
unlabelled M IP-la competitor. Cells were then incubated at 37oC for 90 minutes 
after which they were washed 3 times in PBS and the incorporated radiation 
assessed in a gamma counter. Data are representative of of 3 experiments and are 
plotted as the mean of duplicate determinations. Background radiation has been 
subtracted and thus these plots represent specific counts.
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Figure 5.5.2 Comprehensive binding curves of the effect of TG F-[3 
on M IP -la  receptor levels on FDCP-MIX cells
125
A Equilibrium binding of I labelled M IP-la to FDCP-MIX cells. Cells 
were pre-incubated in medium with or without TGF-(3 at a concentration 
of lOOpM for 18 hrs, and binding of radiolabelled M IP-la assessed as 
outlined in section 4.9.2.
B Scatchard analysis of the data shown in figure 5.5.2 part A. Analysis of 
binding isotherms was performed using the LIGAND computer program 
(Munson and Robard 1980).
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70% reduction in receptor numbers. MIP-la receptors on control cells exhibited a 
Kd of 1.3xlO‘^M compared with l.ZlxlO'^M for the TGF-pl-treated cells. 
Thus, TGF-pl mediated inhibition of MIP-la receptors is due to a decrease in 
receptor number and not to a decrease in receptor affinity.
5.5.3 TGF-pi mediated inhibition of MIP-la receptors on FDCP-MIX cells 
is potent and fully reversible
To fully characterise the kinetics of this receptor downregulation, and to 
ascertain the maximum downregulation that could be obtained, a titration from 
50pM to InM TGF-pl was performed. Figure 5.5.3 shows that after 16hrs, the 
maximum downregulation appears to be approximately 70%, and that this is 
achieved using TGF-pl at a concentration of lOOpM. The maximum 
downregulation achievable varied from between 50-70% in other experiments. 
Increasing the concentration of TGF-pl does not however cause a further decrease 
in MIP-la receptor numbers. The possible functional significance of this level of 
downregulation is addressed in the discussion.
In vivo, it is possible that stem cells are continually exposed to active TGF- 
pi, and figure 5.5.4 shows the effects on MIP-la receptors of long term exposure 
of FDCP-MIX cells to active TGF-pi. These results show that continued daily 
addition of TGF-pi results in prolonged MIP-la receptor downregulation over the 
96hr time course of this experiment. However, a single treatment of TGF-pi 
results in an initial reduction of MIP-la receptors which then return to normal 
levels by 72hrs and indeed overshoot at 96hrs. This suggests that TGF-pi 
mediated inhibition of M IP-la receptor levels is fully reversible, but that on 
prolonged exposure, such as may be encountered in vivo, MIP-la receptor levels 
will be downregulated on cells for the duration of their exposure to TGF-pi.
The MIP-la specific receptor present on FDCP-MIX cells remains to be 
cloned and fully characterised, thus analysis of the effects of TGF-pi on the actual 
mRNA expression of this receptor are not possible. However, as mentioned in the 
introduction, a C-C chemokine receptor has recently been cloned from HL-60 cells
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Figure 5.5.3 Titration of TGF-(3 mediated inhibition of M IP -la  
receptors on FDCP-MIX cells
FDCP-MIX cells exposed to the concentrations of TGF-p detailed above 
were treated as outlined in figure legend 5.5.1, and specific binding of I 
labelled M IP-la (0.5nM) measured. The results are expressed as receptor 
percentage and are representative of at least 3 separate experiments.
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Figure 5.5.4 Time course of TGF-|3 mediated downregulation of 
M IP -la  receptors on FDCP-MIX cells
FDCP-MIX cells exposed to TGF-(3 at a concentration of lOOpM 
were treated as outlined in figure 5.5.1, and specific binding of 
labelled M IP-la (0.5nM) measured. Cells were treated with either 
one dose of TGF-(3 at time 0 (full line), or continual daily doses of 
TGF-P (broken line). The results are expressed as percent receptors 
and are representative of at least 3 separate experiments.
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(Neote et al 1993), and it was of interest to investigate any possible effects TGF- 
p i may have on this receptor type also. Interestingly, figure 5.5.5. shows that 
TGF-pi is capable of downregulating mRNA expression of CC-CKRI in U937 
cells suggesting that TGF-pl may be capable of inhibiting surface expression of 
this MIP-la receptor also. This data further suggests that the inhibitory effect of 
TGF-pi on MIP-la receptors on FDCP-MIX cells may also be regulated at the 
mRNA level.
At present, there are conflicting reports regarding the percentage of 
cytokine receptors which need to be ligand occupied in order to elicit a biological 
response. That is, although a downregulation of MIP-la receptor numbers of up 
to 70% is observed, it is still possible that the remaining 30% are fully capable of 
causing a biological response. As described in the introductory section, the 
receptor for MIP-la present on FDCP-MIX cells is likely to be a member of the 
G-protein linked seven membrane spanning family. A feature of all G-protein 
linked receptors is that upon ligand binding and receptor activation, a rise in 
intracellular calcium levels is observed as part of the signal transduction process. 
This rise in intracellular calcium results from release of calcium fi"om intracellular 
stores, or influx of calcium from the extracellular periphery. Both mechanisms can 
also work together. A number of workers have previously shown that M IP-la is 
capable of causing intracellular calcium mobilisation in both monocytes and 
eosinophils (Sozzani et al 1993, Rot et al 1992), and it was reasoned that M IP-la 
may also signal via calcium in FDCP-MIX cells. Thus, a reduction in receptor 
numbers on the surface of these cells may result in a decrease in the ability of MIP- 
l a  to elicit a calcium flux in these cells, which in turn may result in functional 
compromise. This possibility was therefore investigated with a view to 
determining whether a 50-70% reduction in MIP-la receptors by TGF-j31 could 
have functionally relevant consequences.
Figure 5.5.5 Effect of TGF-p on CC-CKRI MIP-la receptor expression in 
U937 cells
U937 cells were treated with TGF-p at a concentration of 250pM. Total RNA 
was prepared after 0, 6 and 24hrs and 20pg of RNA was run on a 1.4% (wt/vol) 
agarose gel. The RNA was transferred by Northern blotting, and the membrane 
probed using a radiolabelled CC-CKRI specific riboprobe. The autoradiograph 
was exposed for 24hrs. Details of each individual lane are shown in the figure. 
This blot is representative of three separate experiments. Equal loading of total 
RNA was confirmed by ethidium bromide staining.
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5.6 Downregulation of MIP-la receptors on FDCP-MIX cells by TGF-pi is 
reflected in reduced ability of these cells to mobilise calcium in response to 
MIP-la
FDCP-MIX cells were treated overnight with TGF-pi (lOOpM), and then 
examined for their ability to mobilise calcium in response to MIP-la. To check 
that the cells had been efficiently loaded with the fluorescent dye FURA-2, total 
calcium release was induced with the detergent triton-X. As seen in figure 5.6 A, 
addition of triton X to the cells causes a large increase in intensity. This is due to 
lysing of the cells, and release of all intracellular FURA-2 into the extracellular 
medium where it binds calcium, and thus an increase in fluorescence intensity is 
observed. Addition of the calcium chelator EGTA however, results in removal of 
all available calcium ions, and thus a decrease in fluorescence intensity is observed. 
Figure 5.6 B shows a calcium flux in control FDCP-MIX cells in response to 
addition of 60pl of a Img/ml solution of MIP-la. Figure 5.6 C shows a calcium 
flux in FDCP-MIX cells pre-treated for 16 hrs with TGF-pi (lOOpM) in response 
to addition of 60pl of a 1 mg/ml solution of MIP-la. These figures demonstrate 
that the calcium flux elicited in TGF-pl treated FDCP-MIX cells by MIP-la is 
approximately 86% lower than that observed in control FDCP-MIX cells. This 
demonstrates that pre-treatment of FDCP-MIX cells with TGF-pi results in not 
only a significant decrease in MIP-la receptor numbers on these cells, but also a 
reduction in the ability of MIP-la to signal into these cells. Thus, the TGF-pl 
mediated inhibition of MIP-la receptor levels on stem cells may have important 
implications with respect to the suggested role of M IP-la as an endogenous 
physiological stem cell inhibitor.
5.7 Overnight incubation of normal bone marrow cells with TGF-pi reduces 
the ability of MIP-la to inhibit the CFU-A population
If the TGF-pi mediated inhibition of M IP-la receptors on stem cells does 
reduce their ability to respond to MIP-la, then it is possible that this may be 
reflected in a functional biological assay. To investigate this possibility in more
Figure 5.6 Effect of preincubation of FDCP-MIX cells with TGF-p on the
ability of M IP-la to induce calcium mobilisation
FDCP-MIX cells were incubated overnight with or without TGF-p at a 
concentration of lOOpM. Cells were then washed twice in PBS and resuspended at 
a concentration of 5xl0^/ml in calcium free HACM buffer (see Materials and 
Methods). FURA-2 was added to the cell suspension at a concentration of 0.5p.M, 
and the cells incubated at 3?oC for 45 minutes in the dark to allow the FURA-2 
fluorescent dye to permeate the cells. The cells were then washed twice in warm 
PBS, and resuspended in calcium containing HACM buffer at a concentration of 
IxlO^/ml. Cells were incubated at 37°C for 30 minutes, and then used 
immediately. 2mls of each cell suspension was aliquoted into a spectrophotometer 
cuvette, and the appropriate stimulants added directly to the suspension. Changes 
in fluorescence intensity of FURA-2 were assessed in a Perkin-Elmer 
spectrophotometer. Part A shows the effect of addition of lOOpl of a 10% 
solution (v/v) of triton-X, followed by addition of lOOpl of a XM solution of 
EGTA. Part B shows the effect of addition of 60pl of MIP-la at a concentration 
of Img/ml to control FDCP-MIX cells. Part C shows the effect of addition of 60p.l 
of M IP-la at a concentration of Img/ml to TGF-p pre-treated FDCP-MIX cells. 
The Y axis on each graph represents the overall intensity of fluoresence of the dye 
FURA-2 upon calcium binding.
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detail, normal bone marrow cells were incubated with a titration of TGF-pi (IpM 
to 500pM) for 16 hours. This should result in a maximal downregulation of MIP- 
l a  receptors on CFU-A cells. The cells were then washed 3 times in PBS, to 
remove any excess TGF-pi. If the resultant downregulation of M IP-la receptors 
had any functional significance, then this may be manifest in the reduced potency of 
MIP-la in the CFU-A assay. It was anticipated that overnight (16 hrs) incubation 
of normal bone marrow cells with TGF-pi would result in a reduction in the ability 
of MIP-la to inhibit CFU-A colony formation. The results shown in figure 5.7 
demonstrate that this may be the case. For example, it appears that overnight 
incubation of bone marrow cells with TGF-p is capable of inhibiting CFU-A colony 
formation in a dose dependent manner. When using sub-optimal concentrations of 
TGF-p such as 50pM, colony formation is inhibited by approximately 60%. MIP- 
l a  when used at a concentration of lOOpM inhibits CFU-A colony formation by 
around 50%. Both of these molecules are ultimately capable of causing 100% 
inhibition in this assay. However, exposure of CFU-A cells to both TGF-p and 
MIP-la does not result in increased inhibition of colony formation, as might be 
expected from earlier results demonstrating that both are highly potent in this assay 
system. It appears that after TGF-p treatment, M IP-la is incapable of inhibiting 
CFU-A colony formation beyond that achieved by TGF-p suggesting that the cells 
may indeed be less responsive to the inhibitory properties of MIP-la. It should be 
noted that the potencies of both MIP-la and TGF-pi in this particular assay 
appear different from those shown in figures 5.1.1 and 5.1.2. This is most likely 
due to inter assay variation, which is an unavoidable feature of in vitro colony 
forming assays.
The results of this assay are quite intriguing. It appears that overnight 
incubation of normal bone marrow cells with a titration of TGF-pi results in dose 
dependent inhibition of colony formation after 11 days without the requirement for 
subsequent TGF-p addition. This surprising result suggests at least two 
possibilities. Either this short exposure of the cells to TGF-pl is sufficient to keep 
them out of cell cycle and thus prevent them from forming colonies over the 11 day
Figure 5.7 Effect of preincubation of total bone marrow cells with TGF-pi
on the ability of M IP-la to inhibit CFU-A colony formation
Normal bone marrow cells were incubated for 16hrs in SLM/10% DHS at 37°C 
with or without a titration of TGF-pi. Following this, the cells were washed three 
times in PBS. MIP-la was tested for inhibitory activity in the direct addition 
CFU-A assay as described in section 4.5. Varying concentrations of M IP-la were 
added directly to the feeder layers (0.6% agar in a-MEM with sources of M-CSF 
and GM-CSF) of the CFU-A assays, and the TGF-pl pretreated bone marrow 
target cells plated at 5xl0^/ml in the upper layer (0.3% agar in a-MEM). The 
assay plates were incubated at 37°C in a fully humidified atmosphere of 10% CO2, 
5% O2 and 85% N2 for 11 days. Colonies >2mm were scored as being CFU-A 
type. The results depicted are representative of 3 separate experiments.
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time period of this assay, or the washing steps carried out prior to plating the cells 
into the assay dishes was insufficient, and the cells were actually exposed to active 
TGF-|31 for considerably longer than 16 hrs. Also, as will be discussed in the next 
chapter, it is possible that TGF-|31 is not actually inhibiting these cells from cycling, 
but is in fact inducing apoptotic cell death.
In summary, the results from these experiments suggest that TGF-pl 
downregulates MIP-la receptor numbers on stem cells, and this downregulation is 
reflected in decreased secondary messenger release. Further, overnight incubation 
of normal bone marrow with TGF-pi reduces the ability of M IP-la to inhibit 
CFU-A colony formation.
5.8 Effect of M IP-la on TGF-pi expression in murine BMDM
5.8.1 MIP-la and IL-2 increase TGF-pl mRNA expression in murine bone 
marrow derived macrophages
In order to fully understand the interactions between these two molecules in 
the overall control of haemopoietic stem cell proliferation, it was next decided to 
investigate any potential reciprocal effects of MIP-la on TGF-pl. Although it is 
quite clear that TGF-pi functions as an inhibitor independently of MIP-la, it is 
still possible that M IP-la mediates common functions, either wholly or in part, via 
upregulation of TGF-pi. To investigate this possibility, the effect of MIP-la on 
TGF-pi mRNA expression in BMDM was examined. Addition of interleukin 2 
(IL-2) to macrophages has previously been shown to upregulate TGF-pi mRNA 
expression, and was thus included as a positive control. BMDM were grown to 
confluence over seven days as described previously, after which M IP-la (2.5nM), 
IL-2 (100 U/ml) or a combination of the two were added to the cells. Total RNA 
was prepared after 4 hrs and 24 hrs, and analysed for TGF-pl expression using a 
TGF-pi specific radiolabelled probe. Figure 5.8.1 shows that very little TGF-pi 
expression is detectable in resting macrophages at time 0, and 4 hrs after 
commencing the experiment. Addition of IL-2 alone results in an increase in TGF-
Figure 5.8.1 Northern blot analysis of the effect of M IP-la and IL-2 on 
TGF-pi expression in BMDM
BMDM were grown for 7 days, after which they were treated with either IL-2 at a 
concentration of 100 units/ml, MIP-la at a concentration of 2.5nM or a 
combination of both IL-2 and MIP-la. Total RNA was prepared 0, 4 and 24hrs 
following cytokine addition, and 20pg of RNA was run on a 1.4% (wt/vol) agarose 
gel. The RNA was transferred via Northern blotting, and the membrane probed 
using a radiolabelled TGF-pl specific DNA probe. The autoradiograph was 
exposed for 24hrs. Details of each individual lane are shown in the figure. This 
blot is representative of three separate experiments. Equal loading of total RNA 
was confirmed by ethidium bromide staining.
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p i expression evident after 4hrs and 24hrs. Addition of MIP-la alone also causes 
an increase in TGF-pi expression after 4 hrs and 24 hrs, and addition of both MIP- 
l a  and IL-2 causes an increase in TGF-pi expression considerably greater than 
that caused by either cytokine alone. Thus, it appears that MIP-la is indeed 
capable of inducing TGF-pl mRNA expression in bone marrow macrophages, and 
that this property is augmented in the presence of other TGF-pi inducing 
molecules such as IL-2.
5.8.2 M IP-la upregulates TGF-pl protein production by BMDM
As with the inhibitory effect of TGF-pl on M IP-la expression, it is of 
more physiological importance and significance to confirm that the observations 
apparent at the mRNA level are reflected at the secreted protein level. Detection 
of TGF-pl protein by Western blot analysis is notoriously difficult due to very 
poor transfer of TGF-pi protein to nitrocellulose membranes, so it was decided to 
examine any potential increase in TGF-pl protein using a commercially available 
enzyme linked immunosorbent assay (ELISA) system. This assay utilises soluble 
TGF-p type II receptor bound to 96 well plates, which binds any of the three 
mammalian TGF-p isoforms present in cell conditioned medium. The assay only 
detects TGF-pi however, since the second polyclonal antibody is TGF-pi specific. 
Figure 5.8.2 shows that, firstly, resting bone marrow macrophages produce around 
230 pg/ml of TGF-pl. Since all the conditioned media sample is acidified prior to 
analysis in the assay, this result represents the total pool of TGF-pi molecules 
present, and does not distinguish between active and non-active forms. The overall 
levels of TGF-pi present has increased to around 350 pg/ml after 24 hrs, 
presumably due to accumulation of TGF-pl normally produced by the cells, but no 
significant differences are detectable between control cells and those treated with 
either 40ng/ml or 80ng/ml of MIP-la. After 48 hrs however, the levels of TGF-pi 
present in the CM of those cells treated with MIP-la is considerably higher than 
control cells. This increase appears to be related to the dose of MIP-la added to 
the cells 48 hrs previously. Control cell CM contains around 610 pg/ml after 48
Figure 5.8.2 ELISA analysis of the effect of M IP-la on TGF-p protein 
production by BMDM
BMDM were grown for 6 days, after which MIP-la was added at concentrations 
of 40ng/ml (5nM) and 80ng/ml (lOnM). Conditioned medium was harvested at 
times Ohrs, 24hrs and 48 hrs after addition of MIP-la, and then concentrated using 
Centiiprep 10 spin columns. Presence of TGF-pl protein in each conditioned 
medium sample was then quantitated using a TGF-pl specific ELISA system 
(R&D Systems). This assay relies on active TGF-pi binding to the type II TGF-p 
receptor, and as such, each conditioned media sample was acidified to yield active 
TGF-pl. Acidification of samples was carried out by adding 0.2ml of IN HCl to 
1ml of conditioned media for 10 minutes, and then adding 0.2ml of 1.2N 
NaOH/0.5M HEPES. TGF-pl is also present in the BMDM growth medium, and 
so the results represent the amount of TGF-pi present in the BMDM conditioned 
media after subtraction of these levels of TGF-pl. These results are representative 
of at least three separate experiments.
1000
900
800
!> 700 
-  600 
500 
H 400 
300 
200 
100 
0
O
3 “—T
O
o
3
N>
O
O
3
— O
ro ro 4^
œ œ 00
3" 3" 3" 3"
CO CO CO CO
+ +
V, J
o + +
œ 3 00
O o O o
3 3 O 3 3
(O
I 1 t I
S S S
y y -p ■p
p p P P
100
hrs whereas CM from cells treated with 40ng/ml contains approximately 740 pg/ml 
and CM from cells treated with 80 ng/ml contains 1020 pg/ml. Each point was 
assayed in duplicate, with almost identical values in each demonstrating this to be a 
significant difference. This data suggests that the MIP-la mediated increase in 
TGF-pl mRNA is reflected at the protein level, and further suggests that M IP-la 
may function in part as a stem cell inhibitor by upregulation of TGF-pl in either 
target or non-target cells present within the bone marrow environment.
5.9 Inactivation of endogenous TGF-p levels in the CFU-A assay does not 
reduce the ability of M IP-la  to inhibit CFU-A colony formation
In order to test if MIP-la may act as an inhibitor either wholly or in part 
through upregulation of TGF-p, it was reasoned that inhibition of TGF-p function 
may abrogate the ability of MIP-la to inhibit CFU-A colony formation. To this 
end, CFU-A assays were performed using MIP-la in the presence of the TGF-p 
latency associated peptide (LAP), which is a natural and potent antagonist of TGF- 
P function. Figure 5.9 shows that firstly, LAP (80ng/ml) is successfully preventing 
TGF-p (200pM and 400pM) from inhibiting CFU-A colony formation. The results 
further show that MIP-la is potently inhibiting, and that even in the presence of 
LAP, MIP-la is still a potent inhibitor of CFU-A colony formation. This suggests 
that MIP-la does not function as an inhibitor via upregulation of TGF-p, and that 
the two molecules inhibit CFU-A type stem cells entirely independently of each 
other.
Figure 5.9 Effect of LAP on the ability of MIP-la and TGF-p to inhibit CFU-A 
colony formation
MIP-la and TGF-p were tested for inhibitory activity in the direct addition CFU-A 
assay as described in section 4.5. Varying concentrations of MIP-la and TGF-p were 
added directly to the feeder layers of the CFU-A assay (0.6% agar in a-MEM with 
sources of M-CSF and GM-CSF) plus or minus LAP at a concentration of 80ng/ml. 
Normal bone marrow cells were plated at 5xlO^/ml in the upper layer and the assay 
plates were incubated 37°C in a fully humidified atmosphere of 10% CO2, 5% Og and 
85% Ng for 11 days. Colonies >2mm were scored as being CFU-A type. The results 
depicted are representative of 3 separate experiments.
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Chapter 6 - DISCUSSION
6.1 Introduction
It has become clear over the last few years that the proliferation of the 
haemopoietic stem cell is open to both positive and negative regulation by a wide 
array of cytokines and peptide molecules. It has also become clear that, among 
both the positive and negative regulators, considerable overlap in actions, or 
redundancy, is apparent between several members of each group. Our laboratory 
has been particularly interested in the inhibitors of haemopoietic stem cell 
proliferation, and the work presented in this thesis has attempted to investigate the 
extent and possible mechanisms of functional redundancy between these molecules.
To investigate any possible interactions between the inhibitors MIP-la, 
TGF-(3, tetrapeptide and pentapeptide, these molecules were first assayed for 
activity in the in vitro CFU-A assay. As can be seen in the results section, only 
MIP-la and TGF-(3 appear to be capable of inhibiting CFU-A colony formation, 
with no notable inhibition by the tetrapeptide or pentapeptide. The reasons for 
lack of inhibition by both the tetrapeptide and the pentapeptide are unclear but it is 
possible that they are not able to overcome the positive stimuli conferred by the 
high levels of growth factors present in the assay. However, given the potency of 
both MIP-la and TGF-(3 in this assay, it is possible that CFU-A cells are refractory 
to the inhibitory properties of both the tetrapeptide and pentapeptide. The results 
further demonstrate that both MIP-la and TGF-(3 are active in this assay system at 
picomolar concentrations, suggesting functional similarities between them with 
respect to inhibition of CFU-A haemopoietic stem cell proliferation. Indeed, the 
functional similarities between MIP-la and TGF-|3 do not end there. Both MIP- 
l a  and TGF-|3 are also capable of stimulating the proliferation of more mature 
GM-CFC progenitors (Broxmeyer et at 1991, Jacobsen et at 1991a), and both are 
also capable of inhibiting proliferation of human clonogenic kératinocytes 
(Parkinson et at 1993, Moses et al 1985) suggesting that the functional similarities
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between MIP-la and TGF-(3 in haemopoiesis may also be apparent in other 
regenerating tissues.
6.2 Inhibition of MIP-la by TGF-(31 and related family members
Given the lack of inhibition by the tetrapeptide and the pentapeptide, it was 
decided to concentrate on possible interactions between MIP-la and TGF-|3. As 
has been mentioned previously, the in vitro CFU-A assay consists of a multicellular 
environment, and it is possible that either MIP-la or TGF-|3 could be acting 
indirectly by inducing synthesis of the other in either secondary non-target cells 
present in assay, or indeed in the actual target stem cells. Bone marrow 
macrophages are a potential source of both cytokines in the CFU-A assay and in 
the bone marrow, so any possible inductive effects of these molecules on each 
other were examined using these cell types. The results shown in figures 5.2.1 to 
5.2.4 demonstrate that, rather than acting as an inducer of M IP-la mRNA 
expression and protein production in bone marrow derived macrophages, TGF-|3 
potently inhibits both of these functions in macrophages. This data clearly shows 
that TGF-(3 does not act as an inhibitor of haemopoietic stem cell proliferation by 
induction of MIP-la in bone marrow macrophages. Further, the remarkable 
potency with which TGF-p exerts this inhibition suggests that in the presence of 
active TGF-P in vivo, very little M IP-la will be expressed and synthesised. 
However, as will be discussed below, this may be dependent on the presence of 
other growth factors and cytokines which can potentially upregulate expression of 
MIP-la.
It is important to remember when interpreting such experiments that both 
MIP-la and TGF-p are actively involved in the inflammatory response and, from 
their properties described in the introduction, may have antagonistic roles. That is, 
TGF-p generally plays an anti-inflammatory role while MIP-la plays a pro- 
inflammatory role. Thus, the inhibition of MIP-la expression by TGF-p observed 
in macrophages may have little to do with stem cell inhibition and may simply be 
another of the anti-inflammatory functions of TGF-p. Such a scenario would
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predict that TGF-p may also be able to downregulate other members of the pro- 
inflammatory chemokine superfamily such as MIP-ip, and RANTES. As shown in 
figure 5.3.1, TGF-p is indeed capable of downregulating expression of MIP-lp, a 
molecule highly related to MIP-la and which displays weak stem cell inhibitory 
properties being capable of inhibiting CFU-A type cells at approximately 20 fold 
higher concentrations than those required for MIP-la. This result is unsurprising 
since the expression of both MIP-la and MIP-lp appears to be co-regulated in 
response to positive or mitogenic stimulation e.g. LPS or serum. The structure of 
the MIP-lp promoter has recently been elucidated by Proffitt et al (1995), and 
interestingly, the activities of the MIP-la and MIP-ip promoters in transfected 
cells are very similar. The ability of TGF-P to suppress both M IP-la and MIP-ip 
expression may therefore be due to their very similar promoter sequences which 
are capable of binding identical transcription factors. Thus, treatment of 
macrophages with TGF-p (or indeed positive stimuli) may result in cognate 
changes in expression of both MIP-la and MIP-lp. Interestingly, mRNA 
expression of RANTES, a more diverse member of the MIP-la superfamily which 
does not share such a high degree of nucleic acid conservation with M IP-la 
appears to be unaffected by TGF-p. Similarly, Mauviel et al (1993) have 
demonstrated that TGF-pl and TGF-p2 are incapable of affecting cytokine induced 
IL-8 expression in human adult skin fibroblasts. If the inhibition of MIP-la by 
TGF-p is purely an anti-inflammatory function of TGF-p, then these results are 
quite surprising. Indeed, the apparent ability of TGF-p to only inhibit those 
members of the chemokine family which are capable of inhibiting stem cell 
proliferation suggests that this may not simply be an anti-inflammatory function 
and may therefore be more specific to stem cell inhibition.
When attempting to relate these results to possible physiological 
consequences in vivo, it is necessary to take into account other molecules which 
could potentially affect expression of MIP-la. Examples of such molecules 
include other members of the TGF-p superfamily, some of which are capable of 
exerting similar effects to TGF-pi in certain biological systems. Recently, mice
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canying a disrupted TGF-pl allele have been generated to try to unravel some of 
the diverse functions of TGF-p both in development and in the adult. As described 
in the introduction, these mice develop normally to birth, but die some weeks later 
due to uncontrolled inflammatory reactions. As part of their analysis, Schull et al 
(1993) examined inflammatory cytokine expression in the inflamed organs of these 
animals and, interestingly, observed a dramatic increase in the expression of MIP- 
la . There are two possibilities which could account for this observation. The first 
is that MIP-la is upregulated in response to other inflammatory mediators and 
general macrophage activation, and is part of the inflammatory cytokine cascade. 
The second is that, in light of the data presented here, MIP-la is upregulated due 
to the removal of a specific block on MIP-la expression by TGF-pl. M IP-la 
could then potentiate the inflammatory response via induction of other pro- 
inflammatory molecules such as IL-1, IL-6 and TNF-a. Such a conclusion would 
predict that other members of the TGF-p superfamily such as TGF-p2 and TGF-p3 
would be incapable of potently inhibiting MIP-la expression in macrophages, or 
indeed other MIP-la producing cells. The Northern blots shown in figures 5.4.1 
and 5.4.2 demonstrate that this is not the case however, and that both TGF-p2 and 
TGF-p3 are capable of inhibiting MIP-la expression in bone marrow derived 
macrophages. Further, TGF-p3 appears as potent as TGF-pl in this regard, with 
TGF-P2 being slightly less potent.
The reason for this difference in potency is unclear, but similar differences 
in potency between the TGF-p isoforms have been reported previously (Ohta et al 
1987). It is possible that the differences in potency between the isoforms results 
from differing abilities to bind to the specific TGF-p receptors. Indeed, Ohta et al 
(1987) observed that the binding affinity of TGF-P2 to the type I receptor present 
on B6SUtA cells was 20 fold lower than that of TGF-pi. This difference in 
affinities could perhaps explain the 100 fold higher potency with which TGF-pl 
inhibits proliferation of B6SUtA cells. Further, Chiefetz et al (1990) have 
demonstrated that distinct TGF-p receptor subsets determine responsivensess of 
cells to each of the TGF-p isoforms. Lopez-Casillas et al (1993) have also
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demonstrated that TGF-p2 binds to the TGF-p type II receptor with a lower 
affinity than TGF-pi. It would be of interest to perform TGF-p binding studies on 
bone marrow derived macrophages to determine if the degree of inhibition of MIP- 
l a  expression in macrophages by TGF-pi,-p2, -p3 is related to the affinity with 
which each isoform binds to the cells.
Given that all of the TGF-p isoforms are capable of inhibiting M IP-la 
expression, one might predict that the increased M IP-la expression in TGF-pi 
deficient mice is secondary to the absence of TGF-pi. However, it is still possible 
that this represents a specific effect, and that the other TGF-p isoforms in these 
animals are not expressed at high enough levels, or perhaps are expressed in 
different locations to TGF-pl, such that they are unable to actively inhibit MIP-la 
expression.
Interestingly, more diverse members of the TGF-p superfamily such as 
activin and BMP-2 appear to be incapable of inhibiting M IP-la gene expression in 
macrophages at concentrations equivalent to TGF-pi. Although activin has been 
shown to have a role in erythroid differentiation, and is capable of stimulating 
multipotential progenitor cells in vitro (Yu et al 1987, Broxmeyer et al 1988), it 
has not been reported as having stem cell inhibitory properties. Likewise for BMP- 
2. The fact that these molecules appear incapable of inhibiting M IP-la expression 
again suggests that the relationship between TGF-p and M IP-la may be specific 
and related to stem cell inhibition.
More recent experiments performed subsequent to and following on from 
the data presented in this thesis have investigated the possibility of an endogenous 
relationship between MIP-la and TGF-p expression levels in bone marrow derived 
macrophages. To this end, endogenous TGF-pi protein in bone marrow derived 
macrophage cultures was neutralised by adding an excess of TGF-pi latency 
associated peptide (LAP), and the effect of LAP treatment on MIP-la mRNA 
expression analysed by Northern blot. The results of this experiment demonstrate 
that MIP-la expression is elevated (approximately 2 to 3 fold) in macrophage 
cultures treated with LAP suggesting that MIP-la expression, at the mRNA level
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at least, is endogenously suppressed by TGF-pi (J.Maltman, G.Graham, 
unpublished observations). It remains to be seen whether this is effect is reflected 
at the protein level, but given the very low and often undetectable levels of MIP- 
l a  produced by these cells, it is unlikely that such a small change would be 
detectable using conventional techniques. However, the results of this experiment 
suggest that the inhibitory activity of TGF-p on MIP-la expression is not 
dependent on exogenous TGF-p addition and may also be at play in vivo resulting 
in undetectable MIP-la protein secretion.
6.3 Relative expression of MIP-la and TGF-p
These results raise questions over the actual role MIP-la plays as an 
inhibitor of stem cell proliferation in vivo. Its effects on stem cells have been 
extensively studied in vitro, and it quite clearly functions as a potent inhibitor in 
certain in vitro and in vivo assay systems (Graham and Pragnell 1992). The 
potency with which TGF-p is capable of inhibiting MIP-la expression suggests 
however that in normal bone marrow, MIP-la expression will be permanently 
"turned off" or at least substantially downregulated in the presence of active TGF- 
P and in the absence of upregulators of MIP-la expression. Interestingly, a recent 
study by Cluitmans et al (1995) has demonstrated both MIP-la and TGF-p mRNA 
expression in human peripheral blood and normal bone marrow biopsy samples, 
suggesting that these molecules at least have the capacity to be co-expressed in 
normal bone marrow and that MIP-la is not completely suppressed by 
endogenous TGF-p. Whether or not this is reflected at the protein level in vivo 
remains to be elucidated. From our own studies it is clear that although very low 
levels of MIP-la mRNA expression can be seen in bone marrow macrophages, no 
M IP-la protein can be detected in bone marrow extracts using sensitive assays. 
TGF-pi protein on the other hand can be readily detected in bone marrow extracts 
using both sensitive ELISA based methods and the HT-2 bioassay (A.Sim personal 
communication). However, although TGF-p protein can be detected in both 
normal bone marrow and in long term bone marrow cultures (LTBM) (Cashman et
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al 1990), it is difficult to assess how much is actually active, and therefore capable 
of inhibiting expression of MIP-la. Evidence for the possible existence of 
biologically active endogenous TGF-p in LTBM cultures comes from the studies of 
Eaves et al (1991) whereby addition of anti-TGF-p antibodies to normal LTBM 
cultures resulted in activation of proliferation of quiescent primitive progenitors. 
Interestingly, and perhaps unexpectedly in the light of the data presented in this 
thesis, addition of anti-MIP-la antibodies also results in stimulation of primitive 
progenitor cell proliferation also suggesting that MIP-la protein is expressed and 
does play an endogenous inhibitor role. Thus it is possible that, although no MIP- 
l a  protein can be detected in the LTBM cultures or real bone marrow, localised 
production of the molecule in the vicinity of the stem cell can produce high enough 
concentrations to elicit a biological response. The potent proteoglycan binding 
abilities of MIP-la, and indeed its propensity to self-aggregate, may help in this 
context to build up high localised concentrations. If this is the case, proteoglycan 
immobilised MIP-la would be undetectable in the supernatant of LTBM, and 
indeed in bone marrow extracts. It is thus very difficult to draw conclusions 
regarding both the abundance and the relative roles of each cytokine in in vivo 
haemopoiesis. It is clear however that although TGF-(3 is capable of potently 
inhibiting MIP-la expression in vitro, MIP-la expression is not completely 
suppressed in LTBMCs or in human peripheral blood or bone marrow.
6.4 Inhibition of M IP-la specific receptors by TGF-p 1
If one assumes that in vivo, in the presence of active TGF-p, very little 
MIP-la will be produced, then it is of interest to investigate how the target cells of 
MIP-la would respond to the presence of TGF-p. If M IP-la does play an 
important endogenous physiological role in the control of stem cell proliferation, it 
is possible that the stem cells would respond to TGF-p and therefore the 
corresponding decrease in MIP-la protein by upregulation of specific receptors for 
that molecule. This possible "yin-yang" relationship may act to compensate for the 
reduced levels of MIP-la and maintain the stem cells in a quiescent state. To this
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end, the effects of TGF-p on MIP-la receptor levels on the actual target stem cells 
were investigated. As mentioned previously, FDCP-MIX cells are a CFU-A/CFU- 
S stem cell like line which are capable of self renewal and multilineage 
differentiation, and of forming spleen colonies in early passage (Dexter et al 1977, 
Schofield and Dexter 1985). They also express high levels of high affinity 
receptors for MIP-la and have previously been shown to respond, though 
inconsistently, to its inhibitory properties (Graham et al 1993, Clements et al 
1992). Thus these cells appeared ideal candidates for investigating the effect of 
TGF-p on MIP-la receptors. Figures 5.5.1. to 5.5.3 in the results section clearly 
demonstrate that TGF-p is in fact a potent inhibitor of MIP-la binding to the 
surface of FDCP-MIX cells. Scatchard analysis revealed that this was due to a 
reduction in receptor numbers with no change in affinity of the remaining receptors 
for ligand. Further, this effect was fully reversible upon removal of TGF-p from 
the medium. The possible significance of this receptor downregulation will be 
discussed in more detail below.
The MIP-la receptor present on FDCP-MIX cells remains to be cloned 
and characterised. However, a receptor (CC-CKRI) specific for MIP-la and other 
C-C chemokines has been cloned from HL60 cells (Neote et al 1993). This 
receptor is also expressed on U937 cells and THP-1 monocytes, and possibly on 
other cell types also (Avalos et al 1994). As mentioned in the introduction, the 
FDCP-MIX receptor is likely to be different from CC-CKRI, and thus it was of 
interest to investigate the specificity with which TGF-p downregulates the receptor 
type present on FDCP-MIX cells. Also, it was possible to investigate the potential 
mechanism of TGF-p mediated MIP-la receptor downregulation in more detail. A 
cDNA probe was obtained for CC-CKRI, and the effect of TGF-p on mRNA 
expression of CC-CKRI in U937 cells was investigated. Interestingly, TGF-p 
appeared capable of downregulating CC-CKRI mRNA in this cell type suggesting 
that TGF-p may be capable of downregulating all receptors capable of binding 
MIP-la, and probably achieves this through altering mRNA expression.
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Again, this raises the question as to whether or not this is an inflammatory 
or a stem cell related phenomenon. It appears that TGF-p may be capable of 
downregulating receptors for MIP-la on a number of cell types, including those 
cell types unresponsive to the inhibitory properties of MIP-la, and suggests that 
this is a general function of TGF-p. Further evidence suggesting receptor 
downregulation by TGF-p to be a general phenomenon comes from observations 
that TGF-P is also capable of downregulating receptors on primitive haemopoietic 
cells for a number of other cytokines including GM-CSF, G-CSF and IL-3 
(Jacobsen et al 1991). Indeed it has been suggested that this is one possible 
mechanism by which TGF-p acts to inhibit proliferation of these cell types. The 
observed downregulation of CC-CKRI may result in decreased sensitivity to MIP- 
l a  (see below) and decreased inflammatory response of exposed cells. This may 
be part of the natural progression of an inflammatory reaction. For example, high 
concentrations of TGF-p are likely to be present in inflammatory foci due to 
platelet degranulation. TGF-p is capable of attracting monocytes and inducing 
expression of other pro-inflammatory cytokines such as TNF-a and IL-1 in these 
cell types (McCartney-Francis et al 1990). Conversely, upon monocyte 
differentiation into macrophages, TGF-p deactivates macrophages and reduces 
their ability to kill via the respiratory burst (Tsunawaki et al 1988). Thus, the 
downregulation of CC-CKRI may be part of the process by which TGF-p 
deactivates macrophages and reduces their ability to respond to inflammatory 
mediators such as the chemokines and in particular MIP-la. This hypothesis 
suggests that the expression of CC-CKRI and MIP-la is regulated by the presence 
of both TGF-p and other stimulatory cytokines. Interestingly, as wiU be discussed 
later, M IP-la is active as an inducer of both TGF-p mRNA expression and protein 
production. It is likely that production of pro-inflammatory molecules such as 
M IP-la need to be controlled such that excessive production and consequently 
unwanted tissue damage would not occur. In light of the presented data, it is 
possible that MIP-la acts both to inhibit its own expression and to help dampen
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down the inflammatory situation via induction of TGF-p in a negative feedback 
loop.
In summation, it appears that TGF-p is capable of downregulating both 
arms of the MIP-la inhibitory machinery. That is, TGF-p downregulates MIP-la 
mRNA and protein expression in the potential MIP-la producing cells i.e. 
macrophages, and at the same time downregulates MIP-la specific receptors on 
the target stem cells.
6.5 Significance of MIP-la receptor downregulation
Although TGF-p is capable of downregulating M IP-la speciflc receptors 
on FDCP-MIX cells to a maximum of between 50-70%, the functional significance 
of this downregulation required further investigation. Numerous other studies 
reporting on the physiological significance of decreased growth factor receptor 
expression have presented widely different results with respect to the levels or 
numbers of receptors required to elicit a full biological response. For example, it 
has been demonstrated that only 1% of IL-1 receptors need to be occupied for IL- 
1 to elicit a biological response whereas other groups have suggested that as much 
as 50-70% of cell surface receptors need to be occupied (Dinarello et al 1994). 
Thus, it is important to determine whether a 50-70% decrease in MIP-la receptor 
numbers on FDCP-MIX cells (or indeed normal stem cells) will reduce the ability 
of MIP-la to inhibit that cell type.
To address this possibility, it was decided to investigate the effect of TGF-p 
on MIP-la signal transduction processes. As was mentioned in the introduction, 
the receptor for M IP-la present on FDCP-MIX cells is likely to belong to the 
seven membrane spanning family of G-protein linked receptors. Signalling through 
such receptors classically results in an increase in intracellular calcium which then 
acts as a second messenger for further downstream events. Indeed, MIP-la has 
previously been shown to elicit a calcium flux in a number of different cell types 
including eosinophils and monocytes (Rot et al 1993, Sozzani et al 1993). It was
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of interest therefore to investigate the possible effects of TGF-p on the ability of 
FDCP-MIX cells to release calcium upon MIP-la binding to its receptor. A 
reduction or indeed abrogation of this response by TGF-p would suggest that the 
receptor downregulation may indeed have physiological and functional 
consequences. Figure 5.6 in the results section shows that this appears to be the 
case. Overnight incubation of FDCP-MIX cells results in receptor downregulation 
and a substantial reduction in the ability of these cells to mobilise calcium in 
response to MIP-la. It appears therefore that the TGF-p mediated 
downregulation of MIP-la receptors on these cells will affect the MIP-la signal 
transduction pathway and, presumably, further downstream events.
Given the reduction of MIP-la receptors, and reduction in M IP-la 
induced calcium mobilisation by TGF-p, it was anticipated that pre-treating normal 
bone marrow with TGF-p would result in downregulation of M IP-la receptors on 
the CFU-A population, and thus these cells would be less responsive to inhibition 
by MIP-la. Figure 5.7 shows that pre-incubating bone marrow cells with TGF-p 
does indeed reduce the potency of MIP-la in the CFU-A assay and therefore 
clearly has functional consequences. It must be stressed here that the bone marrow 
cells were only exposed to TGF-p overnight, and were then thoroughly washed in 
PBS to remove any excess TGF-p. However, the number of CFU-A colonies 
formed using TGF-p pre-treated bone marrow only was still markedly reduced 
after the eleven day time course of this assay. This suggests two possibilities. The 
first is that washing the cells three times in PBS does not adequately wash off 
TGF-p bound to the cell surface, and therefore, the cells are still exposed to active 
TGF-p after initiation of the assay. Given that the assay is carried out over a 
period of eleven days however, it is unlikely that sufficient TGF-p will remain to 
cause such marked inhibition. It is probable that the exogenously added TGF-p 
will have been internalised and degraded early during the assay time course. The 
other, and more likely, possibility is that TGF-p is inducing programmed cell death, 
or apoptosis, in the majority of the CFU-A cells present in the bone marrow 
population during overnight incubation. However, when using lower
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concentrations of TGF-p, some colony formation does still occur, and presumably 
these cells should still be open to inhibition by MIP-la. The fact that MIP-la 
appears incapable of adding to the "inhibitory" effect of TGF-p suggests that the 
TGF-P mediated downregulation of MIP-la receptor numbers on the clonogenic 
cells does affect the ability of MIP-la to inhibit CFU-A colony formation.
There is considerable precedent for suggesting that TGF-p may induce 
apoptosis in CFU-A cells since TGF-pi has been shown to induce apoptosis m a 
number of both haemopoietic and non-haemopoietic cell types. For example, 
Bursch et al (1993) have demonstrated the involvement of TGF-pi in the induction 
of apoptosis in certain epithelia in vivo. Chuang et al (1994) have further 
characterised the apoptotic signals TGF-pi confers on human hepatoma cells and 
have shown that TGF-pl induced cell death is independent of cytosilic calcium and 
protein kinase C. With respect to haemopoiesis, TGF-pi can prevent the stem cell 
factor mediated rescue of mast cells from apoptosis after IL-3 deprivation (Mekori 
and Metcalfe 1994). Further, TGF-P2 induces apoptosis of murine T cell clones 
(Weller et al 1994), and TGF-pl is capable of abrogating the effects of 
haematopoietins (IL-3, IL-5 and GM-CSF) on eosinophils and induces their 
apoptosis (Alam et al 1994). Interestingly, TGF-pl also induces apoptosis in Ml 
myeloid leukaemia cells, and this effect is mediated by the primary response gene 
MyDlllS, and the proto-oncogenes myb, myc and bcl-2 (Selvakuramin et al 
1994).
Thus, there is considerable evidence that TGF-p can induce apoptosis in 
haemopoietic cell types, and it remains possible that this is occurring on the CFU-A 
stem cells. It would therefore be of interest to investigate if the CFU-A type cells 
incubated overnight with TGF-p exhibit any classical apoptotic morphology such 
as condensation of chromatin, blebbing of the cell surface and fragmentation of 
chromatin. However, it would be very difficult obtaining sufficient numbers of 
these cells for such analysis. Interestingly, data shown in figure 5.5.4 demonstrates 
that the inhibition of MIP-la receptors on FDCP-MIX cells is reversible, implying
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that TGF-pi does not induce apoptosis in these cell types. If these cells were 
undergoing apoptosis then one would predict that, as time progressed, the ability 
of MIP-la to bind to the cells would be markedly lower due to the decreasing 
number of viable cells present. However, MIP-la receptor levels on those cells 
which received continuous addition of TGF-p over a 96hr period remained 
constantly downregulated by around 50% and this level of downregulation did not 
increase as time progressed. It appears therefore that TGF-p does not induce 
apoptosis in FDCP-MIX cells. This may however be a consequence of the fact 
that the FDCP-MIX cells used in the above mentioned experiment were always 
grown in the presence of the growth factor IL-3. In contrast, in the experiments 
involving TGF-p overnight treatment of bone marrow CFU-A cells, bone marrow 
cells were incubated overnight in medium containing only serum and no added 
growth factors. Normally, overnight incubation of bone marrow cells without 
growth factors has no great detrimental effect on the CFU-A compartment because 
colony formation by CFU-A cells is normal. However, the lack of growth factors 
and therefore positive growth stimuli may actually predispose these cells to the 
active induction of apoptosis by TGF-p. Therefore, it is possible that TGF-p, in 
contrast to MIP-la, is actually an inducer of apoptosis in haemopoiesis rather than 
an inhibitor of proliferation.
6,6 Induction of TGF-p by MIP-la
In order to fully understand the possible relationship between M IP-la and 
TGF-p, both in the control of stem cell proliferation and also in potential 
inflammatory reactions, it was decided to examine any possible effects of M IP-la 
on TGF-p mRNA and protein expression. Although it appears quite clear that 
TGF-p does not function as a stem cell inhibitor via induction of MIP-la, it is still 
possible that MIP-la functions, either wholly or in part, through induction of 
TGF-p.
To address this possibility, the effect of M IP-la on TGF-p expression was 
examined in bone marrow derived macrophages, which are capable of expressing
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both TGF-P mRNA and protein. Indeed, MIP-la and IL-2 appear to be capable 
of inducing both TGF-p mRNA and protein production by these cell types. This 
effect is enhanced to a level greater than that achieved using either cytokine alone 
when the cells are treated with both MIP-la and IL-2, a known inducer of TGF-p 
expression. These results suggest that MIP-la may indeed function as a stem cell 
inhibitor via induction of TGF-p expression in secondary cell types such as 
macrophages present within the bone marrow microenvironment or indeed in 
target cells. Such a conclusion would predict that M IP-la will be unable (or less 
able) to inhibit stem cell proliferation in the presence of molecules which act to 
inhibit the function of TGF-p. A number of such molecules are available for 
neutralising TGF-p bioactivity including anti-TGF-p antibodies, the TGF-p type II 
receptor in soluble form and the TGF-pi latency associated peptide (LAP), a 
natural and potent TGF-pl antagonist. Since LAP appeared to be the most potent 
neutraliser of TGF-pi activity, it was decided to use this molecule to investigate if 
M IP-la was capable of inhibiting CFU-A colony formation in the presence of 
blockers of TGF-P function. The results shown in figure 5.9 demonstrate that this 
is clearly the case, with LAP having no effect on the ability of M IP-la to inhibit 
CFU-A cells. It is capable however of reversing the ability of exogenously added 
TGF-p to inhibit CFU-A cells indicating that LAP is efficiently neutralising the 
activity of TGF-p in this assay system. Thus, although M IP-la is capable of 
inducing TGF-p expression in macrophages, it does not appear to function as a 
stem cell inhibitor through this mechanism. Indeed, the results presented in this 
thesis suggest that although MIP-la and TGF-p appear to have overlapping 
functions in the control of stem cell proliferation, they function in this context 
independently of each other.
6.7 The role of MIP-la and TGF-p in haemopoiesis?
When attempting to relate this data to possible in vivo consequences, it is 
necessary to take into account all of the other molecules which are at play during 
steady state and aberrant haemopoiesis. As was mentioned above, these
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experiments were performed in vitro, and thus cannot adequately recreate the 
complexity of the bone marrow. However, the results suggest firstly that in the 
presence of active TGF-p in vivo, very little MIP-la will be produced, and 
secondly, due to receptor downregulation, the target stem cells may not be able to 
respond to any MIP-la which is present. However, steady state haemopoiesis is 
likely to be controlled by an intricate interplay between various different molecules, 
many of which are potentially capable of stimulating proliferation of stem cells. It 
is possible that many of these molecules are capable of positively regulating the 
expression of MIP-la and that the expression of M IP-la is regulated by a balance 
between TGF-p and stimulators of MIP-la expression. This remains to be 
clarified.
The results presented in this thesis raise the question as to what role each of 
these molecules plays in the overall control of haemopoietic stem cell proliferation. 
Clearly they are able to inhibit the same population of stem cells through 
apparently independent mechanisms. It is interesting to note however that TGF-p is 
capable of inhibiting a much wider spectrum of cell types than MIP-la. It may be 
that the endogenous role of TGF-p in haemopoiesis is to inhibit subpopulations of 
stem cells not open to control by MIP-la such as pre-CFU-S. It is also possible 
that M IP-la may only be required as a stem cell inhibitor in times of extreme stress 
e.g. a systemic infection or excessive inflammation. Such a scenario would require 
generation of large numbers of mature immune cells such as macrophages and 
neutrophils. These cells are likely to be generated by the induction of CFU-S type 
cells into cell cycle. The role of MIP-la as a stem cell inhibitor may be to act as a 
negative feedback molecule to control the production of mature myeloid cells, and 
at the same time upregulate TGF-p expression such that TGF-p can act to dampen 
down the inflammatory response through its wide range of anti-inflammatory 
functions. Thus, when enough mature myeloid cells have been produced to deal 
with the inflammation, presumably activation of such large numbers of immune 
cells would result in an increase in expression of M IP-la. The increased 
concentration of this molecule in the bloodstream would feed back to the bone
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marrow, where it can then act to inhibit the cycling CFU-S compartment thus 
controlling the overall levels of mature myeloid cells produced. While TGF-p 
expression may also be increased at the site of inflammation, the levels of active 
TGF-p are likely to be very localised. Active TGF-p has a very short half-life and 
is bound very quickly by the serum component p2-macroglobulin (O'Connor- 
McCourt and Wakefield 1987), and thus it is unlikely that sufficient amounts of 
active TGF-p will feed back to the bone marrow and inhibit the bone marrow 
resident CFU-S cells. Thus, TGF-p may be involved in steady state inhibition of 
stem cells in the locality of the bone marrow microenvironment whereas MIP-la 
may be involved in stem cell inhibition in times of stress. In addition, M IP-la may 
play a role in controlling proliferation of peripheral CFU-S stem cells present in the 
blood. By the same criteria above, it is unlikely that TGF-p would play a major 
role in this context due to its very short half life in the circulation.
6.8 Summary, conclusions and future prospects
The aim of this thesis was to try to elucidate the functional roles of the 
inhibitors of haemopoietic stem cell proliferation. In particular, M IP-la and TGF- 
P appeared to have many similar functions in this regard perhaps suggesting that 
there may be some form of productive interaction between them. That is, one may 
work indirectly via induction of the other. As has been described above, this 
appears not to be the case. TGF-p acts as a potent inhibitor of both M IP-la 
mRNA expression and protein production in macrophages, and also downregulates 
M IP-la specific receptors on the stem cell like line FDCP-MIX. This 
demonstrates that TGF-p is unlikely to function via induction of MIP-la. On the 
other hand, MIP-la appears to act as an inducer of both TGF-p mRNA and 
protein expression by macrophages suggesting that M IP-la may work via 
induction of TGF-p. However, inactivation of endogenous TGF-p does not appear 
to affect either the ability or the potency of MIP-la to inhibit CFU-A colony. In
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conclusion, the data presented in this thesis suggests that M IP-la and TGF-p 
inhibit the proliferation of stem cells through, initially at least, independent 
mechanisms. It is still unclear whether the reciprocal effects between M IP-la and 
TGF-p are a consequence of inflammatory regulation, but the fact that TGF-p 
cannot inhibit expression of other pro-inflammatory chemokines such as IL-8 or 
RANTES suggests these interactions may be more specific to control of stem cell 
proliferation. Both of these molecules have the capacity to be expressed in the 
bone marrow where they can presumably interact in the vicinity of the stem cells. 
This work presents evidence for a heirarchy of stem cell inhibitors such that TGF-p 
will be dominantly expressed over MIP-la. However, it is still unclear what might 
happen in an in vivo situation, where upregulators of M IP-la expression are likely 
to be present. Addition of either anti-MIP-la antibodies or anti-TGF-p antibodies 
to LTBMCs results in entry of primitive cells into cycle suggesting that although 
TGF-p may be dominantly expressed in bone marrow macrophage cultures, both 
are endogenously active in LTBMCs (Eaves et al 1991). In conclusion, although 
TGF-p can downregulate both arms of the MIP-la inhibitory machinery, this is not 
sufficient to wipe out endogenous activity of MIP-la as a stem cell inhibitor.
It would be interesting to examine this scenario in more detail, perhaps 
using a murine model undergoing extensive immune reactions, such that the 
relative expressions of MIP-la and TGF-p can be more easily determined. When 
the putative inhibitory receptor for MIP-la has been cloned and characterised, 
signal transduction analysis will be possible. It will be of interest to compare and 
contrast the resultant changes in gene expression by both M IP-la and TGF-p. 
Although the initial signal transduction systems are likely to be distinct due to the 
different receptor types for these molecules, it is possible that the similar functions 
of these molecules may be due to similar changes in the expression of genes 
regulating cell cycle progression and growth arrest.
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